Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.1.8 - cholinesterase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
Butyrylcholinesterase activity and lymphocyte subpopulations in peripheral blood of Kuwaiti women experiencing recurrent spontaneous abortion.
Ratio of immunochemically determined amniotic fluid acetylcholinesterase to butyrylcholinesterase in the differential diagnosis of fetal abnormalities.
[BEHAVIOR OF THE CHOLINESTERASE ACTIVITY IN THE BLOOD AND IN PLACENTAL TISSUE DURING THE 1ST MONTHS OF PHYSIOLOGICAL PREGNANCY AND IN SPONTANEOUS ABORTIONS.]
Abortion, Threatened
[Changes in the concentration of copper and ceruloplasmin, and cholinesterase activity in the blood in threatened abortion]
acetylcholinesterase deficiency
Congenital myasthenic syndromes.
[Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation]
Acidosis
Chronotropic and dromotropic actions of acetylcholine on the developing fetal heart.
Organophosphate poisoning: modifications in acid base equilibrium and use of sodium bicarbonate as an aid in the treatment of toxicity in dogs.
Suspected chlorpyrifos toxicosis in a llama, and plasma pseudocholinesterase activity in llamas given chlorpyrifos.
[Severe medical sequelae in heroin addicts]
Acidosis, Lactic
Acute toxicity of methyl isocyanate in mammals. II. Induction of hyperglycemia, lactic acidosis, uraemia, and hypothermia in rats.
Acne Vulgaris
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
Acquired Immunodeficiency Syndrome
Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients.
Concentrations of magnesium, zinc and copper in serum of patients with acquired immuno-deficiency syndrome.
[Research on risk factors of short-term outcome in AIDS patients with pneumocystis pneumonia].
Acromegaly
The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly.
Acute Coronary Syndrome
Butyrylcholinesterase Activity Predicts Long-Term Survival in Patients with Coronary Artery Disease.
Butyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome.
Low Serum-Butyrylcholinesterase Activity as a Prognostic Marker of Mortality Associates with Poor Cardiac Function in Acute Myocardial Infarction.
Acute Kidney Injury
Activation of ?7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice.
Clinical characteristics and outcomes of critically ill COVID-19 patients in Sfax, Tunisia.
Predictors of Morbidity and Mortality in Organophosphorus Poisoning: A Case Study in Rural Hospital in Karnataka, India.
Adenocarcinoma
HER-2 amplification but not butyrylcholinesterase multability reflects aggressiveness of European-originated ovarian tumors.
Production of butyrylcholinesterase by Caco-2 cells: lack of relationship with triglyceride production.
Serum pseudocholinesterase levels in murine C3H mammary adenocarcinoma.
Adrenocortical Hyperfunction
Serum paraoxonase 1 and butyrylcholinesterase in dogs with hyperadrenocorticism.
Aggressive Periodontitis
Determination of pseudocholinesterase activity in the gingival crevicular fluid, saliva, and serum from patients with juvenile periodontitis and rapidly progressive periodontitis.
Airway Obstruction
Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.
[Emergency from anesthesia in small children. From laryngospasm to prolonged apnea]
alcohol dehydrogenase deficiency
Ecogenetic and pharmacogenetic studies in Hungary.
Ecogenetic studies in Atacameño Indians.
Alcohol Withdrawal Delirium
[Proceedings: Relationship of serum cholinesterase level in chronic alcoholic liver disease and appearance of delirium tremens: therapeutic effect of oximes]
Alopecia
[Clinical and biochemical alterations in rats treated with high doses of vitamin A]
Alzheimer Disease
"Clicking" fragment leads to novel dual-binding cholinesterase inhibitors.
"Value for money" in treating Alzheimer's disease with the new cholinesterase inhibitors.
(±)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3? Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease.
1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease.
1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
11: disorders of memory and intellect.
2-Hydroxy-N-phenylbenzamides and Their Esters Inhibit Acetylcholinesterase and Butyrylcholinesterase.
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
A 10-year perspective on donepezil.
A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.
A case with cholinesterase inhibitor responsive asymmetric posterior cortical atrophy.
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease.
A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques.
A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
A modified binary particle swarm optimization with a machine learning algorithm and molecular docking for QSAR modelling of cholinesterase inhibitors.
A molecular modeling study of components of the ginger (Zingiber officinale) extract inside human butyrylcholinesterase: implications for Alzheimer disease.
A Multi-layered Variable Selection Strategy for QSAR Modeling of Butyrylcholinesterase Inhibitors.
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapy.
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
A palliative care perspective on deprescribing cholinesterase inhibitors in Alzheimer's disease.
A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease.
A phase II trial of huperzine A in mild to moderate Alzheimer disease.
A Platform for Screening Potential Anticholinesterase Fractions and Components Obtained from Anemarrhena asphodeloides Bge for Treating Alzheimer's Disease.
A population-based study of dosing and persistence with anti-dementia medications.
A potent and selective tacrine analog--biomembrane permeation and physicochemical characterization.
A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease.
A Randomized Phase I Study of Methanesulfonyl Fluoride, an Irreversible Cholinesterase Inhibitor, for the Treatment of Alzheimer's Disease.
A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease.
A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.
A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.
A review on cholinesterase inhibitors for Alzheimer's disease.
A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease.
A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease.
A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease.
A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
A systematic review of carbohydrate-based bioactive molecules for Alzheimer's disease.
A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease.
A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.
A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression.
A top 5 list for French general practice.
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.
Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease.
Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.
Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease.
Acetylcholinesterase and butyrylcholinesterase inhibition by nectriapyrone and tryptophol isolated from endophytic fungus Phomopsis sp.
Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg.
Acetylcholinesterase and butyrylcholinesterase inhibitory activity of Pinus species essential oils and their constituents.
Acetylcholinesterase and its association with heparan sulphate proteoglycans in cortical amyloid deposits of Alzheimer's disease.
Acetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer's Disease Therapy.
Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl derivatives.
Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts.
Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine.
Acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibition studies and antioxidant activities of 33 Scutellaria L. taxa from Turkey.
aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease.
Acquired Localized Hypertrichosis Induced by Rivastigmine.
Acridine-induced subcellular and functional changes in isolated human hepatocytes in vitro.
Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines.
Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.
Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.
Activities and kinetic properties of lumbar cerebrospinal fluid cholinesterases in relation to clinical diagnosis, severity, and progression of Alzheimer's disease.
Acute Effects of Muscarinic M1 Receptor Modulation on A?PP Metabolism and Amyloid-? Levels in vivo: A Microdialysis Study.
Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study.
Adherence to cholinesterase inhibitors in Alzheimer's disease: a review.
Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.
Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease.
Advances in Alzheimer's disease. A review for the family physician.
Advances in the treatment of Alzheimer's disease.
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Advances in the treatment of cognitive impairment in Parkinson's disease.
Adverse drug events affecting medication persistence with rivastigmine patch application.
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains.
Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome.
Ajmalicine and its Analogues against AChE and BuChE for the Management of Alzheimer's Disease: An In-silico study.
Alanine-to-threonine substitutions and amyloid diseases: Butyrylcholinesterase as a case study.
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.
Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease.
Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice.
Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms.
Alzheimer's dementia: current data review.
Alzheimer's disease and the glutamate NMDA receptor.
Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?
Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors.
Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.
Alzheimer's Disease.
Alzheimer's disease.
Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Alzheimer's disease: early diagnosis and treatment.
Alzheimer's disease: recent advances in etiology, diagnosis, and management.
Alzheimer's disease: the pharmacological pathway.
Amaryllidaceae Alkaloids of Norbelladine-Type as Inspiration for Development of Highly Selective Butyrylcholinesterase Inhibitors: Synthesis, Biological Activity Evaluation, and Docking Studies.
Amelioration of scopolamine-induced amnesia by phosphatidylserine and curcumin in the day-old chick.
Aminoalcoholate-driven tetracopper(II) cores as dual acetyl and butyrylcholinesterase inhibitors: Experimental and theoretical elucidation of mechanism of action.
Amiridine-piperazine hybrids as cholinesterase inhibitors and potential multitarget agents for Alzheimer's disease treatment.
Amyloid precursor protein 96-110 and beta-amyloid 1-42 elicit developmental anomalies in sea urchin embryos and larvae that are alleviated by neurotransmitter analogs for acetylcholine, serotonin and cannabinoids.
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Amyloid-? peptides act as allosteric modulators of cholinergic signalling through formation of soluble BA?ACs.
An audit of a specialist old age psychiatry liaison service to a medium and a high secure forensic psychiatry unit.
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
An Efficient Synthesis of bi-Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease.
An evaluation of neonicotinoids' potential to inhibit human cholinesterases: Protein-ligand docking and interaction profiling studies.
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production.
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K).
Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.
Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease.
Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
Antagonism of anticholinesterase (DFP) toxicity by donepezil plus scopolamine: a preliminary study.
Anti-Alzheimer potential, metabolomic profiling and molecular docking of green synthesized silver nanoparticles of Lampranthus coccineus and Malephora lutea aqueous extracts.
Anti-Alzheimer's disease activity of compounds from the root bark of Morus alba L.
Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activity.
Antibacterial, antioxidant, anti-cholinesterase potential and flavonol glycosides of Biscutella raphanifolia (Brassicaceae).
Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for Alzheimer's disease therapy.
Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases.
Antioxidant activity and acetylcholinesterase inhibition of grape skin anthocyanin (GSA).
Antioxidant and Cholinesterase Inhibitory Activity of a New Peptide From Ziziphus jujuba Fruits.
Antioxidant properties of eugenol, butylated hydroxylanisole, and butylated hydroxyl toluene with key biomolecules relevant to Alzheimer's diseases-In vitro.
Antioxidant, Antidiabetic, and Anticholinesterase Activities and Phytochemical Profile of Azorella glabra Wedd.
Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study.
Apolipoprotein ?4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Aporphines and Alzheimer's disease: Towards a Medical Approach Facing the Future.
Aporphinoid Alkaloids Derivatives as Selective Cholinesterases Inhibitors: Biological Evaluation and Docking Study.
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Arylbenzofurans from the Root Bark of Morus alba as Triple Inhibitors of Cholinesterase, ?-Site Amyloid Precursor Protein Cleaving Enzyme 1, and Glycogen Synthase Kinase-3?: Relevance to Alzheimer's Disease.
Assessment and treatment of dementia in medical patients.
Assessment of cholinesterase and tyrosinase inhibitory and antioxidant effects of Hypericum perforatum L. (St. John's wort)
Assessment of enzyme inhibitory and antioxidant activities of lignans from Taxus baccata L.
Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population.
Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Association between low-density lipoprotein receptor-related protein gene, butyrylcholinesterase gene and Alzheimer' s disease in Chinese.
Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors.
Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease.
Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition.
Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010.
Axo-axonal interaction in autonomic regulation of the cerebral circulation.
Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors.
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.
Benefit-risk considerations in the treatment of dementia with Lewy bodies.
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents.
Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer's Agents: Synthesis and Biological Evaluation.
Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease.
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.
Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues.
Biochemical Differentiation of Cholinesterases from Normal and Alzheimer's Disease Cortex.
Biological Activities of Aerial Parts Extracts of Euphorbia characias.
Biological Evaluation of Endophytic Fungus, Chaetomium globosum JN711454, as Potential Candidate for Improving Drug Discovery.
Biophenols: Enzymes (?-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.).
Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia.
Blood markers in Alzheimer disease: subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes.
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.
Butyrycholinesterase K variant and Alzheimer's disease.
Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem.
Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease.
Butyrylcholinesterase attenuates amyloid fibril formation in vitro.
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.
Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-? peptide in mice.
Butyrylcholinesterase is associated with ?-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease.
Butyrylcholinesterase K and Apolipoprotein ?4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer's Disease.
Butyrylcholinesterase K and Apolipoprotein E-?4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.
Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients.
Butyrylcholinesterase K variant and cerebral amyloid angiopathy.
Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland.
Butyrylcholinesterase radioligands to image Alzheimer's disease brain.
Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain).
Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease.
Butyrylcholinesterase-knockout reduces brain deposition of fibrillar ?-amyloid in an Alzheimer mouse model.
Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.
Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer's Disease? A Population-Based Study in Taiwan.
Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study.
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
Capillary zone electrophoresis determination of galanthamine in biological fluids and pharmaceutical preparatives: experimental design and artificial neural network optimization.
Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
Carbazole-based semicarbazones and hydrazones as multifunctional anti-Alzheimer agents.
Cardiac safety of donepezil in elderly patients with Alzheimer disease.
Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.
Caregiver acceptance of adverse effects and use of cholinesterase inhibitors in Alzheimer's disease.
Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis.
Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.
Causes of syncope in patients with Alzheimer's disease treated with donepezil.
CDR State Transition Probabilities in Alzheimer's Disease with and without Cholinesterase Inhibitor Intervention in an Observational Cohort.
Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease.
Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study.
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
Cerebrolysin: a review of its use in dementia.
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Cerebrovascular Pathology and Responsiveness to Treatment in Alzheimer's Disease: A Systematic Review.
Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment.
Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms.
Changes in brain cholinesterases in senile dementia of Alzheimer type.
Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study.
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease : a nonrandomised controlled trial with magnetic resonance spectroscopy.
Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors.
Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.
Chemical Characterization of Narcissus poeticus from Sirente -Velino (Apennines - Italy): Galantamine Accumulation and Distribution of Allergenic Compounds in the Flower.
Chemical composition of the essential oil and hexane extract of Salvia chionantha and their antioxidant and anticholinesterase activities.
Chemical composition, antioxidant and anticholinesterase activity of the essential oil of algerian cachrys sicula L.
Chemical composition, biological properties and bioinformatics analysis of two Caesalpina species: A new light in the road from nature to pharmacy shelf.
Chemistry and functional properties in prevention of neurodegenerative disorders of five Cistus species essential oils.
Chinese Medicine for Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Trials.
Chlorinated tacrine analogs: Design, synthesis and biological evaluation of their anti-cholinesterase activity as potential treatment for Alzheimer's disease.
Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management.
Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
Cholinergic enhancement of frontal lobe activity in mild cognitive impairment.
Cholinergic foundations of Alzheimer's disease therapy.
Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.
Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
Cholinesterase Activity and mRNA Level of Nicotinic Acetylcholine Receptors (alpha4 and beta2 Subunits) in Blood of Elderly Chinese Diagnosed as Alzheimer's Disease.
Cholinesterase activity and mRNA level of nicotinic acetylcholine receptors (alpha4 and beta2 Subunits) in blood of elderly Chinese diagnosed as Alzheimer's disease.
Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid.
Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae).
Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Cholinesterase based amperometric biosensors for assay of anticholinergic compounds.
Cholinesterase enzymes in the blood of patients with Alzheimer's disease.
Cholinesterase inhibition by derivatives of 2-amino-4,6-dimethylpyridine.
Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Cholinesterase Inhibition in Alzheimer's Disease: Is Specificity the Answer?
Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease.
Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.
Cholinesterase inhibitor blockade and its prevention by statins of sympathetic alpha7-nAChR-mediated cerebral nitrergic neurogenic vasodilation.
Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Cholinesterase Inhibitor Donepezil Increases Mitochondrial Biogenesis through AMP-Activated Protein Kinase in the Hippocampus.
Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors.
Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.
Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us?
Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.
Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease.
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.
Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies.
Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project.
Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1-42 antibodies in Alzheimer's disease patients.
Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: a systematic review of randomized controlled trials.
Cholinesterase inhibitors and Alzheimer's disease outcomes.
Cholinesterase Inhibitors and Behavioral & Psychological Symptoms of Alzheimer's Disease.
Cholinesterase inhibitors and beyond.
Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration.
Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease.
Cholinesterase inhibitors and memory.
Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses.
Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's disease.
Cholinesterase inhibitors are compatible with psychosocial intervention for Alzheimer disease patients suggested by neuroimaging findings.
Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.
Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients.
Cholinesterase inhibitors for Alzheimer disease.
Cholinesterase Inhibitors for Alzheimer Disease: Do They Provide More Than Symptomatic Benefits?
Cholinesterase inhibitors for Alzheimer's disease.
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England.
Cholinesterase inhibitors for behavioral disturbance in dementia.
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly.
Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Cholinesterase inhibitors from the roots of Harpagophytum procumbens.
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.
Cholinesterase Inhibitors in Alzheimer's Disease.
Cholinesterase Inhibitors in Alzheimer's Disease. Proceedings of a symposium. Sweden, June 1, 1993.
Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population.
Cholinesterase inhibitors in late-stage Alzheimer's disease.
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.
Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry.
Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.
Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients.
Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.
Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Cholinesterase inhibitors reduce aggression, wandering, and paranoia in Alzheimer disease.
Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the sunnybrook dementia cohort.
Cholinesterase inhibitors stabilize Alzheimer disease.
Cholinesterase inhibitors stabilize Alzheimer's disease.
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.
Cholinesterase inhibitors: a patent review (2007 - 2011).
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease.
Cholinesterase Inhibitors: Cardioprotection in Alzheimer's Disease.
Cholinesterase inhibitors: new roles and therapeutic alternatives.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Cholinesterase Inhibitory Activities of Selected Halogenated Thiophene Chalcones.
Cholinesterase Inhibitory Activity of Some semi-Rigid Spiro Heterocycles: POM analyses and Crystalline Structure of Pharmacophore Site.
Cholinesterase inhibitory activity of tinosporide and 8-hydroxytinosporide isolated from Tinospora cordifolia: In vitro and in silico studies targeting management of Alzheimer's disease.
Cholinesterase inhibitory effects of Rhizophora lamarckii, Avicennia officinalis, Sesuvium portulacastrum and Suaeda monica: Mangroves inhabiting an Indian coastal area (Vellar Estuary).
Cholinesterase Inhibitory Potential of Quercetin towards Alzheimer's Disease - A Promising Natural Molecule or Fashion of the Day? - A Narrowed Review.
Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer's disease.
Cholinesterase-responsive supramolecular vesicle.
Cholinesterases in cerebrospinal fluid. Correlations with clinical measures in Alzheimer's disease.
Cholinesterases in the amyloid angiopathy of Alzheimer's disease.
Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease.
Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease.
Cholinesterases: new roles in brain function and in Alzheimer's disease.
CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients.
CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.
Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.
Clinanthus microstephus, an Amaryllidaceae species with cholinesterase inhibitor alkaloids: structure-activity analysis of haemanthamine skeleton derivatives.
Clinical and analytical considerations in the utilization of cholinesterase measurements.
Clinical Compliance of Donepezil in Treating Alzheimer's Disease in Taiwan.
Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
Clinical trials and therapy.
Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.
Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro.
Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Cochrane review on 'Statins for the treatment of dementia'
Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.
Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Cognitive pharmacotherapy of Alzheimer's disease and other dementias.
Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors.
Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics.
Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
Combination therapy for early Alzheimer's disease: what are we waiting for?
Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Combined in Vitro and in Silico Studies for the Anticholinesterase Activity and Pharmacokinetics of Coumarinyl Thiazoles and Oxadiazoles.
Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice.
Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease.
Combining antioxidant astaxantin and cholinesterase inhibitor huperzine A boosts neuroprotection.
Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: a preliminary anti- Alzheimer's study.
Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Comparative Study of Chemical Composition, Cholinesterase Inhibition and Antioxidant Potential of Mentha pulegium L. Essential Oil.
Comparative study of selective in vitro and in silico BACE1 inhibitory potential of glycyrrhizin together with its metabolites, 18?- and 18?-glycyrrhetinic acid, isolated from Hizikia fusiformis.
Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
Comparison of cholinesterase inhibitor safety in real-world practice.
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease.
Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects.
Comparison studies of cholinesterase inhibitors for Alzheimer's disease.
Competitive substrate inhibition in the histochemistry of cholinesterase activity in Alzheimer's disease.
Computational and experimental studies on the interaction between butyrylcholinesterase and fluoxetine: Implications in health and disease.
Computational and In-Vitro Validation of Natural Molecules as Potential Acetylcholinesterase Inhibitors and Neuroprotective Agents.
Computational and Kinetic Studies of Acetylcholine Esterase Inhibition by Phenserine.
Computational exploration and experimental validation to identify a dual inhibitor of cholinesterase and amyloid-beta for the treatment of Alzheimer's disease.
Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients.
Conjugates of ?-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.
Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors.
Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM).
Converting maslinic acid into an effective inhibitor of acylcholinesterases.
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.
Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.
Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Could the potential benefits of cholinesterase inhibitors in Alzheimer's disease be reduced after adjusting for coexisting diseases and multiple medications?
Coumarin, anthroquinone and stilbene derivatives with anticholinesterase activity.
Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors.
CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
CSF biomarkers predict a more malignant outcome in Alzheimer disease.
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
Current and emerging pharmacological treatment options for dementia.
Current drugs and future hopes in the treatment of Alzheimer's disease.
Current issues in dementia pharmacotherapy.
Current smoking and response to cholinesterase inhibitor therapy in Alzheimer's disease.
Current Strategies and Novel Drug Approaches for Alzheimer Disease.
Current treatment of mild cognitive impairment and Alzheimer's disease.
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease.
Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease.
Deep cerebral microbleeds are associated with poor cholinesterase inhibitor treatment response in people with Alzheimer disease.
Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease.
Defining the role of the caregiver in Alzheimer's disease treatment.
Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Dementia with Lewy bodies: an emerging disease.
Dementia: epidemiology, intervention and concept of care.
Demonstrating the Role of Anticholinergic Activity in a Mood Disorder.
Desensitization of neuronal nicotinic receptors.
Desensitized nicotinic receptors in brain.
Design and development of novel p-aminobenzoic acid derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Design, synthesis and biological evaluation of bambuterol analogues as novel inhibitors of butyrylcholinesterase.
Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors.
Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer's disease.
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors.
Design, synthesis and evaluation of dihydropyranoindole derivatives as potential cholinesterase inhibitors against Alzheimer's disease.
Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer's disease.
Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-?-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease.
Design, synthesis and evaluation of novel tacrine-(?-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
Design, Synthesis, and Biological Evaluation of 1-Benzylamino-2-hydroxyalkyl Derivatives as New Potential Disease-Modifying Multifunctional Anti-Alzheimer's Agents.
Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases.
Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy.
Design, synthesis, in vivo and in vitro studies of 1,2,3,4-tetrahydro-9H-carbazole derivatives, highly selective and potent butyrylcholinesterase inhibitors.
Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer's disease.
Design, synthesis, molecular docking, and cholinesterase inhibitory potential of phthalimide-dithiocarbamate hybrids as new agents for treatment of Alzheimer's disease.
Design, synthesis, molecular modeling and neuroprotective effects of a new framework of cholinesterase inhibitors for Alzheimer's disease.
Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Development and validation of a capillary zone electrophoretic method for rapid and sensitive determination of galanthamine: Application in plant and pharmaceuticals.
Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles.
Development of acetophenone ligands as potential neuroimaging agents for cholinesterases.
Development of donepezil-induced hypokalemia following treatment of cognitive impairment.
Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer's Disease.
Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes.
Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry.
Diagnosis and management of Alzheimer disease.
Diagnosis and treatment of Alzheimer's disease.
Diagnosis and treatment of cognitive impairment.
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries.
Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus.
Differential effects of donepezil on methamphetamine and cocaine dependencies.
Differential laminar distribution of acetylcholinesterase and butyrylcholinesterase containing tangles in the cerebral cortex of Alzheimer's disease.
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Differentiated cerebrovascular effects of physostigmine and tacrine in cortical areas deafferented from the nucleus basalis magnocellularis suggest involvement of basalocortical projections to microvessels.
Differentiation Between Dementia With Lewy Bodies And Alzheimer's Disease Using Voxel-Based Morphometry Of Structural MRI: A Multicenter Study.
Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.
Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice.
Discontinuation, efficacy and safety of cholinesterase inhibitors for Alzheimer's disease: a meta-analysis and meta-regression of 44 randomized clinical trials enrolling 16,245 patients.
Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts.
Discorhabdin alkaloids from Antarctic Latrunculia spp. sponges as a new class of cholinesterase inhibitors.
Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
Discovery of 9-phenylacridinediones as highly selective butyrylcholinesterase inhibitors through structure-based virtual screening.
Discovery of Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for Live-Cell and In Vivo Imaging.
Discovery of drug-like acetylcholinesterase inhibitors by rapid virtual screening of a 6.9 million compound database.
Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode.
Discovery of isoalloxazine derivatives as a new class of potential anti-Alzheimer agents and their synthesis.
Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening.
Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.
Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties.
Discovery, biological evaluation and molecular dynamic simulations of butyrylcholinesterase inhibitors through structure-based pharmacophore virtual screening.
Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor.
Disease stage in Alzheimer disease and treatment effects of rivastigmine.
Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation.
Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study.
DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice.
Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report.
Do Cholinesterase Inhibitors Act Primarily on Attention Deficit? A Naturalistic Study in Alzheimer's Disease Patients.
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Donepezil and life expectancy in Alzheimer's disease: A retrospective analysis in the Tajiri Project.
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats.
Donepezil blocks voltage-gated ion channels in rat dissociated hippocampal neurons.
Donepezil dosing strategies: pharmacokinetic considerations.
Donepezil Effects on Hippocampal and Prefrontal Functional Connectivity in Alzheimer's Disease: Preliminary Report.
Donepezil for Alzheimer's disease.
Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation.
Donepezil in low micromolar concentrations modulates voltage-gated potassium currents in pyramidal neurons of rat hippocampus.
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Donepezil in the treatment of patients with Alzheimer's disease.
Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain.
Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones.
Donepezil overdose: a tenfold dosing error.
Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients.
Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
Donepezil use in Alzheimer disease.
Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Donepezil, a cholinesterase inhibitor used in Alzheimer's disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice.
Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.
Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors.
Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.
Donepezil-related toxic hepatitis.
Donepezil: potential neuroprotective and disease-modifying effects.
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.
Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Drug Design of Inhibitors of Alzheimer's Disease (AD): POM and DFT Analyses of Cholinesterase Inhibitory Activity of ?-amino di-Carbonyl Derivatives.
Drug interactions with cholinesterase inhibitors.
Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease.
Drug-induced urinary incontinence.
Drugs and falls in community-dwelling older people: a national veterans study.
Drugs for Alzheimer's disease. Guidelines for prescribing cholinesterase inhibitors in Australia are similar to those in UK.
Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.
Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives.
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease.
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
Duration of therapy with acetylcholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease as reported in the literature.
Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.
Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?
Effect of APOE and CHRNA7 Genotypes on the Cognitive Response to Cholinesterase Inhibitor Treatment at Different Stages of Alzheimer's Disease.
Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Effect of cholinesterase inhibitors on attention.
Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice.
Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Effect of galantamine on platelet functions in healthy elderly people.
Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: an update.
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Effect of in vivo microdialysis of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on the extracellular concentration of acetylcholine in the striatum of anesthetized rats.
Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia.
Effect of MDL 73,745 on acetylcholine and biogenic amine levels in rat cortex.
Effect of neostigmine on the hippocampal noradrenaline release: role of cholinergic receptors.
Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer's Disease.
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease.
Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease.
Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer's Disease.
Effective pharmacologic management of Alzheimer's disease.
Effective treatment of Alzheimer disease and its complications.
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice.
Effectiveness of donepezil, rivastigmine and ({+/-})huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: Comparison with galantamine.
Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review.
Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.
Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo.
Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy.
Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review.
Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimer's Disease: A Review of Recent Clinical Studies.
Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.
Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease.
Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.
Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.
Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study.
Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study.
Effects of metrifonate on impairment of learning and dysfunction of cholinergic neuronal system in basal forebrain-lesioned rats.
Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats-Is there a potential for Alzheimer's disease treatment?
Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia.
Effects of simultaneous administration of desferrioxamine and tacrine in rats.
Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidemic rats.
Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells.
Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats.
Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease.
Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease.
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.
Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients.
Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan.
EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.
Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease.
Emerging links between type 2 diabetes and Alzheimer's disease.
Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease.
Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys.
Enhancement of Fear Extinction Memory and Resistance to Age-Related Cognitive Decline in Butyrylcholinesterase Knockout Mice and (R)-Bambuterol Treated Mice.
Ensemble Molecular Dynamics of a Protein-Ligand Complex: Residual Inhibitor Entropy Enhances Drug Potency in Butyrylcholinesterase.
Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease.
Estimation of neuroprotective effects of Laurocerasus officinalis Roem. (cherry laurel) by in vitro methods
Estimation of plasma tacrine concentrations using an in vitro cholinesterase inhibition assay.
Evaluating Fmoc-amino acids as selective inhibitors of butyrylcholinesterase.
Evaluating the Memory Enhancing Effects of Angelica gigas in Mouse Models of Mild Cognitive Impairments.
Evaluation of Anticholinesterase and Inflammation Inhibitory Activity of Medicinal Mushroom Phellinus pini (Basidiomycetes) Fruiting Bodies.
Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models.
Evaluation of butyrylcholinesterase inhibitory activity by chlorogenic acids and coffee extracts assed in ITC and docking simulation models.
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
Evaluation of salivary acetylcholinesterase and pseudocholinesterase in patients with Alzheimer's disease: A case-control study.
Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.
Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays.
Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
Evidence-based pharmacotherapy of Alzheimer's disease.
Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation.
Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors.
Exploring the halophyte Cistanche phelypaea (L.) Cout as a source of health promoting products: In vitro antioxidant and enzyme inhibitory properties, metabolomic profile and computational studies.
Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes.
Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.
Factors associated with use of medications with potential to impair cognition or cholinesterase inhibitors among Alzheimer's disease patients.
Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease.
Fatal aspiration pneumonia during transition from donepezil to rivastigmine.
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
FDA approves new cholinesterase inhibitor for Alzheimer's disease.
First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease.
Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy.
Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes.
Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people.
For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?
Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.
Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample.
From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
From molecular structure to Alzheimer therapy.
From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions.
Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease.
Functional and subcellular organelle changes in isolated rat and human hepatocytes induced by tetrahydroaminoacridine.
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease.
Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels.
Galantamine for vascular cognitive impairment.
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.
Galantamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and ?-secretase inhibition activities.
Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[ (18)F]Fluoro-A-85380 PET.
Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.
GC/MS Analysis of Alkaloids in Galanthus fosteri Baker and Determination of Its Anticholinesterase Activity.
Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study.
Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: Effects of sex hormone withdrawal.
Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk.
Genoprotective and neuroprotective effects of Daphne gnidium leaf methanol extract, tested on male mice.
Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study.
Growth Hormone Responses to Low-Dose Physostigmine in Elderly vs. Young Women and Men.
Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.
Hemodynamic effects of cholinesterase inhibition in mild Alzheimer's disease.
High Expression Level of Antioxidants and Pharmaceutical Bioactivities of Endophytic Fungus Chaetomium Globosum JN711454.
High-performance liquid chromatography with fast-scanning fluorescence detection and multivariate curve resolution for the efficient determination of galantamine and its main metabolites in serum.
Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study.
Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease.
Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection.
Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease.
Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease.
Homozygosity for the K variant of BCHE gene increases the risk for development of neurofibrillary pathology but not amyloid deposits at young ages.
Honey as the Potential Natural Source of Cholinesterase Inhibitors in Alzheimer's Disease.
How Prolific is Psychotropic Medicines Use in People with Dementia in Australia Within the Community Setting? A Retrospective Analysis.
How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis.
HPLC-MS/MS chemical characterization and biological properties of Origanum onites extracts: a recent insight.
Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro.
Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
Identification and molecular docking study of fish roe-derived peptides as potent BACE 1, AChE, and BChE inhibitors.
Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A.
Identification of the urinary metabolites of tacrine in the rat.
Imaging butyrylcholinesterase activity in Alzheimer's disease.
Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease.
Immobilized cholinesterases capillary reactors on-flow screening of selective inhibitors.
Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.
Immunomodulation by 9-amino-1,2,3,4-tetrahydroacridine (THA): 1. Down-regulation of natural cell-mediated cytotoxicity in vitro.
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.
Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study.
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia.
Impaired spatial learning and suppression of sharp wave ripples by cholinergic activation at the goal location.
Implementation of the Pharmacists' Patient Care Process in a Medicinal Chemistry Course.
Implications of some selected flavonoids towards Alzheimer's disease with the emphasis on cholinesterase inhibition and their bioproduction by metabolic engineering.
Important error in 'systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias' by muayqil and camicioli.
In silico ligand-receptor docking of potentially selective butyrylcholinesterase inhibitors structurally related to the marine natural product debromoflustramine B.
In silico modeling for dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes in Alzheimer's disease.
In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease.
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
In silico, theoretical biointerface analysis and in vitro kinetic analysis of amine compounds interaction with acetylcholinesterase and butyrylcholinesterase.
IN VITRO ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE INHIBITORY POTENTIALS OF JATROPHA GOSSYPIFOLIA PLANT EXTRACTS.
In vitro and in silico analysis of novel astaxanthin-s-allyl cysteine as an inhibitor of butyrylcholinesterase and various globular forms of acetylcholinesterases.
In vitro and in vivo metabolism and inhibitory activities of vasicine, a potent acetylcholinesterase and butyrylcholinesterase inhibitor.
In vitro anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida).
In vitro antioxidant and cholinesterase inhibitory activities of Elatostema papillosum leaves and correlation with their phytochemical profiles: a study relevant to the treatment of Alzheimer's disease.
In Vitro Antioxidant, Anti-Diabetes, Anti-Dementia, and Inflammation Inhibitory Effect of Trametes pubescens Fruiting Body Extracts.
In vitro metabolism of BYZX in human liver microsomes and the structural elucidation of metabolite by liquid chromatography-mass spectrometry method.
In vitro neuroprotective effects of the leaf and fruit extracts of Juglans regia L. (walnut) through enzymes linked to Alzheimer's disease and antioxidant activity.
In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048.
In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Inactivation of cholinesterase induced by non-steroidal anti-inflammatory drugs with horseradish peroxidase: implication for Alzheimer's disease.
Increase in Platelet Immunoglobulin in Alzheimer's Disease is Lowered Following Cholinesterase Inhibitor Treatment: Preliminary Results.
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists.
Increasing rational use of cholinesterase inhibitors for Alzheimer's disease in Brazil: public health strategy combining guideline with peer-review of prescriptions.
Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing.
Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities.
Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
Influence of different extraction techniques on the chemical profile and biological properties of Anthemis cotula L.: Multifunctional aspects for potential pharmaceutical applications.
Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease.
Influence of tacrine on dopamine-induced reactions of the gastric smooth muscle of rats.
Inhibition of ?-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure-activity relationship with a strong BBB permeability.
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies.
Inhibition of cholinesterase by essential oil from food plant.
Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
Inhibition of murine cytochrome P4501A by tacrine: in vitro studies.
Inhibition of two different cholinesterases by tacrine.
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Inhibitory evaluation of oligonol on ?-glucosidase, protein tyrosine phosphatase 1B, cholinesterase, and ?-secretase 1 related to diabetes and Alzheimer's disease.
Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease.
Innovations: geriatric psychiatry: diagnosis and treatment of neuropsychiatric symptoms in Alzheimer's disease.
Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study.
Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
Interaction between estrogen receptor-alpha and butyrylcholinesterase genes modulates Alzheimer's disease risk.
Interaction of Exogenous Butyrylcholinesterase with ?-Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain.
Intra-operative bradycardia in a patient with Alzheimer's disease treated with two cholinesterase inhibitors.
Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease.
Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.
Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications.
Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.
Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition?
Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?
Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?
Is rivastigmine safe as pretreatment against nerve agents poisoning? A pharmacological, physiological and cognitive assessment in healthy young adult volunteers.
Is the risk of developing Alzheimer's disease really higher in rural areas? A multilevel longitudinal study of 261,669 Australians aged 45 years and older tracked over 11 years.
Isocorilagin, a cholinesterase inhibitor from Phyllanthus niruri.
Isolation, crystal structure determination and cholinesterase inhibitory potential of isotalatizidine hydrate from Delphinium denudatum.
Isolation, identification, and quantification of Pentylcurcumene from Geophila repens: A new class of cholinesterase inhibitor for Alzheimer's disease.
Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability.
Isothiocyanates: cholinesterase inhibiting, antioxidant, and anti-inflammatory activity.
Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Juliflorine: a potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimer's disease therapy.
Kinetics and computational analysis of cholinesterase inhibition by REVERC3, a bisdemethoxycurcumin-rich Curcuma longa extract: Relevance to the treatment of Alzheimer's disease.
Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-D-sedoheptulose derived from Corni fructus as cholinesterase and ?-secretase 1 inhibitors.
Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kinetics of Torpedo californica Acetylcholinesterase Inhibition by Bisnorcymserine and Crystal Structure of the Complex with its Leaving Group.
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion.
Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors.
Lending a helping eye: artists in residence at a memory clinic.
Lepidine B from Lepidium Sativum Seeds as Multi-Functional Anti-Alzheimer's Disease Agent: In Vitro and In Silico Studies.
Lifestyle improvement or anti-dementia drugs in Alzheimer's disease: A comment on Kapaki et al. The cognitive effects of cholinesterase inhibitor treatment in every-day practice. Curr Med Res Opin 2005; 21(6): 871-5.
Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease.
Long-term cholinesterase inhibitor therapy for Alzheimer's disease: implications for long-term care.
Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care Physician.
Long-term cholinesterase inhibitor treatment of Alzheimer's disease.
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting.
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer's disease.
Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.
Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.
Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease.
Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.
Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease.
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.
Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease.
Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation, Reduced Ability to Perform Basic Activities of Daily Living, and Low Body Mass Index in Patients with Progressed Alzheimer's Disease.
M1 agonists as a potential disease-modifying therapy for Alzheimer's disease.
Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.
Melatonin as a structural template in the development of novel drugs for neurodegenerative disorders.
Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review.
Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.
Memantine combined with an acetyl cholinesterase inhibitor - hope for the future?
Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
Memantine for the treatment of dementia.
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy.
Memantine treatment for Japanese patients with moderate to severe Alzheimer's disease: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease.
Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.
Memory loss.
Mesial Frontal Lobe Infarction Presenting as Pisa Syndrome.
Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Metabolite Profiling by Hyphenated Liquid Chromatographic Mass Spectrometric Technique (HPLC-DAD-ESI-Q-TOF-MS/MS) and Neurobiological Potential of Haplophyllum sahinii and H. vulcanicum Extracts.
Methanesulfonyl fluoride (MSF) blocks scopolamine-induced amnesia in rats.
Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease.
Metrifonate and tacrine: a comparative study on their effect on acetylcholine dynamics in mouse brain.
Metrifonate decreases sI(AHP) in CA1 pyramidal neurons in vitro.
Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits.
Metrifonate: a new agent for the treatment of Alzheimer's disease.
Metrifonate: update on a new antidementia agent.
Microwave-assisted synthesis of novel purine nucleosides as selective cholinesterase inhibitors.
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
Modulation of brain acetylcholine levels with cholinesterase inhibitors as a treatment of Alzheimer disease.
Modulation of cholinergic transmission enhances excitability of hippocampal pyramidal neurons and ameliorates learning impairments in aging animals.
Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory.
Modulation of N-methyl-D-aspartate receptors by donepezil in rat cortical neurons.
Modulatory effect of caffeic acid on cholinesterases inhibitory properties of donepezil.
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Molecular design and synthesis of novel peptides from amphibians skin acting as inhibitors of cholinesterase enzymes.
Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and ?-amyloid inhibitors for Alzheimer's disease.
Molecular Dynamics Revealing a Detour-Forward Release Mechanism of Tacrine: Implication for the Specific Binding Characteristics in Butyrylcholinesterase.
Molecular forms of cholinesterases in CSF of Alzheimer's disease/senile dementia of Alzheimer type patients and matched neurological controls.
Molecular modeling and in vitro approaches towards cholinesterase inhibitory effect of some natural xanthohumol, naringenin, and acyl phloroglucinol derivatives.
Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
Multi-target approach for Alzheimer's disease treatment: computational biomolecular modeling of cholinesterase enzymes with a novel 4-N-phenylaminoquinoline derivative reveal promising potentials.
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Multifunctional Activity of Polyphenolic Compounds Associated with a Potential for Alzheimer's Disease Therapy from Ecklonia cava.
Multifunctional cholinesterase inhibitors for Alzheimer's disease: Synthesis, biological evaluations, and docking studies of o/p-propoxyphenylsubstituted-1H-benzimidazole derivatives.
Multifunctional Donepezil Analogues as Cholinesterase and BACE1 Inhibitors.
Multifunctional tacrine-flavonoid hybrids with cholinergic, ?-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.
Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains.
Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Multitarget therapeutic strategies for Alzheimer's disease.
Muscarinic, Ca(++) antagonist and specific butyrylcholinesterase inhibitory activity of dried ginger extract might explain its use in dementia.
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
N-[18F]fluoroethylpiperidin-4-ylmethyl butyrate: a novel radiotracer for quantifying brain butyrylcholinesterase activity by positron emission tomography.
Natural cholinesterase inhibitors from marine organisms.
Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans.
Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease.
Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Neuropharmacological effect of Mangiferin on brain cholinesterase and brain biogenic amines in the management of Alzheimer's disease.
Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease.
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and ?-amyloid in aging and Alzheimer's disease.
Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Neuroprotective Potential of Novel Multi-Targeted Isoalloxazine Derivatives in Rodent Models of Alzheimer's Disease Through Activation of Canonical Wnt/?-Catenin Signalling Pathway.
Neuroprotective Role of Novel Triazine Derivatives by Activating Wnt/? Catenin Signaling Pathway in Rodent Models of Alzheimer's Disease.
Neuropsychological rehabilitation program and behavioral disturbances in early-stage Alzheimer patients.
Neurotransmitter Imbalance in the Brain and Alzheimer's Disease Pathology.
New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease.
New 4-N-phenylaminoquinoline derivatives as antioxidant, metal chelating and cholinesterase inhibitors for Alzheimer's disease.
New anthrarobin acyl derivatives as butyrylcholinesterase inhibitors: synthesis, in vitro and in silico studies.
New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives.
New Drug Research and Development for Alzheimer's Pathology: Present and Prospect.
New drugs for Alzheimer's disease.
New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition.
New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer's Disease Treatment.
New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.
New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment.
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors?
Newly developed drugs for Alzheimer's disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission.
NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?
Nicotine and sensory memory in Alzheimer's disease: an event-related potential study.
Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of "impaired" cholinergic presynaptic function.
No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese.
No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease.
No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases.
No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.
Non-anticholinesterase, non-cholinergic effect of tacrine on gastrointestinal smooth muscle tissues of rat.
Non-cholinergic strategies for treating and preventing Alzheimer's disease.
Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease.
Nontoxic and neuroprotective ?-naphthotacrines for Alzheimer's disease.
Nose-to-brain delivery of tacrine.
Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Novel AChE and BChE Inhibitors Using Combined Virtual Screening, Text mining and In Vitro Binding Assays.
Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
Novel carbamate derivatives as selective butyrylcholinesterase inhibitors.
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.
Novel inhibitors with sulfamethazine backbone: synthesis and biological study of multi-target cholinesterases and ?-glucosidase inhibitors.
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation.
Novel N-benzylpiperidine carboxamide derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
Novel pyridazinone derivatives as butyrylcholinesterase inhibitors.
Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.
Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer's Disease.
Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease.
Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer's compounds: In vitro and in vivo biological evaluation and docking study.
Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and ?-secretase inhibition activities.
Nutraceutical Potential of Phenolics from 'Brava' and 'Mansa' Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in Comparison with Those of 'Picual' and 'Cornicabra'.
Odor Identification Impairment and Change with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment.
Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease.
Older patients are still under-represented in clinical trials of Alzheimer's disease.
Omega-3 Fatty Acids Increase Amyloid-? Immunity, Energy, and Circadian Rhythm for Cognitive Protection of Alzheimer's Disease Patients Beyond Cholinesterase Inhibitors.
On the active site for hydrolysis of aryl amides and choline esters by human cholinesterases.
Oral donepezil reduces hypersensitivity after nerve injury by a spinal muscarinic receptor mechanism.
Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease.
Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.
Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors.
Outlining In Vitro and In Silico Cholinesterase Inhibitory Activity of Twenty-Four Natural Products of Various Chemical Classes: Smilagenin, Kokusaginine, and Methyl Rosmarinate as Emboldening Inhibitors.
Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study.
Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment.
Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.
Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Pelargonidin improves memory deficit in amyloid ?25-35 rat model of Alzheimer's disease by inhibition of glial activation, cholinesterase, and oxidative stress.
Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine.
Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer's disease.
Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
Persistence with cholinesterase inhibitor treatment in Alzheimer's disease.
Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer's disease (AD).
Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease.
Pharmacodynamic and early clinical studies with velnacrine.
Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects.
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.
Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimer's Disease Pharmacogenetics.
Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.
Pharmacogenomics and therapeutic prospects in Alzheimer's disease.
Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors.
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
Pharmacokinetic rationale for the rivastigmine patch.
Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease.
Pharmacokinetics and pharmacodynamics of metrifonate in humans.
Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.
Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.
Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.
Pharmacokinetics, excretion and metabolites analysis of DL0410, a dual?acting cholinesterase inhibitor and histamine?3 receptor antagonist.
Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
Pharmacological basis of drug therapy of Alzheimer's disease.
Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.
Pharmacological Evaluation and Docking Studies of 3-Thiadiazolyl- and Thioxo-1,2,4-triazolylcoumarin Derivatives as Cholinesterase Inhibitors.
Pharmacological strategies for the prevention of Alzheimer's disease.
Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs.
Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics.
Pharmacological treatment of cognitive deficits in Alzheimer's disease.
Pharmacology and clinical efficacy of cholinesterase inhibitors.
Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Pharmacophore based 3DQSAR of phenothiazines as specific human butyrylcholinesterase inhibitors for treatment of Alzheimer's disease.
Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer's disease.
Pharmacophore-based virtual screening and molecular docking to identify promising dual inhibitors of human acetylcholinesterase and butyrylcholinesterase.
Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors.
Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
Phenolic Profiles, Antioxidant, and Inhibitory Activities of Kadsura heteroclita (Roxb.) Craib and Kadsura coccinea (Lem.) A.C. Sm.
Phthalimide-Derived N-Benzylpyridinium Halides Targeting Cholinesterases: Synthesis and Bioactivity of New Potential Anti-Alzheimer's Disease Agents.
Physicians' efficacy requirements for prescribing medications to persons with Alzheimer's disease*.
Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults.
Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain.
Phytochemical Analysis and Cholinesterase Inhibitory and Antioxidant Activities of Enhydra fluctuans Relevant in the Management of Alzheimer's Disease.
Phytochemical Analysis and Evaluation of Biological Activity of Lawsonia inermis Seeds Related to Alzheimer's Disease.
Phytochemical profile and anticholinesterase and antimicrobial activities of supercritical versus conventional extracts of Satureja montana.
Phytochemical profile of a blend of black chokeberry and lemon juice with cholinesterase inhibitory effect and antioxidant potential
Phytochemical profile of a blend of black chokeberry and lemon juice with cholinesterase inhibitory effect and antioxidant potential.
Phytomedicines as potential inhibitors of ? amyloid aggregation: significance to Alzheimer's disease.
Plant-Based Synthesis of Zinc Oxide Nanoparticles (ZnO-NPs) Using Aqueous Leaf Extract of Aquilegia pubiflora: Their Antiproliferative Activity against HepG2 Cells Inducing Reactive Oxygen Species and Other In Vitro Properties.
Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease.
Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer's disease and dementia with Lewy bodies?
Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging.
Plasma Cholinesterase Activity in Alzheimer's Disease.
Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer's disease.
Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia.
Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Poststroke dementia in the elderly.
Potential alternatives to current cholinesterase inhibitors: an in silico drug repurposing approach.
Potential anti-cholinesterase and ?-site amyloid precursor protein cleaving enzyme 1 inhibitory activities of cornuside and gallotannins from Cornus officinalis fruits.
Potential for intermittent stimulation of nucleus basalis of Meynert to impact treatment of alzheimer's disease.
Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Potential Nutraceutical Properties of Leaves from Several Commonly Cultivated Plants.
Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer's disease patients.
Potentially procholinergic effects of medications commonly used in older adults.
Practical Principles for the Management of Alzheimer's Disease.
Pratensein attenuates A?-induced cognitive deficits in rats: Enhancement of synaptic plasticity and cholinergic function.
Precision medicine in Alzheimer's disease: An origami paper-based electrochemical device for cholinesterase inhibitors.
Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.
Prediction models for assessing long-term outcome in Alzheimer's disease: a review.
Predictions of BuChE inhibitors using support vector machine and naive Bayesian classification techniques in drug discovery.
Predictive Factors of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease and Mixed Dementia: A One-Year Naturalistic Study.
Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.
Predictors of long-term cognitive outcome in Alzheimer's disease.
Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?
Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.
Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.
Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease.
Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles.
Prescribing Cholinesterase Inhibitors for Alzheimer Disease: Timing Matters.
Prescribing trends in cognition enhancing drugs in Australia.
Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy.
Present and future of Alzheimer therapy.
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
Prevalence of positive carotid sinus massage and related risk of syncope in patients with Alzheimer's disease.
Preventing Alzheimer's disease : separating fact from fiction.
Preventive role of Indian black pepper in animal models of Alzheimer's disease.
Profiling Auspicious Butyrylcholinesterase Inhibitory Activity of Two Herbal Molecules: Hyperforin and Hyuganin C.
Progress in Alzheimer's disease drug discovery: an update.
Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors.
Progress in drug development for Alzheimer's disease: An overview in relation to mitochondrial energy metabolism.
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
Prospective Application of Two New Pyridine-Based Zinc (II) Amide Carboxylate in Management of Alzheimer's Disease: Synthesis, Characterization, Computational and in vitro Approaches.
Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease.
Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.
Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-?-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.
Pteryxin - A promising butyrylcholinesterase-inhibiting coumarin derivative from Mutellina purpurea.
Purification of Acetylcholinesterase by 9-Amino-1,2,3,4-tetrahydroacridine from Human Erythrocytes.
Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists.
Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast ?-glucosidase, acetylcholinesterase and butyrylcholinesterase.
Quality of life and cholinesterase inhibitors: a qualitative study of patients with Alzheimer's Disease and their carers.
Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.
Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose.
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer's Disease Therapy.
Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity.
Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.
Rapid and sensitive detection of the inhibitive activities of acetyl- and butyryl-cholinesterases inhibitors by UPLC-ESI-MS/MS.
Rapid discovery of a selective butyrylcholinesterase inhibitor using structure-based virtual screening.
Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.
Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis.
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity.
Rationale for transdermal drug administration in Alzheimer disease.
Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's.
Rationalizing therapeutic approaches in Alzheimer's disease.
RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?
rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.
Reaching the population with dementia drugs: what are the challenges?
Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial.
Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program.
Recent developments in tau-based therapeutics for neurodegenerative diseases.
Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease.
Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.
Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease.
Regulators of cholinergic signaling in disorders of the central nervous system.
Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease.
Relation between cholinesterase inhibitor and Pisa syndrome.
Relationship between cholinesterase inhibitors and Pisa syndrome in a cohort of five French patients with Alzheimer's disease.
Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
Relationship between Pisa syndrome and cholinesterase inhibitor use for elderly adults with Alzheimer's disease.
Relative tolerability of Alzheimer's disease treatments.
Removal of Drugs for Alzheimer's Disease from the List of Reimbursable Drugs in France: Analysis of Change in Drug Use, Disease Management and Cognition Using the National Alzheimer Data Bank (BNA).
Report of ten years' activity in an Alzheimer's disease assessment unit.
Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence?
Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.
Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation.
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.
Response to letter from Garcia and colleagues on cholinesterase inhibitors and Alzheimer's disease outcomes.
Responses of hypothalamo-pituitary-adrenal axis to a cholinesterase inhibitor.
Responses to donepezil in Alzheimer's disease and Parkinson's disease.
Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene.
Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study.
Retrospective Study on the Benefits of Combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: The MEMAGE Study.
Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.
Reversal of memory deficits by Coriandrum sativum leaves in mice.
Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.
Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease.
Review: cholinesterase inhibitors may be effective in Alzheimer disease.
Review: Cholinesterase inhibitors may be effective in Alzheimer's disease.
Review: cholinesterase inhibitors reduce burden and care time for informal carers of people with Alzheimer's disease.
Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment.
Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Rivastigmine for Alzheimer's disease.
Rivastigmine for vascular cognitive impairment.
Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.
Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease.
Rivastigmine in Alzheimer disease: efficacy over two years.
Rivastigmine in Parkinson's disease dementia.
Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Rivastigmine modifies the ?-secretase pathway and potentially early Alzheimer's disease.
Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis.
Role of Cholinesterase Inhibitors in Managing Behavioral Problems in Alzheimer's Disease.
Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease.
Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study.
Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Savings from sub-groups?: policy guidance and Alzheimer's disease treatments.
Scocycamides, a Pair of Macrocyclic Dicaffeoylspermidines with Butyrylcholinesterase Inhibition and Antioxidation Activity from the Roots of Scopolia tangutica.
Scouting around 1,2,3,4-Tetrahydrochromeno[3,2-c]pyridin-10-ones for Single- and Multitarget Ligands Directed towards Relevant Alzheimer's Targets.
Screening and identification of secondary metabolites in the bark of Bauhinia variegata to treat Alzheimer's disease by using molecular docking and molecular dynamics simulations.
Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force.
Seizures in an Alzheimer's disease patient as a complication of colonoscopy premedication with meperidine.
Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce amyloid-? Ex Vivo Activation of Peripheral Chemo-Cytokines from Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-Inflammatory Pathway.
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.
Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Selective in vitro and in silico butyrylcholinesterase inhibitory activity of diterpenes and rosmarinic acid isolated from Perovskia atriplicifolia Benth. and Salvia glutinosa L.
Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer's Disease Mouse Model.
Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.
Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors.
Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
Short- and long-term efficacy of cholinesterase inhibitors in older adults with alzheimer's disease and mixed dementia: results of a 21-month observational study.
Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer's Disease: A "Real World" Study.
Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement.
Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors.
Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study.
Simultaneous release of glutamate and acetylcholine from single magnocellular "cholinergic" basal forebrain neurons.
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.
Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task.
Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease.
Species- and concentration-dependent differences of Acetyl- and Butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Spiro Heterocyclic Compounds as Potential Anti-Alzheimer agents (Part 2): their Metal Chelation Capacity, POM Analyses and DFT Studies.
Spotlight on cerebrolysin in dementia.
Spotlight on rivastigmine transdermal patch†: in dementia of the Alzheimer's type.
Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo.
Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients.
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism.
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease.
Structure-activity relationship, in vitro and in vivo evaluation of novel dienyl sulphonyl fluorides as selective BuChE inhibitors for the treatment of Alzheimer's disease.
Structure-based virtual screening leading to discovery of highly selective butyrylcholinesterase inhibitors with solanaceous alkaloid scaffolds.
Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis.
Subchronic use of rivastigmine increases procognitive flexibility across multimodal behavioral tasks in healthy male rats.
Suboptimal Baseline Serum Vitamin B12 Is Associated With Cognitive Decline in People With Alzheimer's Disease Undergoing Cholinesterase Inhibitor Treatment.
Suicide in two patients with a diagnosis of probable Alzheimer disease.
Switching cholinesterase inhibitors in older adults with dementia.
Switching cholinesterase inhibitors in patients with Alzheimer's disease.
Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France.
Syncope with cholinesterase inhibitors.
Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease.
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease.
Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening.
Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.
Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and A?1-42 Aggregation Inhibitors for Alzheimer's Disease Therapy.
Synthesis and biological evaluation of 3-arylbenzofuranone derivatives as potential anti-Alzheimer's disease agents.
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer's Disease.
Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.
Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahydroacridin-9-amine-new tacrine derivate with cholinergic properties.
Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment.
Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
Synthesis and In Vitro Screening of Novel Heterocyclic ?-d-Gluco- and ?-d-Galactoconjugates as Butyrylcholinesterase Inhibitors.
Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer.
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology.
Synthesis and Preliminary Evaluation of Piperidinyl and Pyrrolidinyl Iodobenzoates as Imaging Agents for Butyrylcholinesterase.
Synthesis and structure-activity relationship study of tacrine-based pyrano[2,3-c]pyrazoles targeting AChE/BuChE and 15-LOX.
Synthesis of 5-methyl-2,4-dihydro-3H-1,2,4-triazole-3-one's aryl Schiff base derivatives and investigation of carbonic anhydrase and cholinesterase (AChE, BuChE) inhibitory properties.
Synthesis of 9-Aminoacridine Derivatives as Anti-Alzheimer Agents.
Synthesis of carbon-11-labeled bivalent ?-carbolines as new PET agents for imaging of cholinesterase in Alzheimer's disease.
Synthesis of donepezil-based multifunctional agents for the treatment of Alzheimer's disease.
Synthesis of N-phenylsulfonamide derivatives and investigation of some esterase enzymes inhibiting properties.
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Synthesis of novel purine nucleosides towards a selective inhibition of human butyrylcholinesterase.
Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics.
Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.
Synthesis, Characterization, and Inhibition Study of Novel Substituted Phenylureido Sulfaguanidine Derivatives as ?-Glycosidase and Cholinesterase Inhibitors.
Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases.
Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease.
Synthesis, molecular docking, and biological activity of 2-vinyl chromones: Toward selective butyrylcholinesterase inhibitors for potential Alzheimer's disease therapeutics.
Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and A? aggregation.
Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.
Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias.
Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer's Disease, Vascular Dementia, or Mixed Dementia.
Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia.
Tackling dementia in patients with Parkinson's disease.
Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells.
Tacrine hydrochloride treatment IND: methods for rapid physician and patient enrollment and data retrieval.
Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography.
Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes.
Tacrine therapy for the dementia of Alzheimer's disease.
Tacrine, an Oral Acetylcholinesterase Inhibitor, Induced Hepatic Oxidative Damage, Which Was Blocked by Liquiritigenin through GSK3-beta Inhibition.
Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.
Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.
Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil.
Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease.
Ten years of cholinesterase inhibitors.
Terpenes and Phenylpropanoids as Acetyl- and Butyrylcholinesterase Inhibitors: A Comparative Study.
Tetrahydroaminoacridine block of N-methyl-D-aspartate-activated cation channels in cultured hippocampal neurons.
Tetrahydroaminoacridine improves the recency effect in Alzheimer's disease.
THA disrupts mismatch negativity in Alzheimer disease.
THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease.
The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial.
The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression.
The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: Interim Results after Two Years of Treatment.
The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: Interim results.
The Association Between the Use of Cholinesterase Inhibitors and Cardiovascular Events Among Older Patients With Alzheimer Disease.
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
The benefits of cholinesterase inhibitors: managing the behavioral and neuropsychiatric symptoms of Alzheimer's disease.
The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations.
The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.
The butyrylcholinesterase K variant confers structurally-derived risks for Alzheimer's pathology.
The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women.
The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme.
The butyrylcholinesterase knockout mouse a research tool in the study of drug sensitivity, bio-distribution, obesity and Alzheimer's disease.
The cerebrovascular effects of physostigmine are not mediated through the substantia innominata.
The cerebrovascular role of the cholinergic neural system in Alzheimer's disease.
The cholinergic deficiency syndrome and its therapeutic implications.
The cholinergic hypothesis of Alzheimer's disease: a review of progress.
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
The cholinesterase inhibitors.
The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study.
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
The cognitive effects of cholinesterase inhibitor treatment in every-day practice.
The coming problem of HIV-associated Alzheimer's disease.
The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?
The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.
The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.
The effect of APOE ?4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging.
The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort.
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.
The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques.
The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate.
The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials.
The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex.
The effects of donepezil on quantitative EEG in patients with Alzheimer's disease.
The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease.
The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.
The efficacy and safety of memantine for the treatment of Alzheimer's disease.
The evidence for the efficacy of cholinesterase inhibitors in the treatment of Alzheimer's disease is convincing.
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.
The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer's Disease.
The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.
The impact of some phenolic compounds on serum acetylcholinesterase: kinetic analysis of an enzyme/inhibitor interaction and molecular docking study.
The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
The International Psychogeriatric Association--ninth congress. 15-20 August 1999, Vancouver, Canada.
The interplay of neurotransmitters in Alzheimer's disease.
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
The modulatory role of prime identified compounds in Geophila repens in mitigating scopolamine-induced neurotoxicity in experimental rats of Alzheimer's disease via attenuation of cholinesterase, ?-secretase, MAPt levels and inhibition of oxidative stress imparts inflammation.
The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease.
The neuroprotective mechanism of action of the multimodal drug ladostigil.
The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
The next generation of cholinesterase inhibitors.
The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity.
The pharmacist's role in managing patients with Alzheimer's disease.
The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.
The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.
The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient.
The ratio of acetylcholinesterase to butyrylcholinesterase influences the specificity of assays for each enzyme in human brain.
The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
The response of the autonomic nervous system to the cholinesterase inhibitor, donepezil.
The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis.
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease.
The safety and tolerability of donepezil in patients with Alzheimer's disease.
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
The second Leicester survey of memory clinics in the British Isles.
The Serum Protein and Lipid Oxidation Marker Levels in Alzheimer's Disease and Effects of Cholinesterase Inhibitors and Antipsychotic Drugs Therapy.
The significance of the activity of CSF cholinesterases in dementias.
The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease.
The use of atypical antipsychotics in nursing homes.
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.
The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.
The use of herbal medicine in Alzheimer's disease-a systematic review.
The utility of muscarinic agonists in the treatment of Alzheimer's disease.
Thioesters for the in vitro evaluation of agents to image brain cholinesterases.
Thyroid function in patients with Alzheimer's disease treated with cholinesterase inhibitors.
To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease.
Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.
Traditional Chinese medicines and Alzheimer's disease.
Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.
Treating Alzheimer's disease with cholinesterase inhibitors: what have we learned so far?
Treating Alzheimer's disease: do clinical trial methods produce unnecessary practitioner dilemmas?
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.
Treatment effects of EGb 761 and cholinesterase inhibitors--why available studies do not demonstrate superiority of the latter.
Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer's disease: a longitudinal functional MRI study.
Treatment of advanced Alzheimer's disease with cholinesterase inhibitors.
Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants.
Treatment of Alzheimer's disease with cholinesterase inhibitors.
Treatment of Alzheimer's disease. New developments.
Treatment of attention deficits in neurological disorders.
Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Treatment of Mild Cognitive Impairment.
Treatment of psychosis and dementia in Parkinson's disease.
Treatment of typical Charles Bonnet syndrome with donepezil.
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions.
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.
Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study.
Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer's disease dispensed by the Brazilian public health system - 2008 to 2014: a nation-wide analysis.
Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors.
Trospium and cognition in patients with late onset Alzheimer disease.
Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease.
TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer disease patients.
Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients.
Update on rivastigmine.
Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Use of artificial networks in clinical trials: a pilot study to predict responsiveness to donepezil in Alzheimer's disease.
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Use of cholinesterase inhibitors in Alzheimer's disease.
Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.
Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.
Use of Cholinesterase Inhibitors Increases Initiation of Urinary Anticholinergics in Persons with Alzheimer's Disease.
Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
Using a distribution-based approach and systematic review methods to derive minimum clinically important differences.
Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups.
Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease.
Utilization of Antihypertensives, Antidepressants, Antipsychotics, and Hormones in Alzheimer Disease.
Utilizing combination therapy in the treatment of Alzheimer's disease.
Velnacrine for Alzheimer's disease.
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures.
What are the treatment options for patients with severe Alzheimer's disease?
What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?
Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.
Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties.
Withanolides: Biologically Active Constituents in the Treatment of Alzheimer Disease.
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]
[Access to medicines for Alzheimer's disease provided by the Brazilian Unified National Health System in Minas Gerais State, Brazil].
[Advances in the therapy of dementia.]
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko]
[Alzheimer's disease and cholinesterase]
[Anticholinesterases; peripheral and central effects].
[Antidementia drugs - response or non-response?]
[Autosomal dominant Alzheimer's disease. Study of a Moroccan family]
[Biological therapies of behavioral and psychological symptoms of dementia: update and prospects]
[Cardiovascular effects of cholinesterase inhibitors in Alzheimer's disease]
[Changes in butyrylcholinesterase activity in patients with Alzheimer disease treated with acetylcholinesterase inhibitors.]
[Changing the anticholinesterase in Alzheimer's disease]
[Cholinergic deficiency syndrome as an indicator for the cholinesterase inhibitors]
[Cholinesterase activity assays and their use in the diagnosis of various pathological states including poisoning by neurotoxic agents].
[Cholinesterase inhibitor therapy in long term care settings]
[Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies]
[Cholinesterase inhibitors and depression in the elderly]
[Cholinesterase inhibitors for Alzheimer disease: preliminary recommendations for treatment. Dutch Society for Psychiatry, Section of Geriatric Psychiatry]
[Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for the practice]
[Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for treatment]
[Cholinesterase inhibitors in Alzheimer disease; preliminary recommendations for the practice]
[Cholinesterase inhibitors in Alzheimer's disease]
[Cholinesterase inhibitors in dementia: the precarious balance between efficacy and safety]
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]
[Cholinesterase inhibitors in the treatment of mixed dementia].
[Dementia and Alzheimer disease. Early detection and treatment]
[Dementia-current knowledge and significance for ENT specialists]
[Detection of Alzheimer's disease in general medicine: preliminary results of a Sentinelles general practitioner's network survey]
[Donepezil in patients with Alzheimer's disease--a critical appraisal of the AD2000 study]
[Drug therapy for Alzheimer's disease]
[Gerontology]
[Inhibitory effects of sinapine on activity of acetylcholinesterase in cerebral homogenate and blood serum of rats]
[Interaction of donepezil and muscular blockers in Alzheimer's disease]
[Medical treatment of Alzheimer's disease]
[Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs]
[Mortality-associated factors in patients with Alzheimer's disease treated with galantamine]
[Neuropsychological assessment in the diagnosis and differential diagnosis of fronto-temporal dementia.]
[New therapeutic options in Alzheimer's disease]
[Newly approved drugs for Alzheimer disease: effectiveness and limitation].
[Nicotinic acetylcholine receptor in Alzheimer's disease].
[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]
[Perspective of dementia therapy]
[Posterior cortical atrophy. Pathology, diagnosis and treatment of a rare form of dementia].
[Prescription of cholinesterase inhibitors in Alzheimer's disease in France in 2000-2001: an assessment of compliance with national guidelines for diagnosis and follow-up]
[Present trends in the development of drugs within the cholinesterase inhibitor group as therapeutic agents for Alzheimer's disease]
[Problems and questions of pharmacological therapy of Alzheimer's disease with cholinesterase inhibitors]
[Quality of life and dementia. I. Model of assessment of wellbeing in dementia patients]
[Relation between Pisa syndrome and choline esterase inhibitors in a cohort of Alzheimer's disease patients]
[Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)]
[Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia.]
[Study on the activity of cholinesterase and its distribution in molecular form in the cerebrospinal fluid of patients with Alzheimer's disease, a possible diagnostic marker?]
[Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]
[The clinical relevance of memantine use]
[The effect of a cholinesterase inhibitor on the vitality in Alzheimer disease]
[The efficacy of donepezil in Alzheimer's disease]
[Treatment for non-cognitive symptoms in Alzheimer's disease]
[Treatment of Alzheimer's disease according to the S3 guidelines on dementia. Choline esterase inhibitors for all and for ever?].
[Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?]
[Treatment of dementia with Lewy bodies]
[Treatment of dementia].
[Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)]
[Updated Dementia guideline: reflections from primary care].
[Use of cholinesterase inhibitors in Alzheimer disease]
Amblyopia
Donepezil Does Not Enhance Perceptual Learning in Adults with Amblyopia: A Pilot Study.
Amebiasis
THE SERUM CHOLINESTERASE LEVELS IN AMOEBIASIS.
Amnesia
Ameliorative effect of deoxyvasicine on scopolamine-induced cognitive dysfunction by restoration of cholinergic function in mice.
Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction.
An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.
Characterization of the effects of scopolamine on the habituation of exploratory activity: differential effects of oxotremorine and physostigmine.
Comparison of three different extracts of Centella asiatica for anti-amnesic, antioxidant and anticholinergic activities: in vitro and in vivo study.
Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice.
Donepezil abolishes anticholinergic activity in a patient with amnesia.
Effects of a new synthetic butyrylcholinesterase inhibitor, HBU-39, on cell proliferation and neuroblast differentiation in the hippocampal dentate gyrus in a scopolamine-induced amnesia animal model.
Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats.
FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats.
Long-lasting antiamnesic effect of a novel anticholinesterase inhibitor (MF268).
Role of cholinergic and GABAergic neuronal systems in cycloheximide-induced amnesia in mice.
Synthesis and evaluation of novel 4-[(3H,3aH,6aH)-3-phenyl)-4,6-dioxo-2-phenyldihydro-2H-pyrrolo[3,4-d]isoxazol-5(3H,6H,6aH)-yl]benzoic acid derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents.
Amyloidosis
Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity.
Amyotrophic Lateral Sclerosis
Acetylcholinesterase and ATPases in motor neuron degenerative diseases.
Cholinesterase activity of whole blood and plasma in amyotrophic lateral sclerosis.
Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine.
Anaphylaxis
PLASMA PHOSPHATASE, CHOLINESTERASE AND PEPTONASE IN ANAPHYLACTIC SHOCK.
[Iodine 131 with autography, hyperglycemia, cholinesterase, metabolism, thiomidil, anaphylactic shock, immunisation in hibernation.]
[On changes of cholinesterase activity in the blood of the rabbit by sensitization and anaphylactic shock.]
[Radioactive iodine with autography, hyperglycemia, cholinesterase, metabolism, thiomidil, anaphylactic shock, and immunization in hibernation.]
[Role of cholinesterase in the mechanism of certain phenomena of anaphylactic shock.]
[Variations of the cholinesterase power of the serum during anaphylactic shock and asthmatic attack artificially induced by acetylcholine and histamine aerosols.]
Anemia
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
Analysis of functional abnormalities uncovered during preoperative evaluation of donor candidates for living-related liver transplantation.
Anemia: an indicator for malnutrition in the elderly.
ERYTHROCYTE CHOLINESTERASE ACTIVITY IN HEMOLYTIC ANEMIAS.
Erythrocyte cholinesterase activity in normal pregnancy and in megaloblastic and other anemias of pregnancy and the puerperium.
Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.
Plasma fibrinogen, cholinesterase activity, and anemia: utility of fibrinogen in multiphasic screening and in assessing the activity of diseases.
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
The cholinesterase of erythrocytes in anemias.
[Erythrocyte cholinesterase in neoplastic anemia]
[Factors for the onset of and the exacerbation of tuberculosis. 4. Clinical factors related to the onset and exacerbation of tuberculosis. b. Middle-aged and elderly patients]
[Research in the relation between the defense action of certain antianemic substances (vitamin B12, pteroylglutamic acid) and the cholinesterase effect of the serum in experimental anemia of the rat].
Anemia, Aplastic
GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol.
Anemia, Hypochromic
[Endoscopic diagnosis of colonic tuberculosis]
Anemia, Pernicious
A study of cholinesterase activity of the blood of patients with pernicious anemia.
CHOLINE ESTERASE OF BLOOD CELLS AND PLASMA IN BLOOD DYSCRASIAS, WITH SPECIAL REFERENCE TO PERNICIOUS ANEMIA.
[Cholinesterase in the plasma, erythrocytes and whole blood in pernicious anemia and leukemia.]
Anencephaly
Ratio of immunochemically determined amniotic fluid acetylcholinesterase to butyrylcholinesterase in the differential diagnosis of fetal abnormalities.
Aneurysm
Activity of enzymes with different subcellular localization in the blood plasma of patients with aortic aneurysm.
Cholinergic treatment of amnesia following basal forebrain lesion due to aneurysm rupture--an open-label pilot study.
Angina Pectoris
[The effect of new cholinesterase retarding substance on sympathicotonic circulation disorder, with special reference to angina pectoris.]
Angioedema
Severe angioedema causing airway obstruction after anterior cervical surgery.
Anhedonia
Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats.
Anisocoria
[The clinical features of myasthenia gravis affecting nonskeleton muscles]
Anterior Wall Myocardial Infarction
[Electrocardiographic changes in acute organophosphate poisoning]
Aphasia, Primary Progressive
Primary Progressive Aphasia as a Prodromal State of Dementia With Lewy Bodies: A Case Report.
Apnea
A Case of Pseudocholinesterase Deficiency Resulting From Malnutrition.
A color reaction based rapid screening for null activity of butyrylcholinesterase: a step towards point of care screening for succinylcholine apnea.
A mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha,beta-hydrolase fold protein family.
A single mutation near the C-terminus in alpha/beta hydrolase fold protein family causes a defect in protein processing.
Analysis of mutations in the plasma cholinesterase gene of patients with a history of prolonged neuromuscular block during anesthesia.
Apnea and atypical pseudocholinesterase.
APNEA DUE TO INHERITANCE OF ATYPICAL PSEUDOCHOLINESTERASE.
Apnea following succinylcholine associated with atypical cholinesterase.
Apnea in an atypical-fluoride resistant (E1aE1f) heterozygote for serum cholinesterase.
Atypical Cholinesterase and Prolonged Apnea During Electroconvulsive Therapy.
Atypical plasma cholinesterase, succinylcholine, and prolonged apnea.
Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population.
Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.
Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium.
Characterization of four BCHE mutations associated with prolonged effect of suxamethonium.
Cholinesterase unit establishment and issuing of >>Warning Cards<< for carriers of suxamethonium sensitive serum butyrylcholinesterase variants.
Delayed recovery from paralysis associated with plasma cholinesterase deficiency.
Determination of butyrylcholinesterase (BChE) phenotypes to predict the risk of prolonged apnea in persons receiving succinylcholine in the healthy population of western Iran.
Distribution of cholinesterase activity in the population of Trinidad.
Ethnic differences in the frequency of distribution of serum cholinesterase activity in the Iranian population.
Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine.
Hereditary cholinesterase deficiency: a report of a family with two rare genotypes.
Heterozygous Atypical Cholinesterase: Management During ECT.
Increased sensitivity to succinylcholine in a patient heterozygous for the silent and the fluoride-resistant gene.
Is succinyldicholine the substrate of choice for the measurement of cholinesterase activity?
Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India.
Novel mutations in the BCHE gene in patients with no butyrylcholinesterase activity.
Pesticide poisoning, succinylcholine-induced apnea, and pseudocholinesterase.
Plasma cholinesterase and the duration of succinylcholine-induced apnea.
Prolonged apnea after ECT in organophosphorus poisoning - the need to redefine norms.
Prolonged apnea after orthognathic surgery due to atypical cholinesterase.
Prolonged apnea caused by inherited cholinesterase deficiency after strabismus surgery.
Prolonged apnea following modified electroconvulsive therapy with suxamethonium.
Prolonged apnea following succinylcholine administration in undiagnosed acute organophosphate poisoning.
Prolonged neuromuscular blockade as a result of malnutrition-induced pseudocholinesterase deficiency.
Prolonged Neuromuscular Paralysis Following Rapid-Sequence Intubation with Succinylcholine (April).
Prolonged postoperative apnea complicating gynecologic surgery; atypical cholinesterase and myasthenia gravis.
Prolonged postoperative apnea with pseudocholinesterase deficiency.
Prolonged postoperative succinylcholine-induced apnea with pseudocholinesterase deficiency.
Prolonged succinylcholine-induced apnea caused by atypical cholinesterase: report of case.
Prolonged succinylcholine-induced paralysis in organophosphate insecticide poisoning.
Pseudocholinesterase abnormalities as a cause of postanesthetic apnea.
Rapid detection of BCHE atypical variant (p.Asp70Gly) by high resolution melting curve analysis.
Reversal of succinylcholine induced apnea with an organophosphate scavenging recombinant butyrylcholinesterase.
Succinylcholine-induced prolonged apnea in a 3-week-old newborn: treatment with human plasma cholinesterase.
Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.
The allele frequency of T920C mutation in butyrylcholinesterase gene is high in an Indian population.
The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26.
The relation between plasma cholinesterase and prolonged apnea caused by succinylcholine.
Therapy of prolonged apnea after suxamthonium with purified pseudocholinesterase. New data on kinetics of the hydrolysis of succinyldicholine and succinylmonocholine and further data on N-acetyltransferase-polymorphism.
Transient respiratory depression of the newborn. Its occurrence after succinylcholine administration to the mother.
Two new mutations of the human BCHE gene (IVS3-14T>C and L574fsX576).
[4 families with silent cholinesterase variant]
[A rare case of silent cholinesterase genetic variant (author's transl)]
[Administration of cholinesterase in apnea induced by suxamethonium]
[Apnea caused by succinylcholine and its relation to serum cholinesterase.]
[Cholinesterase and prolonged apnea due to succinylcholine]
[Data on serum cholinesterase activity in cases of prolonged apnea due to succinylcholine]
[EFFECT OF THE STORAGE ON THE PSEUDOCHOLINESTERASE ACTIVITY IN DONOR'S BLOOD AND ITS SIGNIFICANCE IN THE TREATMENT OF APNEA.]
[Emergency from anesthesia in small children. From laryngospasm to prolonged apnea]
[Gene analysis of human cholinesterase variants]
[Phenotype of plasma cholinesterase in prolonged apnea and sensitivity to succinylcholine]
[Plasma cholinesterase (CHE, pseudocholinesterase), its importance in liver diseases and prolonged succinyldicholine-induced apnea]
[Plasma cholinesterase variations as a result of prolonged neuromuscular blockade. Review and problems encountered in two cases of prolonged neuromuscular blockade after muscle relaxation with succinylcholine as compared to mivacurium]
[Polymorphism of plasma cholinesterase in Pyrennees populations. Problems in geographic hematology and pharmacogenetics]
[Procedure for identifying atypical variants of pseudocholinesterase for the prevention of prolonged apnea induced by succinylcholine]
[Prolonged apnea after suxamethonium related to congenital abnormality of plasma pseudocholinesterase]
[Prolonged apnea and cholinesterase defficiency]
[Prolonged apnea caused by atypical pseudocholinesterase]
[Prolonged apnea caused by succinylcholine iodide, related to a lowered blood cholinesterase content.]
[Prolonged apnea due to atypical pseudocholinesterase]
[Pseudocholinesterase deficiency; a complication in bronchoscopy in anesthesia and apnea.]
[Relation between serum cholinesterase polymorphism, long-term apnea and hypoventilation during surgery and in the postoperative period]
[Research on serum cholinesterase activity in subjects with prolonged apnea caused by succinylcholine]
[Serum butyrylcholinesterase variants in eastern Santiago population]
[Succinylcholine apnea in a patient homozygotic for atypical cholinesterase gene]
[Succinylcholine-induced apnea and familial cholinesterase deficiency]
[Succinyldicholin sensitivity resulting from genetically determined serumcholinesterase variants]
[The effect of etomidate on the activity of human pseudocholinesterase. In vivo-in vitro-enzymekinetics (author's transl)]
Appendicitis
[Cholinesterase activity in acute appendicitis]
Arrhythmia, Sinus
Monitoring the chronic effects of anticholinesterase pesticides in aerial applicators.
Arrhythmias, Cardiac
Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure.
Inhibitory effect of quinidine on plasma pseudocholinesterase activity in pregnant women.
Manifestations of and risk factors for acute myocardial injury after acute organophosphorus pesticide poisoning.
Pseudocholinesterase in patients with coronary artery disease with cardiac arrhythmias.
Role of plasma pseudocholinesterase activity in the diagnosis of acute myocardial infarction with special reference to cardiac arrhythmias.
[Complete atrioventricular block during galantamine therapy]
Arteritis
[Studies on blood cholesterase in chronic arteritis; activities of certain cholinesterase inhibitors in normal subjects and in chronic arteritis.]
Arthritis, Rheumatoid
Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: correlation with systemic inflammatory markers and oxidative stress, preliminary report.
Choline esterase activity in rheumatoid arthritis.
Cholinesterase activity in patients with rheumatoid arthritis.
Arthrogryposis
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Arthus Reaction
[CHOLINESTERASE IN SERUM AND ERYTHROCYTES DURING THE ARTHUS PHENOMENON.]
Ascariasis
[Cholinesterase activity and acetylcholine of the blood serum in experimental ascariasis.]
[The effect of thiamine on cholinesterase activity and the quantity of acetylcholine in the blood serum in experimental ascariasis.]
Asphyxia Neonatorum
[CHOLINESTERASE ACTIVITY OF THE BLOOD SERUM IN FETAL DEATH, ASPHYXIA NEONATORUM AND FETAL DEFORMITIES.]
Asthma
Acetylcholine and cholinesterase in the blood of patients suffering with bronchial asthma.
Microbial biotransformation of bioactive and clinically useful steroids and some salient features of steroids and biotransformation.
Pharmacologic treatments of dementia.
Plasma esterase activity in patients with aspirin-sensitive asthma or urticaria.
Risk factors for allergy due to the two-spotted spider mite (Tetranychus urticae) among table grape farm workers.
[Blood levels of acetylcholine and serum cholinesterase activity in children with neurodermatitis constitutionalis with and without bronchial asthma]
[Cholinesterase in the blood serum in allergic bronchial asthma.]
[Disorders of cholinergic regulation in patients with bronchial asthma]
[Erythrocyte acetylcholinesterase activity and non-specific cholinesterase and ceruloplasmin activity in serum of patients with bronchial asthma]
Astrocytoma
Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
Asymptomatic Infections
Cholinesterase as an inflammatory marker of subclinical infection of dairy cows infected by Neospora caninum and risk factors for disease.
Ataxia
Clinical signs and biochemical changes in calves caused by injection of ivermectin.
Relationship between the pharmacological effects and the biodisposition of [3H]diisopropylfluorophosphate in mice after inhalation.
Striatal neurochemical changes and motor dysfunction in mipafox-treated animals.
Atherosclerosis
Pseudocholinesterase and lipoprotein lipase in atherosclerosis.
Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review.
[Changes of choline, cholesterol and cholinesterase in the blood in atherosclerosis.]
[Dynamic activity of cholinesterase and choline content in various forms of atherosclerosis.]
[Effect of vitamin E on activity of blood cholinesterase in atherosclerosis.]
[On cholinesterase activity in rabbit brain during experimental atherosclerosis and functional loading]
Atrial Fibrillation
Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support.
Changes of myocardial enzyme activities in atrial fibrillation.
Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.
The production of block and auricular fibrillation in the heart-lung preparation by inhibitors of cholinesterase.
[Changes in blood cholinesterase activity in patients with heart defects accompanied by auricular fibrillation treated by electric defibrillation]
Avitaminosis
[Role of hormonal and seasonal factors in the effect of vitamin E on cholinesterase activity in the nervous system]
Babesiosis
Evaluation of some acute phase proteins in cattle naturally infected with Babesia bigemina.
The effect of diminazene aceturate on cholinesterase activity in dogs with canine babesiosis.
Bacteremia
Liver function tests in patients with bacteremia.
Bacterial Infections
Liver function tests in patients with bacteremia.
Value of Serum Cholinesterase Activity in the Diagnosis of Septic Shock Due to Bacterial Infections.
[Decrease in plasmatic cholinesterase activity in severe bacterial infections: comparison with the decrease observed in severe liver cirrhosis]
[Research on risk factors of short-term outcome in AIDS patients with pneumocystis pneumonia].
Basal Ganglia Diseases
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Beriberi
[True and pseudo cholinesterase in the central nervous system and blood of pigeons with beriberi]
beta-Thalassemia
Biochemical genetics and mental retardation: a study of hemoglobins, Australia antigen and the enzymes pseudocholinesterase and glucose-6-phosphate dehydrogenase.
[SERUM CHOLINESTERASE IN PATIENTS WITH COOLEY'S ANEMIA AND IN THEIR FAMILIES.]
Biliary Tract Diseases
Colorimetric determination of serum cholinesterase: its value in hepatic and biliary tract diseases.
[Ceruloplasmin, cholinesterase and aldolase activity in children with biliary tract disease]
Bradycardia
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
Bradycardia produced by pyridostigmine and physostigmine.
Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.
Causes of syncope in patients with Alzheimer's disease treated with donepezil.
Cholinergic Crisis Owing to Distigmine Bromide Complicated by Hyperosmolar Hyperglycemic State.
Cholinesterase inhibitor treatment may double the risk of hospitalisation for bradycardia.
Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.
Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System.
Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.
Different properties of the bradycardia produced by neostigmine and edrophonium in the cat.
Donepezil overdose: a tenfold dosing error.
Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.
Fresh frozen plasma as a successful antidotal supplement in acute organophosphate poisoning.
Intra-operative bradycardia in a patient with Alzheimer's disease treated with two cholinesterase inhibitors.
Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats.
Much caution does no harm! Organophosphate poisoning often causes pancreatitis.
Pharmacologic treatments of dementia.
Prevalence of positive carotid sinus massage and related risk of syncope in patients with Alzheimer's disease.
Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.
Syncope with cholinesterase inhibitors.
The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.
[Acute respiratory failure associated with cholinergic crisis: report of five cases and review of the literature].
[Analysis of the bradycardia action of cholinesterase inhibitor paraoxon (diethyl-p-nitrophenylphosphate) on isolated hearts of warm-blooded animals.]
[Hemodynamic effects in antagonism of neuromuscular blockage: atropine-pyridostigmine versus ipratropium bromide-pyridostigmine]
[Reversal of neuromuscular block with sugammadex in five heart transplant pediatric recipients].
[Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia.]
[Sugammadex, a new drug for reversion of muscle relaxants].
Brain Concussion
Evaluating the Memory Enhancing Effects of Angelica gigas in Mouse Models of Mild Cognitive Impairments.
Brain Diseases
Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy.
Delayed-onset encephalopathy and coma in acute organophosphate poisoning in humans.
Etiology and prognosis of liver cirrhosis in elderly patients.
Poor prediction of blood transfusion requirements in adult liver transplantations from preoperative variables.
Predictive value of serum procollagen-III-peptide for the survival of patients with cirrhosis.
Predictors of one-year pretransplant survival in patients with cirrhosis.
Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases.
Survival and prognostic indicators in compensated and decompensated cirrhosis.
The utility of EEG in dementia: a clinical perspective.
Tissue Distribution and Pharmacodynamics of Rivastigmine after Intranasal and Intravenous Administration in Rats.
[Endogenous digitalis-like factor in liver cirrhosis and cholestasis]
Brain Edema
Cerebral edema induced in mice by a convulsive dose of soman. Evaluation through diffusion-weighted magnetic resonance imaging and histology.
Changes in mouse brain metabolism following a convulsive dose of soman: a proton HRMAS NMR study.
Brain Infarction
Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.
Increased monoamine metabolite concentrations and cholinesterase activities in cerebrospinal fluid of patients with acute stroke.
Brain Injuries
Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury.
Effect of tetrahydroaminoacridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury.
Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig.
Unexpected extrapyramidal symptoms and pulmonary aspergillosis in exertional heatstroke with fulminant liver failure: a case report.
Brain Injuries, Traumatic
Cholinomimetic agents and neurocognitive impairment following head injury: a systematic review.
Neuropharmacological modulation of cognitive deficits after brain damage.
Serum Total Cholinesterase Activity on Admission Is Associated with Disease Severity and Outcome in Patients with Traumatic Brain Injury.
Treatment of attention deficits in neurological disorders.
Brain Ischemia
Ameliorative effects of the centrally active cholinesterase inhibitor, NIK-247, on impairment of working memory in rats.
Correlations Between Cholinesterase Activity and Cognitive Scores in Post-Ischemic Rats and Patients with Vascular Dementia.
Network pharmacology study on the active components of Pterocypsela elata and the mechanism of their effect against cerebral ischemia.
Sub-regional hippocampal vulnerability in various animal models leading to cognitive dysfunction.
Brain Neoplasms
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors.
Amine oxidase, pressor amines, and cholinesterase in brain tumours.
Expression of muscarinic binding sites in primary human brain tumors.
Breast Neoplasms
Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer.
Breast cancer metastasis alters acetylcholinesterase activity and the composition of enzyme forms in axillary lymph nodes.
Chemical profile, antiproliferative, antioxidant, and enzyme inhibition activities and docking studies of Cymbopogon schoenanthus (L.) Spreng. and Cymbopogon nervatus (Hochst.) Chiov. from Sudan.
Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer.
Diagnostic and prognostic significance of serum cholinesterase and lactate dehydrogenase in breast cancer.
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Serum butyrylcholinesterase and zinc in breast cancer.
[Influence of total parenteral nutrition (TPN) on nutritional incidences in patients with recurrent cancer]
Bronchial Hyperreactivity
Ozone inhibition of tissue cholinesterase in guinea pigs.
Bronchial Spasm
Drug-induced bronchospasm.
Bronchitis
A top 5 list for French general practice.
Bronchitis, Chronic
Postlaryngectomy pharyngocutaneous fistula: incidence, predisposing factors, and therapy.
Brucellosis
[Acetylcholine, cholinesterase, catecholamine and vitamin indices in chronic brucellosis]
Budd-Chiari Syndrome
Single-Center Retrospective Study of Clinical and Laboratory Features That Predict Survival of Patients With Budd-Chiari Syndrome After Liver Transplant.
Bulbo-Spinal Atrophy, X-Linked
Acetylcholinesterase inhibitor responsive myasthenia in a Filipino male with X-linked recessive spinal and bulbar muscular atrophy.
Bundle-Branch Block
Changes in cholinesterase activity distribution in ventricular muscle in chronic, experimental bundle branch block in the dog.
CADASIL
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Carcinogenesis
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors.
Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer.
Breast cancer metastasis alters acetylcholinesterase activity and the composition of enzyme forms in axillary lymph nodes.
Estimation of Serum Butyryl Cholinesterase in Patients with Oral Squamous Cell Carcinoma: A Cross-Sectional Study.
Protein thiols and butryrylcholinestrase in saliva of oral cancer patients.
Role of serum cholinesterase in patients treated with salvage radical prostatectomy.
Significance of serum butyrylcholinesterase levels in oral cancer.
Carcinoma
Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas.
Activated cholinergic signaling provides a target in squamous cell lung carcinoma.
Acute phase proteins and biomarkers of oxidative status in feline spontaneous malignant mammary tumours.
Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors.
Butyrylcholinesterase: An economical marker of disease activity in oral squamous cell carcinoma before and after therapy.
Cholesteryl esters in human malignant neoplasms.
Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer.
Diagnostic and prognostic significance of serum cholinesterase and lactate dehydrogenase in breast cancer.
Estimation of Serum Butyryl Cholinesterase in Patients with Oral Squamous Cell Carcinoma: A Cross-Sectional Study.
Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types.
Hypercholinesterasemia in patients with hepatocellular carcinoma: a new paraneoplastic syndrome.
Impact of pretreatment cholinesterase level on survival of inoperable intrahepatic or hepatic-hilar carcinomas treated with three-dimensional conformal radiotherapy.
Modified properties of serum cholinesterases in primary carcinomas.
Oxidative stress and inflammatory response biomarkers in dogs with mammary carcinoma.
Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy.
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy.
Pretreatment serum pseudocholinesterase level as a novel prognostic biomarker for upper tract urothelial carcinoma.
Serum cholinesterase and lactate dehydrogenase levels in cases of squamous cell carcinoma of oral cavity.
Serum cholinesterase levels in patients with cancer.
Significance of preoperative butyrylcholinesterase level as an independent predictor of survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy.
Studies of cholinesterase activity. V. Serum cholinesterase in patients with carcinoma.
Synthesis of New Biscoumarin Derivatives, In Vitro Cholinesterase Inhibition, Molecular Modelling and Antiproliferative Effect in A549 Human Lung Carcinoma Cells.
[A study of the effect of endoxan on the serum cholinesterase activity in gynecologic carcinomas]
[Diagnostic value of biochemical tumor markers in serum of patients with cancer of the ovary]
[Serum cholinesterase activity in stomach carcinoma]
[Serum cholinesterase activity of patients with carcinoma of the cervix]
[Serum cholinesterase in liver cirrhosis and certain carcinomas.]
[The significance of serum cholinesterase in carcinoma patients.]
Carcinoma, Bronchogenic
[Assessment of serum cholinesterase activity in the differential diagnosis of bronchial carcinoma]
[Determination of cholinesterase activity and iron-copper ratio in the differential diagnosis of bronchial carcinoma]
Carcinoma, Hepatocellular
Abnormalities of serum cholinesterase isozyme in liver cirrhosis and hepatoma (Part II).
Arylesterase isoenzymes and activity in normal healthy adults and in patients with cancer and with other diseases.
Cholinesterase activity of liver and blood serum from rats during the development of hepatoma by carcinogen feeding.
Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of Aleuria aurantia lectin-reactive serum cholinesterase to immunoreactive protein.
Goodyschle A, a new butenolide with significant BchE inhibitory activity from Goodyera schlechtendaliana.
High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma.
Histochemical and cytochemical study of butyrylcholinesterase activity in rat hepatocellular carcinomas induced by 3'-methyl-4-dimethylaminoazobenzene.
Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib.
Increase of fucosylated serum cholinesterase in relation to high risk groups for hepatocellular carcinomas.
Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases.
Quality of life after hepatectomy in patients with hepatocellular carcinoma: implication of change in hepatic protein synthesis.
Some properties and electrophoretic patterns of rat liver esterases in relation to hepatocarcinogenesis by 3'-methyl-4-(dimethylamino) azobenzene.
Survival and prognostic indicators in compensated and decompensated cirrhosis.
The human hepatoma cell line, HepG2, secretes functional cholinesterase.
[Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases]
[Clinical evaluation of the measurement of hepatosplenic volume ratio by computed tomography]
Carcinoma, Medullary
Acetylcholinesterase and butyrylcholinesterase activities in human thyroid cancer cells.
Carcinoma, Papillary
Acetylcholinesterase and butyrylcholinesterase activities in human thyroid cancer cells.
Carcinoma, Renal Cell
Cholesteryl esters in human malignant neoplasms.
Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types.
Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy.
Carcinoma, Squamous Cell
Serum cholinesterase and lactate dehydrogenase levels in cases of squamous cell carcinoma of oral cavity.
Cardiomegaly
Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload.
Cardiomyopathies
Changes in cholinesterase activities after daunorubicin administration to rabbits.
Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
Congenital "histiocytoid" cardiomyopathy: evidence suggesting a developmental disorder of the Purkinje cell system of the heart.
Role of acetylcholine in pyridostigmine-induced myocardial injury: possible involvement of parasympathetic nervous system in the genesis of cardiomyopathy.
Cardiotoxicity
Phosphine toxicity: a story of disrupted mitochondrial metabolism.
Validation of Corrected and Dispersed QT as Predictors of Adverse Outcomes in Acute Cardiotoxicities.
Cardiovascular Diseases
C5 variant is associated with decreased risk of coronary artery disease in outpatients with severe hypercholinesterasemia.
Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists' practice.
Cholinesterase: Conflicting Aspects of Two Cardiovascular Diseases.
Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes.
Serum pseudocholinesterase: high density lipoprotein cholesterol ratio as an index of risk for cardiovascular disease.
Vascular dementia.
[Serum cholinesterase activity in patients with cardiovascular diseases]
[Study of cholinesterase activity in mixed saliva of patients with somatic pathology.]
Catalepsy
Morphine-induced catalepsy in the rat: effect on striatal acetylcholine & cholinesterase.
Striatal cholinergic activity during morphine-induced catalepsy in the rat: development of tolerance.
[Neurochemical aspects of corrective effect of fluoracizine in triphthazine-induced catalepsy in rats]
[The role of catecholamines, acetylcholine and cholinesterase activity in the development of the cataleptic action of triftazin following repeated administration]
Cataplexy
Locus coeruleus neurons: cessation of activity during cataplexy.
Potentiation of a functional autoantibody in narcolepsy by a cholinesterase inhibitor.
Cataract
Cataract due to cholinesterase inhibitors in the guinea-pig.
Effect of a cholinesterase inhibitor on salmonid lens: a possible cause for the increased incidence of cataract in salmon Salmo salar (L.).
Induction of subcapsular cataracts in cynomolgus monkeys by echothiophate.
Risk factors for cataract: a case control study.
[Cholinesterase activity in the humor of the anterior chamber and in the blood in patients with glaucoma and cataract]
Central Nervous System Neoplasms
Pseudocholinesterase activity in cerebrospinal fluid as a biomarker of solid central nervous system tumors in children.
Serum cholinesterase: a potential assistant biomarker for hand, foot, and mouth disease caused by enterovirus 71 infection.
Cerebellar Ataxia
[Familial early onset cerebellar ataxia with hypoalbuminemia]
Cerebral Amyloid Angiopathy
Butyrylcholinesterase K variant and cerebral amyloid angiopathy.
Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy.
Cerebral Infarction
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
[Histochemical demonstration of glial enzyme activity. II. Reagent and neoplastic glia]
Cerebrovascular Disorders
A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.
Cholinergic dysfunction in vascular dementia.
Cholinesterase inhibitors and vascular dementia: another string to their bow?
Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.
Predictive Factors of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease and Mixed Dementia: A One-Year Naturalistic Study.
Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.
[Changes in blood cholinesterase activity in cerebrovascular disorders]
Chagas Disease
Cholinesterase inhibition reduces arrhythmias in asymptomatic Chagas disease.
Correlation of plasma butyrylcholinesterase concentration with Acethylcholinesterase H353N polymorphism in the inflammatory response of Chagas disease patients.
[Cholinesterase activity in plasma and erythrocytes of patients with cardiac and undetermined forms of Chagas disease]
Chemical and Drug Induced Liver Injury
[Effect of splenic humoral factors on the cholinesterase activity of liver tissue and blood serum in experimental toxic hepatitis in rats]
[The effect of sodium- and calcium chloride mineral water from the Spalis spring (Druskininkai health resort) on serum pseudocholinesterase activity and the protein-synthesizing function of the liver in experimental acute toxic hepatitis]
Cholangiocarcinoma
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Cholecystitis
[A change in the activity of serum cholinesterase in cholecystitis]
Cholestasis
Clinical studies on plasma protein C. Correlation with serum cholinesterase.
Evaluation of the diagnostic value of serum bile acid in the detection and functional assessment of liver diseases.
Metabolic changes during prolonged total parenteral nutrition in intensive care.
One-year dietary toxicity study with methidathion in beagle dogs.
[Endogenous digitalis-like factor in liver cirrhosis and cholestasis]
[Preprothrombin in acute viral hepatitis B]
Cholesteatoma
Correlation between peri-operative complication in middle ear cholesteatoma surgery using STAMCO, ChOLE, and SAMEO-ATO classifications.
Evaluating hearing outcome, recidivism and complications in cholesteatoma surgery using the ChOLE classification system.
Mapping the ChOLE classification to hearing outcomes and disease-specific health-related quality of life.
Practical applicability of the STAMCO and ChOLE classification in cholesteatoma care.
[Characteristics of diagnosis and surgical treatment of various forms of congenital temporal bone cholesteatoma].
Cholesteatoma, Middle Ear
Correlation between peri-operative complication in middle ear cholesteatoma surgery using STAMCO, ChOLE, and SAMEO-ATO classifications.
cholinesterase deficiency
A case of pseudocholinesterase deficiency in the neonate.
A case of pseudocholinesterase deficiency in the PACU.
A Case of Pseudocholinesterase Deficiency Resulting From Malnutrition.
A conundrum: general or neuraxial anesthesia and the use of ROTEM.
A family with hereditary serum cholinesterase deficiency.
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
A patient with Sanfilippo syndrome and pseudocholinesterase deficiency, further complicated by post-tonsillectomy haemorrhage.
A third type of serum cholinesterase deficiency in Eskimos.
Acetylcholinesterase activity in cerebrospinal fluid of patients with Alzheimer's disease and senile dementia.
Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide.
Allergic reaction to suxamethonium during emergency caesarean section and pseudocholinesterase deficiency in the same patient.
An unusual presentation of cholinesterase deficiency.
Apnoea due to suxamethonium associated with familial pseudocholinesterase deficiency.
Atracurium for ECT in plasma cholinesterase deficiency.
Awareness during emergence from anaesthesia: significance of neuromuscular monitoring in patients with butyrylcholinesterase deficiency.
Break the Spasm with Succinylcholine, but Risk Intraoperative Awareness with Undiagnosed Pseudocholinesterase Deficiency.
Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: a systematic review.
Butyrylcholinesterase deficiency identified by preoperative patient interview.
Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet.
Butyrylcholinesterase deficiency.
Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium.
Cholinesterase deficiency and the Churg-Strauss syndrome.
Cholinesterase deficiency.
Cholinesterase variants: rapid characterisation by PCR/SSCP and evidence for molecular homogeneity.
Comparison between succinylcholine and rocuronium as neuromuscular blocking agents for electroconvulsive therapy in a patient with pseudocholinesterase deficiency.
COMPLETE PSEUDOCHOLINESTERASE DEFICIENCY: GENETIC AND IMMUNOLOGIC CHARACTERIZATION.
Corrected scoliosis, cholinesterase deficiency, and cesarean section: a case report.
Customized anesthetic preservation of ictal threshold in electroconvulsive therapy: role of adjunctive remifentanil with etomidate.
Delayed Emergence From Anesthesia: A Simulation Case for Anesthesia Learners.
Delayed recovery from paralysis associated with plasma cholinesterase deficiency.
Delayed recovery from paralysis by succinylcholine in patient with preoperatively unrecognized and inherited pseudocholinesterase deficiency.
Dental local anesthesia for patients with pseudocholinesterase deficiency.
Discrimination of phenotypes in human serum cholinesterase deficiency.
ECT Modified by Atracurium.
Emergency anaesthesia in a patient with plasma cholinesterase deficiency.
Family of a patient with serum cholinesterase deficiency.
Fresh frozen plasma and edrophonium in a patient with a plasma cholinesterase deficiency.
Genetic analysis of a Japanese patient with butyrylcholinesterase deficiency.
Genetic mutations associated with susceptibility to perioperative complications in a longitudinal biorepository with integrated genomic and electronic health records.
Genetic screening in the Persian Jewish community: A pilot study.
Grand mal seizures after 2-chloroprocaine epidural anesthesia in a patient with plasma cholinesterase deficiency.
Hereditary cholinesterase deficiency.
Hereditary cholinesterase deficiency: a report of a family with two rare genotypes.
Hereditary pseudocholinesterase deficiency discovery after electroconvulsive therapy.
Hereditary serum cholinesterase deficiency associated with severe lipid deposition in the kidney.
Heterozygous pseudocholinesterase deficiency: a case report and review of the literature.
In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase.
LEFT-SIDED AMOEBIC LIVER ABSCESS WITH PULMONARY INVOLVEMENT, PERICARDITIS, AND PSEUDOCHOLINESTERASE DEFICIENCY.
Letter: chloroprocaine and pseudocholinesterase deficiency.
Mivacurium apnoea: a trap for the unwary.
Mivacurium in infants and children.
Mivacurium-induced prolonged neuromuscular block.
Novel mutations in the BCHE gene in patients with no butyrylcholinesterase activity.
Optimizing electroconvulsive therapy in non-suspected pseudocholinesterase deficiency: laryngeal mask use and neuromuscular selection.
Organophosphate exposure with pseudocholinesterase deficiency.
Patient information sheet for plasma cholinesterase deficiency.
Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide.
Pharmacogenetics and anaesthetic drugs: Implications for perioperative practice.
Plasma cholinesterase deficiency in a neonate.
Plasma cholinesterase deficiency in a neonate: a follow-up.
Plasma cholinesterase deficiency in a premature neonate.
Plasma cholinesterase deficiency in Turkish patients - a reply.
Plasma cholinesterase deficiency in Turkish patients.
Plasma cholinesterase deficiency.
Plasma cholinesterase deficiency. A possible complication during anesthesia.
Plasma pseudo cholinesterase deficiency leading to seven hour apnoea in a child undergoing adeno-tonsillectomy.
Plasma pseudocholinesterase deficiency associated with diethylstilbestrol therapy.
Postoperative ileus, pregnancy-related cholinesterase deficiency and suxamethonium after-pains. A case report.
Pregnancy-induced cholinesterase deficiency.
Prehospital airway management complicated by reported pseudocholinesterase deficiency.
Premature awakening and underuse of neuromuscular monitoring in a registry of patients with butyrylcholinesterase deficiency.
Prevalence of congenital deficiency in serum cholinesterase.
Problem with detection of an insertion-type mutation in the BCHE gene in a patient with butyrylcholinesterase deficiency.
Prolonged apnea caused by inherited cholinesterase deficiency after strabismus surgery.
Prolonged mivacurium neuromuscular block in children.
Prolonged neuromuscular block associated with cholinesterase deficiency.
Prolonged neuromuscular block associated with mivacurium.
Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency.
Prolonged neuromuscular block in a patient undergoing renal transplantation.
Prolonged neuromuscular block with mivacurium in a patient with cholinesterase deficiency.
Prolonged neuromuscular blockade as a result of malnutrition-induced pseudocholinesterase deficiency.
Prolonged Neuromuscular Paralysis Following Rapid-Sequence Intubation with Succinylcholine (April).
Prolonged paralysis in pseudocholinesterase deficiency.
Prolonged paralysis related to mivacurium: a case study.
Prolonged postoperative apnea with pseudocholinesterase deficiency.
Prolonged postoperative succinylcholine-induced apnea with pseudocholinesterase deficiency.
Properties of the trace enzyme in human serum cholinesterase deficiency.
Pseudocholinesterase activity of human whole blood, bank blood, and blood protein solutions.
Pseudocholinesterase Deficiency - Is Succinylcholine Still Needed to Facilitate Endotracheal Intubation?
Pseudocholinesterase deficiency and electroconvulsive therapy.
Pseudocholinesterase deficiency associated with HELLP syndrome.
Pseudocholinesterase Deficiency Considerations: A Case Study.
PSEUDOCHOLINESTERASE DEFICIENCY IN A OCTOGENARIAN UNDERGOING TOTAL INTRAVENOUS ANESTHESIA; IMPLICATIONS FOR NEUROMONITORING.
Pseudocholinesterase Deficiency in an ECT Patient: A Case Report.
Pseudocholinesterase deficiency in specific populations.
Pseudocholinesterase deficiency.
Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences.
Pseudocholinesterase deficiency: a dangerous, unrecognized complication of the ovarian hyperstimulation syndrome.
Pseudocholinesterase deficiency: an additional preoperative consideration in outpatient diagnostic procedures.
Pseudocholinesterase Deficiency: What the Proceduralist Needs to Know.
Pseudocholinesterases. II. Two cases of pseudocholinesterase deficiency.
Recognizing Pseudocholinesterase Deficiency in the Post-operative Patient: Diagnosis and Management in the ICU.
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus.
Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency.
Reply: Pseudocholinesterase deficiency in specific populations.
Rocuronium antagonized by sugammadex for series of electroconvulsive therapy (ECT) in a patient with pseudocholinesterase deficiency.
Safe use of landiolol hydrochloride in a patient with marked pseudocholinesterase deficiency.
Screening for plasma cholinesterase deficiency: an automated succinylcholine based assay.
Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Serum cholinesterase deficiency in renal failure.
Serum cholinesterase deficiency. I. Disease and inheritance.
Serum cholinesterase deficiency. II. Pregnancy.
Serum cholinesterase: effect on the action of suxamethonium following administration to a patient with cholinesterase deficiency.
Sick Sinus Syndrome Observed in a Patient with Cholinesterase Deficiency.
Succinylcholine sensitivity and plasma cholinesterase deficiency.
Suxamethonium and mivacurium sensitivity from pregnancy-induced plasma cholinesterase deficiency.
Suxamethonium apnoea in an infant; expression of familial pseudocholinesterase deficiency in three generations.
The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency.
Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium.
Transient plasma cholinesterase deficiency in preterm infants.
Unexpected prolonged neuromuscular block after mivacurium: a case report.
Unknown Pseudocholinesterase Deficiency in a Patient Undergoing TIVA with Planned Motor Evoked Potential Monitoring: A Case Report.
Urgent cesarean delivery and prolonged ventilatory support in a parturient with Fontan circulation and undiagnosed pseudocholinesterase deficiency.
Use of atracurium in a patient with plasma cholinesterase deficiency.
Variations in serum cholinesterase activity in different age and sex groups.
Violent fasciculations may not signal pseudocholinesterase deficiency.
[A case of silent gene of heterozygote inherited serum cholinesterase deficiency]
[A case report of a family with serum cholinesterase deficiency]
[A family of adult polycystic kidney disease associated with pseudocholinesterase deficiency]
[A family of pseudocholinesterase deficiency (silent type II)]
[Butyrylcholinesterase deficiency: how to analyse the cholinesterase activity in small children?]
[Cholinesterase deficiency]
[Coexistence of ankylosing pelvispondylitis and cholinesterase deficiency in univitelline twins]
[Delay of decurarization related to pseudocholinesterase deficiency]
[On the problem of pseudocholinesterase deficiency syndrome. Anesthesia accident in a 4-months-old infant during an ophthalmological operation in congenital buphthalmos.]
[Prolonged apnea after suxamethonium administration during staphylococcal toxic shock]
[Prolonged curarisation following succinylcholine injection on butyrylcholinesterase deficiency and potentiated by a lithium treatment: a case report].
[Prolonged neuromuscular block after administration of mivacurium caused by plasma psueudocholinesterase deficiency]
[Prolonged neuromuscular block after mivacurium injection]
[Pseudocholinesterase deficiency; a complication in bronchoscopy in anesthesia and apnea.]
[Pseudocholinesterase deficiency]
[Relation of the functional disorder of external respiration to cholinesterase deficiency in burn patients in the septicotoxemia stage]
[Residual relaxant block due to pseudocholinesterase deficiency - First manifestation in an elderly patient].
[Succinylcholine-induced apnea and familial cholinesterase deficiency]
[Succinyldicholin sensitivity resulting from genetically determined serumcholinesterase variants]
[Update on the current role of plasma cholinesterase].
Churg-Strauss Syndrome
Cholinesterase deficiency and the Churg-Strauss syndrome.
Coccidiosis
[Alteration of enzyme activities in serum of Eimeria stiedai infected rabbits (author's transl)]
Coinfection
Relationship of nematode cholinesterase activity and nematode burdens to the development of resistance to trichostrongyle infections in sheep.
Colic
Health effects from exposure to organophosphate pesticides in workers and residents in Israel.
Colitis, Ulcerative
Erythrocyte and serum cholinesterase in ulcerative colitis.
Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses.
[Hepatic changes in patients with nonspecific ulcerative colitis]
[Serum cholinesterase activity in ulcerative colitis]
Collagen Diseases
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
Colonic Neoplasms
Acetyl- and butyrylcholinesterase activities decrease in human colon adenocarcinoma.
Chemical profile, antiproliferative, antioxidant, and enzyme inhibition activities and docking studies of Cymbopogon schoenanthus (L.) Spreng. and Cymbopogon nervatus (Hochst.) Chiov. from Sudan.
[Changes in the activity of serum lactate dehydrogenase and serum cholinesterase in surgical treatment of cancer of the colon]
Colonic Pseudo-Obstruction
Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility.
Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans.
Prokinetics in the treatment of acute intestinal pseudo-obstruction.
Review article: the pharmacological treatment of acute colonic pseudo-obstruction.
Colorectal Neoplasms
A single unit of transfused allogeneic blood increases postoperative infections.
Cholinesterases are down-expressed in human colorectal carcinoma.
Combination of Serum Albumin and Cholinesterase Levels as Prognostic Indicator in Patients ith Colorectal Cancer.
Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma.
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
[Decrease of serum cholinesterase in colorectal cancer]
Coma
Body mass index as a prognostic factor in organophosphate-poisoned patients.
Clinical emergency treatment of 68 critical patients with severe organophosphorus poisoning and prognosis analysis after rescue.
Delayed-onset encephalopathy and coma in acute organophosphate poisoning in humans.
Early Serum Biomarkers for Intensive Care Unit Treatment within the First 24 Hours in Patients with Intracerebral Hemorrhage.
Organophosphate poisoning presenting as diabetic ketoacidosis.
Prognostic Factors Determining Morbidity and Mortality in Organophosphate Poisoning.
Prognostic factors of organophosphate poisoning between the death and survival groups.
[Blood serum cholinesterase and various comatose states.]
[Evaluation of gastric lavage treatment for severe acute organophosphorus pesticides poisoning complicated by respiratory failure requiring mechanical ventilation]
[Poisoning with cholinesterase inhibitors]
Common Cold
Nonsense mutation in exon 2 of the butyrylcholinesterase gene: a case of familial cholinesterasemia.
Communicable Diseases
Cholinesterase's activities of infected mice by Brucella ovis.
[Association of mutant alleles of serum cholinesterase with various multi-factorial and infectious diseases]
[Blood cholinesterase in infectious diseases.]
[Cholinesterase power of the serum in acute infectious disease.]
[Pseudocholinesterase in patients with and without liver diseases (author's transl)]
Confusion
Dementia with Lewy bodies: clinical features and treatment.
Serum cholinesterase levels after thermal injury. Is treatment required?
[Antidementia drugs - response or non-response?]
Congenital Abnormalities
Acetylcholinesterase and butyrylcholinesterase measurement in the pre-natal detection of neural tube defects and other fetal malformations.
Amniotic fluid cholinesterase measurement as a rapid method for the exclusion of fetal neural tube defects.
Biochemical effects of chlorpyrifos on two developmental stages of Xenopus laevis.
Distribution profiles of paraoxonase and cholinesterase phenotypes in a Spanish population.
Scanning gel densitometry of amniotic fluid acetylcholinesterase and butyrylcholinesterase: quantification of 'faint-positive' bands in fetal malformations.
[CHOLINESTERASE ACTIVITY OF THE BLOOD SERUM IN FETAL DEATH, ASPHYXIA NEONATORUM AND FETAL DEFORMITIES.]
[Prolonged apnea after suxamethonium related to congenital abnormality of plasma pseudocholinesterase]
Congenital Disorders of Glycosylation
Congenital myasthenic syndromes due to mutations in ALG2 and ALG14.
Congenital Hypothyroidism
Suxamethonium apnoea associated with pregnancy and liver dysfunction in a treated cretin.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Congenital myasthenic syndromes due to mutations in ALG2 and ALG14.
Folding anomalies of neuroligin3 caused by a mutation in the alpha/beta-hydrolase fold domain.
Conjunctivitis
The Correlative Study of Serum Pseudo-cholinesterase, Biological Parameters and Symptoms Among Occupational Workers.
[Clinical and biochemical alterations in rats treated with high doses of vitamin A]
Contracture
Pyridostigmine-induced decrement in skeletal muscle contracture is not augmented by soman.
Role of butyrylcholinesterase in canine tracheal smooth muscle function.
[Cholinesterase activity in muscles and muscular sensitivity to acetylcholine in contractures induced by immobilization of extremities.]
[Intracellular calcium ion mobilization and nicotinic acetylcholine receptor-mediated signal transduction in neuro-skeletal muscle synapse]
Coronary Aneurysm
Predictive factors of coronary aneurysm in Kawasaki disease--correlation between coronary arterial lesions and serum albumin, cholinesterase activity, prealbumin, retinol-binding protein and immature neutrophils.
Coronary Artery Disease
Butyrylcholinesterase activity and risk factors for coronary artery disease.
Butyrylcholinesterase Activity Predicts Long-Term Survival in Patients with Coronary Artery Disease.
Butyrylcholinesterase K variant and the APOE-epsilon4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients.
Butyrylcholinesterase K variants increase the risk of coronary artery disease in the population of western Iran.
Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia.
Effect of intensive lipid-lowering therapies on cholinesterase activity in patients with coronary artery disease.
Influence of Serum Cholinesterase Levels on Patients Suspected of Having Stable Coronary Artery Disease.
Levels of serum lipids, apolipoproteins A-I and B and pseudocholinesterase activity and their discriminative values in patients with coronary by-pass operation.
Pseudocholinesterase in patients with coronary artery disease with cardiac arrhythmias.
Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease.
Serum pseudocholinesterase levels in the patients of coronary artery disease & their 'normal' first degree relatives.
Studies on pseudocholinesterase in patients with coronary artery disease.
Variation of the Butyrylcholinesterase (BChE) and Acetylcholinesterase (AChE) genes in coronary artery disease.
Coronary Disease
Cholinergic stimulation with pyridostigmine prevents the impairment in ventricular function during mental stress in coronary artery disease patients.
Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.
Pyridostigmine reduces QTc interval during recovery from maximal exercise in ischemic heart disease.
[Butyrylcholinesterase activity and trace element levels in different variants of coronary disease]
Corticobasal Degeneration
Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Cough
Drug-induced bronchospasm.
COVID-19
Microfabricated potentiometric sensor for personalized methacholine challenge tests during the COVID-19 pandemic.
Serum cholinesterase associated with COVID-19 pneumonia severity and mortality.
Temporal changes in laboratory markers of survivors and non-survivors of adult inpatients with COVID-19.
[Serum C-reactive protein, cholinesterase and prealbumin are correlated with prognosis of severe coronavirus disease 2019 patients].
Craniocerebral Trauma
Acetylcholine and neuronal activity; cholinesterase patterns and acetylcholine in the cerebrospinal fluids of patients with craniocerebral trauma.
Significance of serum cholinesterase levels in human head injury.
The use of cholinesterase in severe head injury.
[Activities of lactate dehydrogenase, acetylcholinesterase and cholinesterase in the cerebrospinal fluid and blood of patients with craniocerebral injuries]
[Cholinesterase activity in death due to traumatic shock, craniocerebral injury and stress]
Craniopharyngioma
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors.
Creutzfeldt-Jakob Syndrome
The utility of EEG in dementia: a clinical perspective.
Crohn Disease
Are single measurements of pseudocholinesterase and albumin markers for inflammatory activity or nutritional status in Crohn's disease?
Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease.
Course of pseudocholinesterase isozymes during an acute phase in Crohn's disease.
Low level of pseudocholinesterase in patient with Crohn's disease.
Molecular forms of pseudocholinesterase in patients with Crohn's disease.
Pseudocholinesterase in Crohn's disease.
Cushing Syndrome
Abnormal blood chemistry data in Cushing's syndrome: comparison with those for fatty liver.
Changes of platelets, serum lactic dehydrogenase, gamma-glutamyltranspeptidase, choline esterase and creatine phosphokinase levels in patients with Cushing's syndrome.
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
cystathionine beta-synthase deficiency
Lipid, Oxidative and Inflammatory Profile and Alterations in the Enzymes Paraoxonase and Butyrylcholinesterase in Plasma of Patients with Homocystinuria Due CBS Deficiency: The Vitamin B12 and Folic Acid Importance.
Cystic Fibrosis
Detection of human DNA mutations with nonradioactive, allele-specific oligonucleotide probes.
Mapping the human acetylcholinesterase gene to chromosome 7q22 by fluorescent in situ hybridization coupled with selective PCR amplification from a somatic hybrid cell panel and chromosome-sorted DNA libraries.
Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment.
Cysticercosis
Experimental treatment of cysticercosis with metrifonate.
Cysts
Cholinesterase activity of cerebral tumors and tumorous cysts.
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Factors Influencing Cyst Infection in Autosomal Dominant Polycystic Kidney Disease.
Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
[Cholinesterase activity in tumors and neoplastic cysts of the brain.]
Deafness
Toxic deafness. II. The effect of arsenic, salicylates and quinine on choline esterase activity in the blood and temporal lobe of guinea pigs.
Dehydration
Adverse drug reactions during heatwaves.
Combined effect of short-term dehydration and sublethal acute oral dicrotophos exposure confounds the diagnosis of anticholinesterase exposure in common quail (Coturnix coturnix) using plasma cholinesterase activity.
The effect of dehydration on the ultrastructure and cholinesterase activity of the subcommissural organ in the rat.
Delirium
A Review for Usefulness of Atypical Antipsychotics and Cholinesterase Inhibitors in Delirium.
Acetylcholinesterase and butyrylcholinesterase in cardiosurgical patients with postoperative delirium.
Cholinesterase alterations in delirium after cardiosurgery: a German monocentric prospective study.
Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients.
Cholinesterase inhibitor treatment in patients with delirium.
Cholinesterase inhibitors and delirium after cardiac surgery.
Cholinesterase inhibitors for delirium.
Cholinesterase inhibitors for delirium: what is the evidence?
Cholinesterase inhibitors for the treatment of delirium in non-ICU settings.
Cholinesterases and Anticholinergic Medications in Postoperative Pediatric Delirium.
Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage.
Diagnostic Value of Cholinesterase Activity for Postoperative Delirium.
Diagnostic Value of Cholinesterase Activity for the Development of Postoperative Delirium after Cardiac Surgery.
Donepezil for anticholinergic drug intoxication: a case report.
Donepezil improves symptoms of delirium in dementia: implications for future research.
Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: A population-based study.
Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.
Enzymes of drug metabolism during delirium.
Evaluating early administration of the hydroxymethylglutaryl-CoA reductase inhibitor simvastatin in the prevention and treatment of delirium in critically ill ventilated patients (MoDUS trial): study protocol for a randomized controlled trial.
Evidence for Pharmacological Management in Delirium.
Incidence of cholinesterase inhibitor therapy initiation among hospitalized patients.
Initiation of cholinesterase inhibitors in an inpatient setting.
Interventions for preventing delirium in hospitalised non-ICU patients.
Is Lower Plasma Cholinesterase Activity Really a Candidate Biomarker for Postoperative Delirium After Noncardiac Surgery?
Low cholinesterase activity is a risk factor for delirium after cardiac surgery: A prospective cohort study.
Low Plasma Cholinesterase Activity is Associated With Postoperative Delirium After Noncardiac Surgery in Elderly Patients: A Prospective Observational Study.
Low preoperative plasma cholinesterase activity as a risk marker of postoperative delirium in elderly patients.
Pharmacological management of anticholinergic delirium - theory, evidence and practice.
Pharmacological Management of Delirium in Hospitalized Adults - A Systematic Evidence Review.
Physostigmine in Anticholinergic Poisoning: An Old Antidote With Resurgence.
Prevention of Post-operative Delirium in the Elderly Using Pharmacological Agents.
Prolonged anticholinergic delirium following antihistamine overdose.
Relevance of peripheral cholinesterase activity on postoperative delirium in adult surgical patients (CESARO): A prospective observational cohort study.
Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery--a randomized controlled trial.
Rivastigmine in the treatment of delirium in older people: a pilot study.
Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor.
The Cholinergic System and Inflammation: Common Pathways in Delirium Pathophysiology.
Treatment of post-electroconvulsive therapy delirium and agitation with donepezil.
Usefulness of atypical antipsychotics and choline esterase inhibitors in delirium: a review.
[Psychopharmalogical treatment of delirium in the elderly].
[Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]
Dementia
A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan.
A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
A population-based study of cholinesterase inhibitor use for dementia.
A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs.
A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia.
A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
A review of rivastigmine: a reversible cholinesterase inhibitor.
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.
A systematic review and meta-analysis of ethnic differences in use of dementia treatment, care, and research.
A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.
A versatile equation to describe reversible enzyme inhibition and activation kinetics: modeling beta-galactosidase and butyrylcholinesterase.
Abnormalities in muscarinic cholinergic receptors and their G-protein coupling systems in the cerebral frontal cortex in Alzheimer's disease.
Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease.
Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.
Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
ACP Journal Club. Review: cholinesterase inhibitors but not memantine increase syncope in older adults with mild cognitive impairment or dementia.
ACP Journal Club. Review: Cholinesterase inhibitors do not prevent dementia in patients with mild cognitive impairment.
ACP Journal Club. Review: cholinesterase inhibitors do not reduce progression to dementia from mild cognitive impairment.
Activities and kinetic properties of lumbar cerebrospinal fluid cholinesterases in relation to clinical diagnosis, severity, and progression of Alzheimer's disease.
Acute effects of oral pyridostigmine bromide on conditioned operant performance in rats.
Acute inability to mobilise resulting from probable donepezil-induced myoclonus.
Acute treatment of psychotic symptoms in a newly diagnosed Lewy body dementia patient with an accelerated titration schedule of rivastigmine and de-escalation of antipsychotics.
Advances in psychopharmacology: mood disorders and dementia.
Advances in the treatment of cognitive impairment in Parkinson's disease.
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Age-impaired impulse flow from nucleus basalis to cortex.
Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats.
Alendronate reduces the cognitive and neurological disturbances induced by combined doses of d-galactose and aluminum chloride in mice.
Allium cepa fraction attenuates STZ-induced dementia via cholinesterase inhibition and amelioration of oxidative stress in mice.
Altered Nucleus Basalis Connectivity Predicts Treatment Response in Mild Cognitive Impairment.
Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
An atypical cutaneous reaction to rivastigmine transdermal patch.
An audit of a specialist old age psychiatry liaison service to a medium and a high secure forensic psychiatry unit.
An observational study of the needs and quality of life amongst patients in the treatment of Alzheimer's dementia with cholinesterase inhibitors.
Anti-amnestic Effect of Curcumin in Combination with Donepezil, an Anticholinesterase Drug: Involvement of Cholinergic System.
Anticholinergic Drug Burden in Persons with Dementia Taking a Cholinesterase Inhibitor: The Effect of Multiple Physicians.
Antidementia drugs: prescription by level of cognitive impairment or by socio-economic group?
Antidepressants for agitation and psychosis in dementia.
Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia.
Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study.
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Assessing capacity to consent to treatment with cholinesterase inhibitors in dementia using a specific and standardized version of the MacArthur Competence Assessment Tool (MacCAT-T).
Assessing cognitive change in Parkinson's disease: development of practice effect-corrected reliable change indices.
Assessment and treatment of dementia in medical patients.
Association of out-of-pocket costs on adherence to common neurologic medications.
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors.
Behavioral and neuropsychiatric outcomes in Alzheimer's disease.
Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.
Bioactive Compounds and Traditional Herbal Medicine: Promising Approaches for the Treatment of Dementia.
Bipolar affective disorder, type II, apparently precipitated by donepezil.
Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia.
Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.
BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.
Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies.
Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients.
Butyrylcholinesterase K: an association with dementia with Lewy bodies.
Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could BCHE Genotyping Be Helpful in Alzheimer's Therapy?
Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia.
Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.
Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase.
Cardiac monitoring for cholinesterase inhibitors: a survey.
Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta-Analysis and Systematic Review.
CDR State Transition Probabilities in Alzheimer's Disease with and without Cholinesterase Inhibitor Intervention in an Observational Cohort.
Cerebral acetylcholinesterase imaging: development of the radioprobes.
Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study.
Cerebrolysin: a review of its use in dementia.
Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type.
Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy.
Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex.
Chlorpyrifos shares stimulus properties with pentylenetetrazol as evaluated by an operant drug discrimination task.
Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data.
Cholinergic modulation of MEG resting-state oscillatory activity in Parkinson's disease related dementia.
Cholinergic muscarinic M1/M4 receptor networks in dementia with Lewy bodies.
Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
Cholinesterase activity in plasma, erythrocytes, and cerebrospinal fluid of patients with dementia of the Alzheimer type.
Cholinesterase enzymes in the blood of patients with Alzheimer's disease.
Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Cholinesterase inhibition in the scopolamine model of dementia.
Cholinesterase inhibition in treatment of Alzheimer's dementia.
Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia.
Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.
Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies.
Cholinesterase inhibitor use in geriatric outpatients with dementia.
Cholinesterase Inhibitor Use in Patients With Dementia Admitted to a Palliative Care Unit.
Cholinesterase Inhibitor Use in U.S. Nursing Homes: Results from the National Nursing Home Survey.
Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study.
Cholinesterase Inhibitors and Behavioral & Psychological Symptoms of Alzheimer's Disease.
Cholinesterase inhibitors and dramatic emotional therapy for dementia patients.
Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration.
Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.
Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System.
Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.
Cholinesterase inhibitors and memantine for symptomatic treatment of dementia.
Cholinesterase inhibitors and peripheral neuromuscular function in dementia.
Cholinesterase inhibitors and the risk of pulmonary disorders in hospitalized dementia patients.
Cholinesterase inhibitors and use of psychotropic medications in a sample of patients with dementia.
Cholinesterase inhibitors and vascular dementia: another string to their bow?
Cholinesterase inhibitors for behavioral disturbance in dementia.
Cholinesterase inhibitors for delirium.
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Cholinesterase inhibitors for dementia with Lewy bodies.
Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis.
Cholinesterase inhibitors for Parkinson's disease dementia.
Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Cholinesterase inhibitors from botanicals.
Cholinesterase inhibitors from Sargassum and Gracilaria gracilis: seaweeds inhabiting South Indian coastal areas (Hare Island, Gulf of Mannar).
Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?
Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.
Cholinesterase inhibitors in dementia: yes, no, or maybe?
Cholinesterase inhibitors in non-Alzheimer dementias.
Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry.
Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.
Cholinesterase inhibitors in the treatment of dementia.
Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
Cholinesterase inhibitors modulate autonomic function in patients with Alzheimer´s disease and mixed dementia.
Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.
Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the sunnybrook dementia cohort.
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Cholinesterase inhibitors were associated with increased risk for syncope and its consequences in older persons with dementia.
Cholinesterase inhibitors. Comparing the options for mild-to-moderate dementia.
Cholinesterase inhibitors: applying pharmacokinetics to clinical decision making.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and mechanisms for treatment response.
Cholinesterases in cerebrospinal fluid. A longitudinal study in Alzheimer disease.
Cholinesterases in cerebrospinal fluid. Correlations with clinical measures in Alzheimer's disease.
Cholinesterases: roles in the brain during health and disease.
Clinical and analytical considerations in the utilization of cholinesterase measurements.
Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase Inhibitors, in Patients with Cognitive Impairment: A Comparative Open Study*
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
Clinical practice with antidementia drugs in a geriatric clinic.
Clinical trials of new drugs for Alzheimer disease.
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.
Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.
Cognitive correlates of ?4?2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
Cognitive dysfunction and dementia in Parkinson disease.
COGNITIVE DYSFUNCTION IN FMR1 PREMUTATION CARRIERS.
Cognitive impairment in Parkinson's disease and dementia with Lewy bodies.
Cognitive impairment in Parkinson's disease.
Cognitive pharmacotherapy of Alzheimer's disease and other dementias.
Cognitive stimulation therapy as a sustainable intervention for dementia in sub-Saharan Africa: feasibility and clinical efficacy using a stepped-wedge design.
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer.
Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis.
Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
Comparison of cholinesterase inhibitor safety in real-world practice.
Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study.
Compression or expansion of dementia in Germany? An observational study of short-term trends in incidence and death rates of dementia between 2006/07 and 2009/10 based on German health insurance data.
Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes.
Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II.
Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM).
COPD Exacerbation and Cholinesterase Therapy in Dementia Patients.
Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB.
Cortical Lewy body disease and Parkinson's disease dementia.
Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Current Understanding of Psychosis in Parkinson's Disease.
Cytotoxic and genotoxic effects of ss-(triphenylpho-s-phonio)ethyl carboxylate and of N,N'-bis(dihexylphos-phinoylmethyl)-1,4-diaminocyclohexane.
Decreased erythrocyte cholinesterase activity in dementia.
Delayed blink reflex in dementia with Lewy bodies is sensitive to cholinergic modulation.
Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage.
Dementia associated with Parkinson's disease.
Dementia care and cholinesterase inhibitors.
Dementia in Down's syndrome.
Dementia in Parkinson's Disease.
Dementia in Parkinson's disease.
Dementia in Parkinson's disease: cause and treatment.
Dementia in Taiwan: past, present, and future.
Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia.
Dementia with cerebrovascular disease: the benefits of early treatment.
Dementia with Lewy bodies.
Dementia with Lewy bodies: an emerging disease.
Dementia with Lewy bodies: review and pharmacotherapeutic implications.
Dementia with lewy bodies: therapeutic opportunities and pitfalls.
Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.
Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey.
Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.
Diagnosis and treatment of cognitive impairment.
Differentiation Between Dementia With Lewy Bodies And Alzheimer's Disease Using Voxel-Based Morphometry Of Structural MRI: A Multicenter Study.
Diffuse Lewy body disease.
Discontinuation of cholinesterase inhibitor treatment in institutionalised patients with advanced dementia.
Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts.
Disease stage in Alzheimer disease and treatment effects of rivastigmine.
Dissociating cholinergic influence on alertness and temporal attention in primates in a simple reaction time paradigm.
Do caregivers' experiences correspond with the concerns raised in the literature? Ethical issues relating to anti-dementia drugs.
Does this patient have Alzheimer disease? Diagnosing and treating dementia.
Donepezil and cognitive remediation therapy to augment treatment of alcohol use disorder related mild cognitive impairment (AUD-MCI): An open label pilot study with historical controls.
Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type.
Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.
Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial.
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial.
Donepezil improves symptoms of delirium in dementia: implications for future research.
Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury.
Dose-related physostigmine-induced ventricular arrhythmia: case report.
Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea.
Duration of therapy with acetylcholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease as reported in the literature.
Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
Education and use of dementia drugs: a register-based study of over 600,000 older people.
Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: A population-based study.
Effect of cholinergic medication, before and after focal photothrombotic ischemic cortical injury, on histological and functional outcome in aged and young adult rats.
Effect of Delirium on Physical Function in Noncardiac Thoracic Surgery Patients.
Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study.
Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
Effect of galantamine on platelet functions in healthy elderly people.
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease.
Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors.
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review.
Effects of 21 months of cholinesterase inhibitors on cognitive and functional decline in demented patients.
Effects of antidepressants on longevity and dementia onset among adults with Down syndrome: a retrospective study.
Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data.
Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.
Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.
Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.
Effects of donepezil on sleep disturbances in patients with dementia with Lewy bodies: An open-label study with actigraphy.
Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
Effects of Ginkgo biloba Extract EGb 761, Donepezil and their Combination on Central Cholinergic Function in Aged Rats.
Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia.
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies.
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis.
Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil.
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.
Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies.
Enhancing attention in neurodegenerative diseases: current therapies and future directions.
Enhancing Dementia Care: A Primary Care-Based Memory Clinic.
Epidemiology of Dementia in Elderly Chronic Obstructive Pulmonary Disease Patients Living in China's Northwestern High-Elevation Area.
Etiology and predictors of urinary incontinence and its effect on quality of life.
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase.
Exploring dementia management attitudes in primary care: a key informant survey to primary care physicians in 25 European countries.
Factors associated with use of medications with potential to impair cognition or cholinesterase inhibitors among Alzheimer's disease patients.
Fall-Related Hospitalizations in Nursing Home Residents Co-Prescribed a Cholinesterase Inhibitor and Beta-Blocker.
Feeling the need ... the need for speed (of processing training) in Parkinson disease.
Five-year risk of admission to long-term care home and death for older adults given a new diagnosis of dementia: a population-based retrospective cohort study.
Galantamine improves sleep quality in patients with dementia.
Generation and validation of algorithms to identify subjects with dementia using administrative data.
Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders.
Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.
Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider.
Guidelines for the medical treatment of patients with Alzheimer's disease.
Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.
How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study.
How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis.
Immunomodulation by 9-amino-1,2,3,4-tetrahydroacridine (THA): 1. Down-regulation of natural cell-mediated cytotoxicity in vitro.
Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.
Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study.
Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia.
In vivo and in vitro metabolism and pharmacokinetics of cholinesterase inhibitor deoxyvasicine from aerial parts of Peganum harmala Linn in rats via UPLC-ESI-QTOF-MS and UPLC-ESI-MS/MS.
Increased cholinergic activity under conditions of low estrogen leads to adverse cardiac remodeling.
Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing.
Initiation of cholinesterase inhibitors in an inpatient setting.
Innovations: geriatric psychiatry: diagnosis and treatment of neuropsychiatric symptoms in Alzheimer's disease.
Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase.
Intermittent Stimulation of the Nucleus Basalis of Meynert Improves Working Memory in Adult Monkeys.
Interventions for preventing delirium in hospitalised non-ICU patients.
Investigational treatment for vascular cognitive impairment.
Involuntary weight loss associated with cholinesterase inhibitors in dementia.
Is donepezil effective for multiple sclerosis-related cognitive dysfunction? A critically appraised topic.
Late life depression and dementia: a mental health literacy survey of Australian general practitioners.
Lewy body dementia and Parkinson's disease with dementia.
Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?
Little evidence that cholinesterase inhibitors prevent progression of mild cognitive impairment to dementia, but they are associated with adverse effects.
Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies.
Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
Managing the patient with dementia in long-term care.
Mania after administration of cholinesterase inhibitors in patients with dementia and comorbid bipolar disorder: two case reports.
Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population.
Medication Adherence in Patients With Dementia: An Austrian Cohort Study.
Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.
Memantine ER/Donepezil: A Review in Alzheimer's Disease.
Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease.
Mental health economics, health service provision, and the practice of geriatric psychiatry.
Mesial Frontal Lobe Infarction Presenting as Pisa Syndrome.
Mixed dementia: emerging concepts and therapeutic implications.
Monoamine metabolite concentrations and cholinesterase activities in cerebrospinal fluid of progressive dementia patients: relation to clinical parameters.
Muscarinic, Ca(++) antagonist and specific butyrylcholinesterase inhibitory activity of dried ginger extract might explain its use in dementia.
N-[3,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide Analogues: Novel Acetyl- and Butyrylcholinesterase Inhibitors.
Natural cholinesterase inhibitors from marine organisms.
Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update.
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.
Neuroimaging characteristics of dementia with Lewy bodies.
Neuropsychiatric feature profiles of patients with Lewy body dementia.
Neuropsychological rehabilitation program and behavioral disturbances in early-stage Alzheimer patients.
New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.
Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review.
Nonmedical influences on the use of cholinesterase inhibitors in dementia care.
Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors.
Overcoming the barriers to the diagnosis of dementia.
Parkinson's disease dementia can be easily detected in routine clinical practice.
Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment.
Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series.
Patient and companion shared decision making and satisfaction with decisions about starting cholinesterase medication at dementia diagnosis.
Patients characteristics with cholinesterase inhibitor resistant hallucinations in dementia with Lewy bodies.
Patients with dementia syndrome in public and private services in southern Brazil.
Patterns of Potentially Inappropriate Bladder Antimuscarinic Use in People with Dementia: A Retrospective Cohort Study.
Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia.
Persistence of cholinesterase inhibitor treatment in dementia: insights from a naturalistic study.
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.
PET probes for imaging brain acetylcholinesterase.
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.
Pharmacokinetic rationale for the rivastigmine patch.
Pharmacokinetic studies of cholinesterase inhibitors.
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease.
Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics.
Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.
Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.
Pharmacotherapy of Parkinson disease dementia and Lewy body dementia.
Pisa syndrome in a cohort of Alzheimer's disease patients.
Plasma acetylcholinesterase activity correlates with intracerebral ?-amyloid load.
Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer's disease and dementia with Lewy bodies?
Posttraumatic stress disorder exacerbation with cholinesterase inhibitor in a patient with dementia.
Potentially inappropriate prescribing in dementia: a state-of-the-art review since 2007.
Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Pre-Stroke Cholinesterase Inhibitor Treatment Is Beneficially Associated with Functional Outcome in Patients with Acute Ischemic Stroke and Pre-Stroke Dementia: The Fukuoka Stroke Registry.
Predictive Factors of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease and Mixed Dementia: A One-Year Naturalistic Study.
Predictors of Cholinesterase Discontinuation during the First Year after Nursing Home Admission.
Predictors of mortality in M?ori, Pacific Island, and European patients diagnosed with dementia at a New Zealand Memory Service.
Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.
Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy.
Prevalence of cholinesterase inhibitors in subjects with dementia in Europe.
Primary care physician volume and quality of care for older adults with dementia: a retrospective cohort study.
Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum.
Prophylactic cognitive enhancers for improvement of cognitive function in patients undergoing electroconvulsive therapy: A systematic review and meta-analysis.
Psychiatric aspects of Parkinson's disease--an update.
Psychosis in Parkinson's disease.
Published randomized controlled trials of drug therapy for dementia often lack complete data on harm.
Rapid eye movement sleep atonia in patients with cognitive impairment.
Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study.
Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program.
Recent developments in tau-based therapeutics for neurodegenerative diseases.
Recent Knowledge on Medicinal Plants as Source of Cholinesterase Inhibitors for the Treatment of Dementia.
Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type.
Regulation of attention and response to therapy in dementia by butyrylcholinesterase.
Relationship and stage of dementia differences in caregiver perspectives on the meaning of activity.
Relationship of vascular risk to the progression of Alzheimer disease.
Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence?
Responses to donepezil in Alzheimer's disease and Parkinson's disease.
Review: cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia.
Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures.
Revisiting choline alphoscerate profile: a new, perspective, role in dementia?
Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Rivastigmine for Alzheimer's disease.
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis.
Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.
Rivastigmine in Parkinson's disease dementia.
Rivastigmine in the treatment of patients with Alzheimer's disease.
Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Role of cholinesterase inhibitors in dementia care needs rethinking.
Role of cholinesterase inhibitors in dementia care: memory clinics and cholinesterase inhibitors have their place.
Role of cholinesterase inhibitors in dementia care: NICE's economic analysis has limitations.
Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.
Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Screening for Adverse Drug Reactions in Dementia Patients on Cholinesterase Inhibitor Therapy.
Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force.
Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
Serum and CSF cholinesterase activity in various kinds of dementia.
Serum brain-derived neurotrophic factor, nerve growth factor and neurotrophin-3 levels in dementia.
Serum Butyrylcholinesterase Activity: A Biomarker for Parkinson's Disease and Related Dementia.
Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer's Dementia Are Frequently Below the Recommended Levels.
Serum Level and Activity of Butylcholinesterase: A Biomarker for Post-Stroke Dementia.
Sex Differences in the Prevalent Use of Oral Formulations of Cholinesterase Inhibitors in Older Adults with Dementia.
Short- and long-term efficacy of cholinesterase inhibitors in older adults with alzheimer's disease and mixed dementia: results of a 21-month observational study.
Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease.
SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
Sleep disorders in Alzheimer's disease and other dementias.
Spotlight on cerebrolysin in dementia.
Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Structure-activity relationship, in vitro and in vivo evaluation of novel dienyl sulphonyl fluorides as selective BuChE inhibitors for the treatment of Alzheimer's disease.
Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives.
Successful treatment of behavioural problems in dementia using a cholinesterase inhibitor: the ethical questions.
Switching cholinesterase inhibitors in older adults with dementia.
Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.
Syncope with cholinesterase inhibitors.
Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease.
Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias.
Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer's Disease, Vascular Dementia, or Mixed Dementia.
Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia.
Tacrine does not alter the potency of succinylcholine in the rat.
Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography.
Tacrine therapy is associated with reduced mortality in nursing home residents with dementia.
Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Ten years of cholinesterase inhibitors.
Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB.
The ABC of Alzheimer's disease: cognitive changes and their management in Alzheimer's disease and related dementias.
The age gap between patients in clinical studies and in the general population: a pitfall for dementia research.
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia.
The cholinergic deficiency syndrome and its therapeutic implications.
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
The cholinesterase inhibitors.
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.
The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort.
The effect of cholinesterase inhibitors on risk of nursing home placement among medicaid beneficiaries with dementia.
The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia.
The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia.
The effects of repetitive transcranial magnetic stimulation in older adults with mild cognitive impairment: a protocol for a randomized, controlled three-arm trial.
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
The impact of Medicare prescription drug coverage on the use of antidementia drugs.
The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.
The interplay of cholinergic function, attention, and falls in Parkinson's disease.
The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients.
The neuropsychiatry of Parkinson's disease.
The psychopharmacology of European herbs with cognition-enhancing properties.
The second Leicester survey of memory clinics in the British Isles.
The significance of the activity of CSF cholinesterases in dementias.
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
The use of atypical antipsychotics in nursing homes.
The use of medications with known or potential anticholinergic activity in patients with dementia receiving cholinesterase inhibitors.
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Transdermal patch delivery of acetylcholinesterase inhibitors.
Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.
Treating the dementia of 'Iris' with a cholinesterase inhibitor.
Treating the dementia of Iris with a cholinesterase inhibitor.
Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.
Treatment of attention deficits in neurological disorders.
Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings.
Treatment of behavioural symptoms and dementia in Parkinson's disease.
Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Treatment of dementia: anything new?
Treatment of Mild Cognitive Impairment.
Treatment of psychosis and dementia in Parkinson's disease.
Treatment of psychotic symptoms in patients with Parkinson disease.
Treatment of tardive dyskinesia with donepezil: a pilot study.
Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia.
Treatments for Parkinson disease--past achievements and current clinical needs.
Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson's Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage.
Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer's disease dispensed by the Brazilian public health system - 2008 to 2014: a nation-wide analysis.
Trends in Drug Prescription Rates for Dementia: An Observational Population-Based Study in France, 2006-2014.
Upper gastrointestinal bleeding in elderly adults with dementia receiving cholinesterase inhibitors: a population-based cohort study.
Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples.
Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.
Use of cognitive enhancers and associated medical care costs among patients with dementia: a nationwide study in Taiwan.
Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity.
Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland.
Using a distribution-based approach and systematic review methods to derive minimum clinically important differences.
Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
Vascular dementia.
Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System.
When a Parkinson's disease patient starts to hallucinate.
Who will be eligible? An investigation of the dementia population eligible for cholinesterase treatment following the change in NICE guidance.
Withanolides: Biologically Active Constituents in the Treatment of Alzheimer Disease.
Withanoside IV and its active metabolite, sominone, attenuate Abeta(25-35)-induced neurodegeneration.
Withdrawal of Antidementia Drugs in Older People: Who, When and How?
[Advances in the therapy of dementia.]
[Cardiac effects of cholinesterase inhibitors: a reason for restraint?]
[Cholinergic deficiency syndrome as an indicator for the cholinesterase inhibitors]
[Cholinesterase inhibitor and ginkgo extracts in therapy of dementia. A comparison of effectiveness based on controlled studies]
[Cholinesterase inhibitors for the treatment of dementia in Parkinson's disease.]
[Cholinesterase inhibitors in dementia: the precarious balance between efficacy and safety]
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]
[Cholinesterase inhibitors in the treatment of mixed dementia].
[Delirious states in elderly persons. Therapeutic modalities]
[Dementia and bipolar disorder on the borderline of old age].
[Dementia in Parkinsn's disease.]
[Dementia in Parkinson's disease]
[Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine]
[Detection of the cholinesterase inhibitor tacrine and its main metabolites]
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?]
[Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient]
[Doubtful evidence for the use of the cholinesterase inhibitor donepezil in patients with dementia -- a systematic review]
[Drug therapy for Alzheimer's disease]
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
[Early diagnosis, therapy, and long-term follow up of dementia]
[Good evidence for benefits of cholinesterase inhibitors in Parkinson dementia is still missing]
[Limited efficacy of cholinesterase inhibitors in Alzheimer's dementia.]
[Metabolic syndrome in Alzheimer's disease: clinical and developmental influences]
[Registries for neurological drugs landscape].
[Reminyl efficacy in dementia with Levi bodies]
[Role of secondary care too small in Dutch College of General Practitioners' (NHG) practice guideline 'Dementia'].
[Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia.]
[The clinical relevance of memantine use]
[The current diagnostic approach for chronic progressive dementia]
[Therapy of Dementia: State of the Art].
[Treatment and care strategies for Alzheimer's disease and related dementias]
[Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors]
[Treatment of Alzheimer's disease according to the S3 guidelines on dementia. Choline esterase inhibitors for all and for ever?].
[Treatment of Alzheimer's disease: the current situation?].
[Treatment of dementia with Lewy bodies]
[Treatment of dementia].
[Updated Dementia guideline: reflections from primary care].
Dementia, Multi-Infarct
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
Dementia, Vascular
11: disorders of memory and intellect.
Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia.
Cerebrolysin: a review of its use in dementia.
Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients.
Cholinesterase inhibitors and vascular dementia: another string to their bow?
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Cholinesterase inhibitors in the treatment of dementia.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
Cognitive pharmacotherapy of Alzheimer's disease and other dementias.
Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM).
Correlations Between Cholinesterase Activity and Cognitive Scores in Post-Ischemic Rats and Patients with Vascular Dementia.
Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia: A meta-analysis.
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis.
Evaluating the Memory Enhancing Effects of Angelica gigas in Mouse Models of Mild Cognitive Impairments.
Feasibility of vascular dementia treatment with cholinesterase inhibitors.
Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.
Increased serum butyrylcholinesterase activity in type IIb hyperlipidaemic patients.
Investigational treatment for vascular cognitive impairment.
Is it possible to treat vascular dementia?
Poststroke dementia in the elderly.
Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy.
Review: Cerebral microvascular pathology in aging and neurodegeneration.
Rivastigmine in subcortical vascular dementia: an open 22-month study.
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Serum and CSF cholinesterase activity in various kinds of dementia.
Serum brain-derived neurotrophic factor, nerve growth factor and neurotrophin-3 levels in dementia.
Spotlight on cerebrolysin in dementia.
Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer's Disease, Vascular Dementia, or Mixed Dementia.
Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia.
Systematic review on the efficacy and safety of herbal medicines for vascular dementia.
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.
Twin drug design, synthesis and evaluation of diosgenin derivatives as multitargeted agents for the treatment of vascular dementia.
Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management.
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]
[How Treatable is Vascular Dementia?].
[Treatment of dementia].
Demyelinating Diseases
Butyrylcholinesterase activity in multiple sclerosis neuropathology.
Cysteine thioesters as myelin proteolipid protein analogues to examine the role of butyrylcholinesterase in myelin decompaction.
Dengue
Serum cholinesterase activity in patients with dengue haemorrhagic fever.
Dermatitis
Ataxia, depression, and dermatitis associated with the use of dichlorvos-impregnated collars in the laboratory cat.
[Differences in blood cholinesterase activity as a possible differential diagnostic criterion of eczema, atopic dermatosis and allergic eczema-like dermatitis]
[Effects of glutathione on serum cholinesterase activity in so-called allergic dermatitis]
Dermatitis, Atopic
Studies in the transaminase, cholinesterase, and alkaline phosphatase activity in the serum of patients with disseminated neurodermatitis.
Dermatomycoses
[Changes in cholinesterase activity and catecholamine content in the blood plasma in dermatomycoses]
Diabetes Mellitus
A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation.
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?
Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: correlation with antioxidant activity.
Butyrylcholinesterase and diabetes mellitus in the CHE2 C5- and CHE2 C5+ phenotypes.
Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry.
Determination of inhibitory activities of enzymes, related to Alzheimer's disease and diabetes mellitus of plane tree (Platanus orientalis L.) extracts and their antioxidant, antimicrobial and anticancer activities.
Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease.
Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays.
Fatty Liver, and Not Visceral Fat, Is More Associated with Liver Fibrosis and Diabetes in Non-Obese Japanese Individuals: A Cross-Sectional Study.
Gestational diabetes mellitus (GDM) decreases butyrylcholinesterase (BChE) activity and changes its relationship with lipids.
Hepaticojejunostomy--analysis of risk factors for postoperative bile leaks and surgical complications.
Novel inhibitors with sulfamethazine backbone: synthesis and biological study of multi-target cholinesterases and ?-glucosidase inhibitors.
Plasma 25-hydroxyvitamin d is independently associated with hemoglobin concentration in male subjects with type 2 diabetes mellitus.
Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast ?-glucosidase, acetylcholinesterase and butyrylcholinesterase.
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus.
Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats.
Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects: different association patterns in subjects with type 2 diabetes mellitus.
Serum butyrylcholinesterase activity in dogs with diabetes mellitus.
Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach.
Serum cholinesterase activity and proteosynthetic function of liver in patients with diabetes mellitus.
Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients.
Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Synthesis, Characterization, and Inhibition Study of Novel Substituted Phenylureido Sulfaguanidine Derivatives as ?-Glycosidase and Cholinesterase Inhibitors.
The results of the "essential laboratory tests" applied to new outpatients--re-evaluation of diagnostic efficiencies of the test items.
Variant K of butyrylcholinesterase and risk of early-onset type 1 diabetes mellitus in Euro-Brazilians.
Variant K of butyrylcholinesterase and types 1 and 2 of diabetes mellitus.
[Assessment of the guidelines for efficacious utilization of laboratory tests in primary care medicine]
[Diagnostic coefficients of ischemic heart disease in diabetes mellitus]
[Serum cholinesterase determination in diabetes mellitus patients, using indicator paper]
[Significance of serum pseudocholinesterase activity in diabetes mellitus]
[Transaminase, lactic dehydrogenase and pseudocholinesterase activity of the blood in diabetes mellitus.]
Diabetes Mellitus, Type 1
Assessment of the platelet parameters and serum butyrylcholinesterase activity in type 1 diabetes patients with ketoacidosis.
Osmotic stress due to changes in plasma glucose and its regulation in IDDM patients.
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus.
Variant K of butyrylcholinesterase and risk of early-onset type 1 diabetes mellitus in Euro-Brazilians.
Diabetes Mellitus, Type 2
A study of measurement of serum cholinesterase in type 2 diabetes and hypertension.
Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?
Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: correlation with antioxidant activity.
Effects of Coenzyme Q10 Supplementation on Serum Values of Gamma-glutamyl transferase, Pseudocholinesterase, Bilirubin, Ferritin, and High-Sensitivity C-Reactive Protein in Women with Type 2 Diabetes.
Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease.
Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes.
Influence of different extraction techniques on the chemical profile and biological properties of Anthemis cotula L.: Multifunctional aspects for potential pharmaceutical applications.
Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion.
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus.
Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects: different association patterns in subjects with type 2 diabetes mellitus.
Serum butyrylcholinesterase and the risk of future type 2 diabetes: The Kansai Healthcare Study.
Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach.
Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance.
Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes.
Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients.
Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders.
Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Diabetes, Gestational
Acylated ghrelin concentrations are markedly decreased during pregnancy in mothers with and without gestational diabetes: relationship with cholinesterase.
Butyrylcholinesterase activity in gestational diabetes: correlation with lymphocyte subpopulations in peripheral blood.
Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: correlation with antioxidant activity.
Gestational diabetes mellitus (GDM) decreases butyrylcholinesterase (BChE) activity and changes its relationship with lipids.
Maternal circulating levels of some metabolic syndrome biomarkers in gestational diabetes mellitus.
Pseudocholinesterase in gestational diabetes: positive correlation with LDL and negative correlation with triglyceride.
[Application of Bayes Probability Model in Differentiation of Yin and Yang Jaundice Syndromes in Neonates].
Diabetic Ketoacidosis
Assessment of platelets morphological changes and serum butyrylcholinesterase activity in children with diabetic ketoacidosis: a case control study.
Digestive System Diseases
Changes in high density lipoproteins in patients with hepatobiliary diseases. Levels and lipid composition of HDL2 and HDL3 and LCAT reaction.
Cholinesterase in hepatobiliary diseases.
Disseminated Intravascular Coagulation
Clinical studies on plasma protein C. Correlation with serum cholinesterase.
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Down Syndrome
Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome.
An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production.
Clinical trials in children with Down syndrome: Issues from a cognitive research perspective.
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Effects of antidepressants on longevity and dementia onset among adults with Down syndrome: a retrospective study.
Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study.
Plasma cholinesterase polymorphism in Down's syndrome.
Pseudocholinesterase activity and E1 phenotypes in Down's syndrome and mental retardation.
Serum cholinesterase (pseudocholinesterase) in Down's syndrome: 1. Phenotype frequencies at the E1 and E2 loci.
Serum cholinesterase (pseudocholinesterase) in Down's syndrome: 2. Quantitative levels.
The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
Drug-Related Side Effects and Adverse Reactions
Adverse Drug Reactions Associated With Cholinesterase Inhibitors-Sequence Symmetry Analyses Using Prescription Claims Data.
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer's Disease.
Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.
Memantine in everyday clinical practice: a comparison of studies in Germany and Greece.
Physiological and performance effects of pyridostigmine bromide in healthy volunteers: a dose-response study.
Potential Nutraceutical Properties of Leaves from Several Commonly Cultivated Plants.
Screening for Adverse Drug Reactions in Dementia Patients on Cholinesterase Inhibitor Therapy.
Duodenal Ulcer
Serum and red cell cholinesterase activity in duodenal ulcer.
THE CONCENTRATION OF ACETYLCHOLINE AND THE LEVEL CHOLINESTERASE ACTIVITY IN THE SERUM OF PATIENTS WITH GASTRIC ULCER, DUODENAL ULCER AND ALCOHOLIC CHRONIC PANCREATITIS.
[DUODENAL ULCER AND PROTRACTED CHOLINESTERASE INHIBITION. OBSERVATION OF 2 PATIENTS WITH MYASTHENIA GRAVIS.]
[Problems in the genetics of peptic ulcer. II. An analysis of the associations of the disease with certain simply heritable traits]
Dysentery
[Activity of serum cholinesterase and catalase in patients with typhoid and dysentery]
[On the problem of the relationship between vitamin B1 metabolism and cholinesterase activity in dysentery in children.]
Dyskinesias
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.
Chronic Neurological Disorders: Genetic and Epigenetic Markers for Monitoring of Pharmacotherapy.
Dyslipidemias
Emerging links between type 2 diabetes and Alzheimer's disease.
Fish Oil and Primrose Oil Suppress the Progression of Alzheimer's Like Disease Induced by Aluminum in Rats.
Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia.
Serum cholinesterase activity in diabetes and associated pathologies.
Dyspnea
Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases.
Effects of subchronic inhalation exposure to an organophosphorus insecticide compound containing dichlorvos on wistar rats' otoacoustic emissions.
Poisoning of an urban family due to misapplication of household organophosphate and carbamate pesticides.
The possible role of intravenous lipid emulsion in the treatment of chemical warfare agent poisoning.
[A patient with facioscapulohumeral muscular dystrophy accompanied by myasthenia gravis]
[Clinical analysis of patients with community-acquired pneumonia requiring hospitalization classified by age group]
Dystonia
Acetylcholinesterase and butyrylcholinesterase in cerebrospinal fluid from patients with dystonia.
Cholinesterase inhibitors and pisa syndrome: a pharmacovigilance study.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors.
Ecchymosis
[Clinical and laboratory characteristics of juvenile myelomonocytic leukemia].
Eclampsia
Atypical cholinesterase in a psychotic patient with eclampsia.
Ectopia Cordis
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Eczema
Serum pseudocholinesterase in eczema.
[Blood enzyme activities in men and women with certain diseases]
[Differences in blood cholinesterase activity as a possible differential diagnostic criterion of eczema, atopic dermatosis and allergic eczema-like dermatitis]
Ehrlichiosis
Butyrylcholinesterase as a marker of inflammation and liver injury in the acute and subclinical phases of canine ehrlichiosis.
Encephalitis
Evaluation of cholinergic functions in patients with Japanese encephalitis and Herpes simplex encephalitis.
Encephalitis, Herpes Simplex
Evaluation of cholinergic functions in patients with Japanese encephalitis and Herpes simplex encephalitis.
Encephalitis, Japanese
Evaluation of cholinergic functions in patients with Japanese encephalitis and Herpes simplex encephalitis.
Japanese Encephalitis Virus Infection Results in Transient Dysfunction of Memory Learning and Cholinesterase Inhibition.
Encephalocele
Ratio of immunochemically determined amniotic fluid acetylcholinesterase to butyrylcholinesterase in the differential diagnosis of fetal abnormalities.
End Stage Liver Disease
Changes of plasma cholinesterase activity during orthotopic liver transplantation in man.
Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D.
[Reevaluation of the typing criteria for patients with chronic severe hepatitis]
[The therapeutic value of alpha-fetoprotein and cholinesterase in patients with hepatitis B virus related acute onset chronic liver failure].
Endometriosis
[Genetic aspects of endometriosis: features of the distribution of polymorphic gene frequencies]
Endometritis
Bovine Endometritis and the Inflammatory Peripheral Cholinergic System.
Endotoxemia
Physostigmine reverses disturbances of the intestinal microcirculation during experimental endotoxemia.
Serum butyrylcholinesterase and paraoxonase 1 in a canine model of endotoxemia: Effects of choline administration.
Serum choline and butyrylcholinesterase changes in response to endotoxin in calves receiving intravenous choline administration.
Entamoebiasis
Serum cholinesterase and alkaline phosphatase levels and serum protein fractions in Entamoeba histolytica infections.
Enteritis
Anti-foodborne enteritis effect of galantamine potentially via acetylcholine anti-inflammatory pathway in fish.
Inflammatory and oxidative biomarkers of disease severity in dogs with parvoviral enteritis.
Environmental Illness
Environmental illness: fatigue and cholinesterase activity in patients reporting hypersensitivity to electricity.
Epilepsies, Partial
[A hypothesis based on histochemical data regarding the site from which originate the automatic movements present in rhinencephalic epilepsy and an added note concerning the distribution of cholinesterase activity in the amygdaloid complex of man.]
Epilepsy
High-performance counter-current chromatography isolation and initial neuroactivity characterization of furanocoumarin derivatives from Peucedanum alsaticum L (Apiaceae).
Older adults with epilepsy demonstrate cognitive impairments compared with patients with amnestic mild cognitive impairment.
Potential of nafimidone derivatives against co-morbidities of epilepsy: In vitro, in vivo, and in silico investigations.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Treatment of memory disorders in epilepsy.
[Action of cholinesterase & electrophoretic blood protein fractions in epilepsy & paresis.]
[Changes in faradic epilepsy of dogs caused by cholinesterase.]
[Decrease of cholinesterase in areas of the cerebral cortex "isolated" for a long period and hypersensitive to epilepsy.]
[Role of the acetylcholine--cholinesterase system in the development of epilepsy]
Epilepsy, Reflex
[Effect of cholinesterase on experimental reflex epilepsy.]
[Electrographic observations on the "antidisposition" mechanism of action toward reflex epilepsy on the cholinesterase treatment.]
Epistaxis
Effect of pyridostigmine (Mestinon) on human platelet aggregation.
Erythema
Clinical factors that affect blood gases in non-smoking women with chronic liver disease.
Skin decontamination efficacy of sulfur mustard and VX in the pig model: A comparison between Fuller's earth and RSDL.
Esophageal Achalasia
Esophageal aperistalsis and achalasia produced in dogs by prolonged cholinesterase inhibition.
Esophageal and Gastric Varices
A conundrum: general or neuraxial anesthesia and the use of ROTEM.
Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi).
Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis.
Survival and prognostic indicators in compensated and decompensated cirrhosis.
Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification.
Esophageal Spasm, Diffuse
Symptomatic diffuse esophageal spasm. Manometric follow-up and response to cholinergic stimulation and cholinesterase inhibition.
Essential Hypertension
[Association of mutant alleles of serum cholinesterase with various multi-factorial and infectious diseases]
[Effects of A.T.P. (adenosinetriphosphoric acid) on the blood cholinesterase of patients with essential hypertension and hyperthyroidism; preliminary report.]
[Serum cholinesterase levels in essential hypertension.]
Fasciculation
Amitraz Poisoning: The not so (Un)common Poisoning.
Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats.
Fresh frozen plasma as a successful antidotal supplement in acute organophosphate poisoning.
Letter: Absence of suxamethonium fasciculations in patients with atypical plasma cholinesterase.
Letter: Absence of suxamethonium fasciculations in patients with atypical pseudocholinesterase.
Pathophysiology of fasciculations in ALS as studied by electromyography of single motor units.
Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX.
Presence of suxamethonium fasciculations in patients with atypical plasma cholinesterase.
Pulmonary function changes induced by experimental dichlorvos toxicosis in calves.
Striatal neurochemical changes and motor dysfunction in mipafox-treated animals.
Study of respiratory failure in organophosphate and carbamate poisoning.
Violent fasciculations after small dose succinylcholine infusion as a first sign of atypical pseudocholinesterase.
Violent fasciculations may not signal pseudocholinesterase deficiency.
[Myasthenia gravis with anti-acetylcholine receptor antibody or anti-muscle specific kinase antibody].
Fatigue Syndrome, Chronic
Peripheral cholinergic function in humans with chronic fatigue syndrome, Gulf War syndrome and with illness following organophosphate exposure.
Fatty Liver
Abnormal blood chemistry data in Cushing's syndrome: comparison with those for fatty liver.
Acetylcholinesterase (AChE) inhibition aggravates fasting-induced triglyceride accumulation in the mouse liver.
Changes in high density lipoproteins in patients with hepatobiliary diseases. Levels and lipid composition of HDL2 and HDL3 and LCAT reaction.
Development and application of serum cholinesterase activity measurement using benzoylthiocholine iodide.
Fatty liver and serum cholinesterase are independently correlated with HbA1c levels: Cross-sectional analysis of 5384 people.
Idiopathic fatty liver of pregnancy with a subsequent uncomplicated pregnancy and a progressive increase in serum cholinesterase activity during the third trimester. A case report.
Prolonged neuromuscular block associated with acute fatty liver of pregnancy and reduced plasma cholinesterase.
Relationship between content of hepatic glutathione S-transferases and the kinetics of indocyanine green elimination in various liver diseases.
Relationship between serum leptin and fatty liver in Japanese male adolescent university students.
Serum butyrylcholinesterase and the risk of future type 2 diabetes: The Kansai Healthcare Study.
Serum butyrylcholinesterase/HDL-cholesterol ratio and atherogenic index of plasma in patients with fatty liver disease.
Serum cholinesterase activity and proteosynthetic function of liver in patients with diabetes mellitus.
Serum cholinesterase in patients with fatty liver.
Serum levels of C3 and cholinesterase in various diseases of the liver.
The results of the "essential laboratory tests" applied to new outpatients--re-evaluation of diagnostic efficiencies of the test items.
[Assessment of the guidelines for efficacious utilization of laboratory tests in primary care medicine]
[Changes in transaminase before and after tonsillectomy]
[Fatty liver and obesity in university students]
[ON THE DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS AND FATTY LIVER. THE SIGNIFICANCE OF PERCUTANEOUS LIVER BIOPSY AND SERUM CHOLINESTERASE ACTIVITY.]
[Serum cholinesterase activity in non-alcoholic fatty liver. Effect of obesity on the activity and role of its measurement in the differential diagnosis in chronic hepatitis]
[Ultrasonic and laboratory studies on fatty liver in white-collar workers]
Fetal Death
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
[CHOLINESTERASE ACTIVITY OF THE BLOOD SERUM IN FETAL DEATH, ASPHYXIA NEONATORUM AND FETAL DEFORMITIES.]
Fetal Hypoxia
[Effect of acute fetal anoxia during labor on enzyme activity of some transaminases and cholinesterase]
Fibroma
[Cholinesterase activity in blood & uterine muscle in fibromatosis.]
Frontotemporal Dementia
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence?
Rivastigmine in frontotemporal dementia: an open-label study.
[Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)]
Frontotemporal Lobar Degeneration
Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy.
[New therapeutic strategies for behavioral and psychological symptoms of dementia]
Ganglion Cysts
[Effect of Alternanthera philoxeroides on enzymic histochemistry of oncomelania hupensis]
[Megacolon congenitum (Hirschsprung's disease) in adults]
[Protective effect of exogenous glial cell line derived neurotrophic factor on neurons after sciatic nerve injury in rats]
Gastritis
[Acetylcholine and cholinesterase indices in chronic gastritis]
Gastrointestinal Diseases
Cholinesterase inhibitors: a patent review (2007 - 2011).
[Activity of non-specific cholinesterase in acute gastrointestinal diseases in infants]
Gastroschisis
Ratio of amniotic fluid acetylcholinesterase to pseudocholinesterase as an antenatal diagnostic test for exomphalos and gastroschisis.
Gestational Trophoblastic Disease
Plasma cholinesterase and trophoblastic disease. Gestational trophoblastic disease and reduced activity of plasma cholinesterase.
Gilbert Disease
Relationship between content of hepatic glutathione S-transferases and the kinetics of indocyanine green elimination in various liver diseases.
Glaucoma
An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production.
Blood cholinesterase activity of glaucoma patients treated with phospholine iodide.
Cholinesterase activities in plasma and erythrocytes in glaucoma patients treated with substances without any anticholin-esterase effect.
Cholinesterase activities in plasma and erythrocytes in glaucoma patients.
CHOLINESTERASE ACTIVITY IN PLASMA AND ERYTHROCYTES. A CLINICO-HAEMATOLOGICAL STUDY BASED ON NORMAL SUBJECTS AND ON PATIENTS WITH GLAUCOMA, OF WHOM SOME NOT TREATED WITH AND SOME TREATED WITH ANTICHOLINESTERASES.
Cholinesterase activity in the serum and aqueous in glaucoma.
Cholinesterase inhibitors: a patent review (2007 - 2011).
Cholinesterase inhibitors: pharmacology, symptoms of poisoning, and treatment. Studies on the cholinesterase activities in glaucoma patients.
EFFECT OF PHOSPHOLINE IODIDE ON BLOOD CHOLINESTERASE LEVELS OF NORMAL AND GLAUCOMA SUBJECTS.
Effects of Distigmine on Electrical Field Stimulation-Induced Contraction of Mouse Urinary Bladder Smooth Muscles.
Natural cholinesterase inhibitors from marine organisms.
Pseudocholinesterase, cholinesterase and congenital glaucoma.
Risk factors for cataract: a case control study.
Studies on plasma cholinesterase isoenzymes in glaucoma.
Studies on serum pseudocholinesterase in glaucoma.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
The effect of phospholine iodide eye drops on blood cholinesterase in glaucoma patients.
[A new cholinesterase inhibitor in the treatment of glaucoma]
[Cholinesterase activity in the humor of the anterior chamber and in the blood in patients with glaucoma and cataract]
[Cholinesterase activity of erythrocytes in patients with glaucoma.]
[Cholinesterase activity of plasma in glaucoma.]
[Cholinesterase inhibitors. Pharmacology, symptoms and treatment of poisoning. Investigation of cholinesterase activities in glaucoma patients]
[Clinical evaluation of the effectiveness of cholinesterase inhibition with neuromidin in the treatment of primary glaucoma patients].
[Examination of cholinesterase activity of the serum and aqueous humor in glaucoma.]
[Pressure-lowering effect of a new cholinesterase inhibitor, Ubretid on glaucoma]
[Significance of serum cholinesterase determination in patients with glaucoma]
Glaucoma, Open-Angle
Cholinesterase in aqueous humor of man and open-angle glaucoma.
Glioblastoma
Expression of alternatively terminated unusual human butyrylcholinesterase messenger RNA transcripts, mapping to chromosome 3q26-ter, in nervous system tumors.
Glioma
A histochemical study of the activity of nonspecific cholinesterase in C6 glioma cells in culture.
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors.
Characterization of activities and forms of cholinesterases in human primary brain tumors.
Cholesteryl esters in human malignant neoplasms.
Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
Molecular forms of acetyl- and butyrylcholinesterase in human glioma.
Observation of the Elevation of Cholinesterase Activity in Brain Glioma by a Near-Infrared Emission Chemsensor.
Glomerulonephritis
Industrial toxicology of metals of the platinum group.
Glucose Intolerance
Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders.
Glucose Metabolism Disorders
Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Beta-thalassaemia, G-6-PD deficiency, and atypical cholinesterase in Cyprus.
Glycogen Storage Disease Type VI
Hypercholinesterasemia with isoenzymic alteration in a family.
Goiter
Prevalence of goiter and its associated factors among primary school children in Chole District, Arsi Zone, Ethiopia: a cross- sectional study.
[Changes in the acetylcholine concentration and acetylcholinesterase activity in the thyroid gland tissues and in serum cholinesterase activity in goiter]
[Studies on the thyroid gland. 3. Cholinesterase activity of the blood and serum in patients before and after resection of the goiter]
Goldenhar Syndrome
Airway management using the pediatric GlideScope in a child with Goldenhar syndrome and atypical plasma cholinesterase.
Guillain-Barre Syndrome
The impact of aerial application of organophosphates on the cholinesterase levels of rural residents in the Vaalharts district, Northern Cape Province, South Africa.
[Electrophoresis of cholinesterases of the cerebrospinal fluid in the Guillain-Barré syndrome]
Hallucinations
Capgras syndrome in Dementia with Lewy Bodies.
Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies.
Cholinesterase inhibitors might alleviate methamphetamine-induced delusions, hallucinations and cognitive impairment, while reducing craving and addiction.
Chronic Neurological Disorders: Genetic and Epigenetic Markers for Monitoring of Pharmacotherapy.
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.
Compensatory shifts in visual perception are associated with hallucinations in Lewy body disorders.
Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB.
Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.
Dementia in Parkinson's Disease.
Dementia with lewy bodies: therapeutic opportunities and pitfalls.
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.
Diffuse Lewy Body Disease.
Diffuse Lewy body disease.
Distinguishing Lewy body dementias from Alzheimer's disease.
Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies.
Imagine that: cholinesterase inhibitor treatment of complex visual hallucinations of unknown aetiology.
Lewy body dementia: case report and discussion.
Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population.
Neuropsychiatric symptoms in patients with dementias associated with cortical lewy bodies: pathophysiology, clinical features, and pharmacological management.
New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.
Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series.
Patients characteristics with cholinesterase inhibitor resistant hallucinations in dementia with Lewy bodies.
THE EFFECT OF D-LYSERGIC ACID DIETHYLAMIDE TARTRATE (LSD-25) AND D-2-BROMO LYSERGIC ACID TARTRATE (BOL-148) ON SPECIFIC CHOLINESTERASE AND MONOAMINE OXIDASE OF RAT LIVER AS POSSIBLE FACTORS IN THE MECHANISM OF HALLUCINATION. A HISTOCHEMICAL STUDY.
Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case report.
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be associated with reduced cholinergic input to these areas.
When a Parkinson's disease patient starts to hallucinate.
[Antidementia drugs - response or non-response?]
[Behavioral and psychological symptoms of dementia and their management].
[Delirious states in elderly persons. Therapeutic modalities]
[New therapeutic strategies for behavioral and psychological symptoms of dementia]
[Psychotic symptoms in Parkinson's disease].
[Treatment of neuropsychiatric symptoms in Alzheimer's disease]
Hand, Foot and Mouth Disease
Serum cholinesterase: a potential assistant biomarker for hand, foot, and mouth disease caused by enterovirus 71 infection.
Head and Neck Neoplasms
Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy.
Headache Disorders
Light therapy modulates serotonin levels and blood flow in women with headache. A preliminary study.
Hearing Loss
Hearing screening and cholinesterase activity among rural workers exposed to pesticides.
Heart Arrest
Cardiotoxic effects of dichlorvos (DDVP) in albino rats.
Heart Block
Correlative electrophysiological and anatomical studies concerning the site of origin of escape rhythm during complete atrioventricular block in the dog.
[Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia.]
Heart Defects, Congenital
[Blood cholinesterase activity in children with congenital heart defects]
Heart Diseases
Cholinesterase inhibition reduces arrhythmias in asymptomatic Chagas disease.
Syncope with cholinesterase inhibitors.
[Acute poisoning by an organophosphoric compound. Effects of pralidoxime on cardiac disorders and serum, erythrocyte and tissue cholinesterase activity]
[Cardiac effects of cholinesterase inhibitors: a reason for restraint?]
[Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs]
Heart Failure
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure.
Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure.
Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
Manifestations of and risk factors for acute myocardial injury after acute organophosphorus pesticide poisoning.
Postlaryngectomy pharyngocutaneous fistula: incidence, predisposing factors, and therapy.
Prognostic nomogram for the severity of acute organophosphate insecticide self-poisoning: a retrospective observational cohort study.
Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices.
Prognostic Significance of Serum Cholinesterase Level in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT-HFpEF Registry.
Serum cholinesterase activity and its diagnostic and prognostic significance in patients with chronic cardiac failure.
Serum cholinesterase as a prognostic biomarker for acute heart failure.
Serum cholinesterase is an important prognostic factor in chronic heart failure.
Serum cholinesterase: a potential assistant biomarker for hand, foot, and mouth disease caused by enterovirus 71 infection.
The acetylcholine content and cholinesterase activities in the rabbit heart in experimental heart failure and the effect of g-strophanthin treatment upon them.
[Cholinergic system of the heart].
HELLP Syndrome
Pseudocholinesterase deficiency associated with HELLP syndrome.
Reduced pseudocholinesterase activity in patients with HELLP syndrome.
Hematologic Diseases
A study of cholinesterase activity in the blood of patients with hematologic disease.
Erythrocyte cholinesterase titers in hematologic disease states.
Hematologic Neoplasms
Serum cholesterol and apoprotein B levels and serum cholinesterase activity in selected hematologic malignancies.
Hematoma, Subdural
CHOLINESTERASE IN SUBDURAL HEMATOMAS.
[CHOLINESTERASE ACTIVITY IN SUBDURAL HEMATOMA.]
Hemoglobinuria
Immunochemistry of mammalian cholinesterases.
Hemoglobinuria, Paroxysmal
Immunochemistry of mammalian cholinesterases.
Hemorrhagic Fever with Renal Syndrome
[On blood serum cholinesterase activity in patients with hemorrhagic fever with renal syndrome]
Hemorrhagic Stroke
[Blood serum enzymatic spectrum in vascular diseases of the brain]
Hepatic Encephalopathy
Choline acetyltransferase and acetylcholinesterase activities are unchanged in brain in human and experimental portal-systemic encephalopathy.
Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy.
Nucleos(t)ide analogs improve long-term prognosis in patients with chronic hepatitis B-associated liver failure.
Prognostic factors for chronic severe hepatitis and construction of a prognostic model.
Serum cholinesterase in infective hepatitis and hepatic coma.
Serum levels of C3 and cholinesterase in various diseases of the liver.
Severe depression of serum cholinesterase activity associated with two cases of hepatic encephalopathy.
[Effectiveness of nutritional support for the liver-cell deficiency in the liver cirrhosis]
[Multivariate analysis of hepatic encephalopathy occurrence in patients with liver failure].
Hepatic Insufficiency
[Kwashiorkor syndrome in exudative enteropathy]
[Management of children with fatal liver diseases with reference to eventual liver transplantation]
[Prolonged apnea after suxamethonium administration during staphylococcal toxic shock]
[Serum cholinesterase in liver insufficiency in dog and in horse.]
Hepatitis
Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with interferon-beta in patients with HB(e)Ag-positive chronic active hepatitis.
Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
Current status of liver function tests in Japan.
Dynamic relationship between infantile hepatitis syndrome and cytomegalovirus infection.
Measurement of serum cholinesterase activity: a useful test in the management of acute hepatitis.
Serum cholinesterase (pseudocholinesterase) in Down's syndrome: 2. Quantitative levels.
Serum cholinesterase in infective hepatitis and hepatic coma.
Serum cholinesterase in patients with fatty liver.
Serum levels of C3 and cholinesterase in various diseases of the liver.
Studies of cholinesterase activity. II. Serum cholinesterase in hepatitis and cirrhosis.
The behavior of aspartic and alanine aminotransferases, lactic dehydrogenase, cholinesterase, prothrombin, beta-glucuronidase, bilirubin, thymol turbidity test and serum proteinograms under the influence of corticotherapy in the course of viral hepatitis in children.
The pharmacodynamics of mivacurium in the rabbit with carbon tetrachloride-induced liver disease.
Treatment not helpful in Alzheimer's.
[Activity of aldolase, pseudocholinesterase and transaminases in the blood serum in epidemic hepatitis.]
[Activity of serum cholinesterase in certain liver diseases, particularly in virus hepatitis]
[Behavior of serum cholinesterase in viral hepatitis in infancy]
[Case-controlled study of entecavir treatment for chronic severe hepatitis B]
[Cholinesterase activity in the blood and liver of mice with mouse hepatitis virus infection]
[Cholinesterase of the blood serum and erythrocytes in epidemic hepatitis.]
[Cholinesterase, iron & transaminase in blood serum: comparative study in acute hepatitis, chronic liver diseases & extrahepatic obstructive jaundice.]
[Clinical research on the effect of Oxymatrine on serum cholinesterase]
[Clinical value of measuring the activity of serum cholinesterase and its isoenzyme in chronic hepatitis and liver cirrhosis]
[Comparative studies on the behavior of serum cholinesterase activity, transaminases (SGOT and SGPT) and the serum albumin picture during the treatment of epidemic hepatitis with glucocorticoids (prednisone) and anabolic steroids (methandrostenolone) in childhood]
[Determination of cholinesterase in obstructive jaundice and in the course of virus hepatitis]
[Discriminatory function of serum proteins in liver and biliary tract diseases]
[Relationship between cholinesterase, prothrombin activity and albumin and the pathology of the liver]
[Serum cholinesterase activity in non-alcoholic fatty liver. Effect of obesity on the activity and role of its measurement in the differential diagnosis in chronic hepatitis]
[Serum cholinesterase activity in the biological pattern of epidemic hepatitis.]
[Serum cholinesterase activity in viral hepatitis]
[Serum cholinesterase level in patients with viral hepatitis treated with prednisolone]
[Serum cholinesterase synthesis in children with liver diseases with special reference to acute icteric and anicteric hepatitis]
[Some features specific of the spectrum of proteins, cholinesterase and peroxidase isoenzymes of the blood serum in viral hepatitis]
[The cause of serum cholinesterase activity decrease in hepatitis and liver cirrhosis.]
[Usefulness of serum pseudocholinesterase isoenzymes in acute and chronic liver diseases and neoplasms (experimental and clinical study)]
Hepatitis A
An ultramicro technique for the assay of serum cholinesterase: results in normal children and in children with infectious hepatitis.
Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study.
PLASMA ESTERASE ACTIVITY IN PATIENTS WITH LIVER DISEASE AND THE NEPHROTIC SYNDROME.
[Clinical value of determining the serum cholinesterase level in infectious hepatitis treated with prednisolone]
[Course of activity of serum cholinesterase in various liver diseases especially in infectious hepatitis of adults]
[Drug-induced hepatitis]
Hepatitis B
Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with interferon-beta in patients with HB(e)Ag-positive chronic active hepatitis.
Immunohistological investigations of PAS-negative globular intracisternal hyalin in human liver biopsy specimens.
Plasma cholinesterase: double-edged parameter in the diagnosis of acute organophosphorus poisoning.
[The therapeutic value of alpha-fetoprotein and cholinesterase in patients with hepatitis B virus related acute onset chronic liver failure].
Hepatitis B, Chronic
Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy.
Gamma-glutamyl transpeptidase to cholinesterase and platelet ratio in predicting significant liver fibrosis and cirrhosis of chronic hepatitis B.
Hepatitis C
Serum albumin is present at higher levels in alcoholic liver cirrhosis as compared to HCV-related cirrhosis.
Hepatitis C, Chronic
Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C.
[Relationship between the level of serum TNF-alpha of patients with chronic hepatitis C and treatment with interferon-alpha and the influencing factors]
Hepatitis D
Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D.
Hepatitis D, Chronic
Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D.
Hepatitis, Chronic
Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with interferon-beta in patients with HB(e)Ag-positive chronic active hepatitis.
Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
Discrimination of liver cirrhosis from chronic hepatitis by analysis of serum cholinesterase isozymes using affinity electrophoresis with concanavalin A or wheat germ agglutinin.
Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of Aleuria aurantia lectin-reactive serum cholinesterase to immunoreactive protein.
Enzyme-linked immunosorbent assay (ELISA) for Aleuria aurantia lectin-reactive serum cholinesterase to differentiate liver cirrhosis and chronic hepatitis.
High plasma concentration of myeloperoxidase in cirrhosis: a possible marker of hypersplenism.
Serum cholinesterase in patients with fatty liver.
Serum levels of C3 and cholinesterase in various diseases of the liver.
[Clinical value of measuring the activity of serum cholinesterase and its isoenzyme in chronic hepatitis and liver cirrhosis]
[ON THE DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS AND FATTY LIVER. THE SIGNIFICANCE OF PERCUTANEOUS LIVER BIOPSY AND SERUM CHOLINESTERASE ACTIVITY.]
[Place of serum cholinesterase in the diagnosis of chronic liver diseases]
[Serum cholinesterase activity in non-alcoholic fatty liver. Effect of obesity on the activity and role of its measurement in the differential diagnosis in chronic hepatitis]
Hepatolenticular Degeneration
Oral zinc therapy normalizes serum uric acid level in Wilson's disease patients.
Hepatomegaly
Factors Influencing Cyst Infection in Autosomal Dominant Polycystic Kidney Disease.
[Serum cholinesterase and arylesterase in cirrhosis and steatosic hepatomegaly]
Hepatorenal Syndrome
[Reevaluation of the typing criteria for patients with chronic severe hepatitis]
Hernia, Umbilical
Diagnosis of neural tube defects by estimation of amniotic fluid acetylcholinesterase.
Ratio of amniotic fluid acetylcholinesterase to pseudocholinesterase as an antenatal diagnostic test for exomphalos and gastroschisis.
Herpes Zoster
Evaluation of the developmental and reproductive toxicity of chlorpyrifos in the rat.
Hirschsprung Disease
Autonomic nerves in rectum and colon in Hirschsprung's disease. A cholinesterase and catecholamine histochemical study.
Cholinesterase activities in resected bowel specimens from children with Hirschsprung's disease.
Congenital megacolon; a comparison of the spastic and hypertrophied segments with respect to Cholinesterase activities and sensitivities to Acetylcholine, DFP and the barium ion.
Experience with a cholinesterase histochemical technique for rectal suction biopsies in the diagnosis of Hirschsprung's disease.
Histologic diagnosis of Hirschsprung's disease. The value of concurrent hematoxylin and eosin and cholinesterase staining of rectal biopsies.
The determination of total cholinesterase in rectal biopsy tissue from patients with Hirschsprung's disease.
[Diagnostic value of cholinesterase activity in superficial biopsies of the rectum]
[Value of the assay of cholinesterase activity in superficial biopsies of the rectum in the diagnosis of Hirschsprung's disease]
HIV Infections
The association of the platelet count and the peripheral CD8+ cell count in Japanese HIV-infected hemophiliacs.
Hodgkin Disease
Hodgkin's lymphoma presenting in two siblings with atypical pseudocholinesterase.
Homocystinuria
Homocysteine inhibits butyrylcholinesterase activity in rat serum.
Homocysteine reduces cholinesterase activity in rat and human serum.
In vitro homocysteine inhibits platelet Na+,K+-ATPase and serum butyrylcholinesterase activities of young rats.
Lipid, Oxidative and Inflammatory Profile and Alterations in the Enzymes Paraoxonase and Butyrylcholinesterase in Plasma of Patients with Homocystinuria Due CBS Deficiency: The Vitamin B12 and Folic Acid Importance.
Reduction of butyrylcholinesterase activity in rat serum subjected to hyperhomocysteinemia.
Hookworm Infections
Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study.
Huntington Disease
Pseudocholinesterase activity and phenotypes in mentally ill patients.
The plasma cholinesterase variants in mentally ill patients.
[Cholinesterase and Huntington's chorea]
Hydrocephalus
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Early Serum Biomarkers for Intensive Care Unit Treatment within the First 24 Hours in Patients with Intracerebral Hemorrhage.
Hydronephrosis
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Hydrophthalmos
[On the problem of pseudocholinesterase deficiency syndrome. Anesthesia accident in a 4-months-old infant during an ophthalmological operation in congenital buphthalmos.]
Hyperalgesia
The antiallodynic effects of intrathecal cholinesterase inhibitors in a rat model of neuropathic pain.
The interaction between intrathecal neostigmine and GABA receptor agonists in rats with nerve ligation Injury.
Hypercholesterolemia
Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
Pharmacology of DMSO.
Hyperemia
Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition.
Cortical acetylcholine efflux with hypercapnia and nociceptive stimulation.
[Serum cholinesterase in reactive hyperemia.]
Hypergammaglobulinemia
Horseshoe kidney and membranous glomerulonephritis with cold activation of complement.
Hyperglycemia
Acute toxicity of methyl isocyanate in mammals. II. Induction of hyperglycemia, lactic acidosis, uraemia, and hypothermia in rats.
Amitraz Poisoning: The not so (Un)common Poisoning.
Antihyperglycemic Effect of Quercetin in Ovariectomized Rats Treated with Tamoxifen.
Emerging links between type 2 diabetes and Alzheimer's disease.
Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3.
Methyl parathion and fenvalerate toxicity in American kestrels: acute physiological responses and effects of cold.
Suspected chlorpyrifos toxicosis in a llama, and plasma pseudocholinesterase activity in llamas given chlorpyrifos.
The First Use of Pralidoxime in a Child With Rivastigmine Poisoning.
The Neuroprotective Effect of Dark Chocolate in Monosodium Glutamate-Induced Nontransgenic Alzheimer Disease Model Rats: Biochemical, Behavioral, and Histological Studies.
[Iodine 131 with autography, hyperglycemia, cholinesterase, metabolism, thiomidil, anaphylactic shock, immunisation in hibernation.]
[Iodine 131 with radioautography hyperglycemia, cholinesterase, metabolism, thiomidil, in hibernation.]
[Radioactive iodine with autography, hyperglycemia, cholinesterase, metabolism, thiomidil, anaphylactic shock, and immunization in hibernation.]
Hyperhidrosis
Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.
Hyperhomocysteinemia
A versatile equation to describe reversible enzyme inhibition and activation kinetics: modeling beta-galactosidase and butyrylcholinesterase.
Butyrylcholinesterase activity is reduced in haemodialysis patients: is there association with hyperhomocysteinemia and/or oxidative stress?
Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon4, and hyperhomocysteinemia in neurodegenerative dementias.
Folic acid pretreatment prevents the reduction of Na(+),K(+)-ATPase and butyrylcholinesterase activities in rats subjected to acute hyperhomocysteinemia.
Homocysteine reduces cholinesterase activity in rat and human serum.
Homocysteine thiolactone and human cholinesterases.
Reduction of butyrylcholinesterase activity in rat serum subjected to hyperhomocysteinemia.
Hyperinsulinism
Emerging links between type 2 diabetes and Alzheimer's disease.
Hyperkalemia
Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats.
Hyperlipidemias
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
Cholinesterase in serum and low density lipoprotein of hyperlipidemic patients.
Effect of simian virus 40 subcutaneous tumors on circulating lipids and lipoproteins in the Syrian hamster.
Hereditary serum cholinesterase deficiency associated with severe lipid deposition in the kidney.
Serum butyrylcholinesterase and the risk of future type 2 diabetes: The Kansai Healthcare Study.
Serum cholinesterase activity in hyperlipidemia and the in vitro effect of isoniazid on serum cholinesterase.
[The preanalytical stage of under measuring of concentration of catalytic activity of enzymes: the characteristics and tasks of standardization].
Hyperlipoproteinemia Type II
Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.
Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
[Evaluation of the pseudocholinesterase activity in hyperlipoproteinemia type II and type IV]
Hyperlipoproteinemia Type IV
[Evaluation of the pseudocholinesterase activity in hyperlipoproteinemia type II and type IV]
Hyperlipoproteinemias
Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.
Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
Serum pseudocholinesterase and ceruloplasmin in various types of hyperlipoproteinemia.
Similar behaviour of lecithin:cholesterol acyltransferase and pseudocholinesterase in liver disease and hyperlipoproteinemia.
[Cholinesterase activity in hyperlipoproteinemia patients in middle age]
[Evaluation of the pseudocholinesterase activity in hyperlipoproteinemia type II and type IV]
Hyperparathyroidism
Bilateral Forearm Fractures During Modified Electroconvulsive Therapy in a Male Patient With a History of Hyperparathyroidism and Elevated Pseudocholinesterase Activity.
Hyperpigmentation
Characterization of phytochemical components of Ferula halophila extracts using HPLC-MS/MS and their pharmacological potentials: a multi-functional insight.
Exploring the halophyte Cistanche phelypaea (L.) Cout as a source of health promoting products: In vitro antioxidant and enzyme inhibitory properties, metabolomic profile and computational studies.
Influence of different extraction techniques on the chemical profile and biological properties of Anthemis cotula L.: Multifunctional aspects for potential pharmaceutical applications.
Hypersensitivity
Allergic reaction to suxamethonium during emergency caesarean section and pseudocholinesterase deficiency in the same patient.
Deep neuromuscular blockade and surgical conditions during laparoscopic ventral hernia repair: A randomised, blinded study.
Dexmedetomidine decreases hyperalgesia in neuropathic pain by increasing acetylcholine in the spinal cord.
Effect of Delirium on Physical Function in Noncardiac Thoracic Surgery Patients.
Environmental illness: fatigue and cholinesterase activity in patients reporting hypersensitivity to electricity.
Hypersensitivity to the cholinesterase inhibitor di-iso-propoxy-phosphoryl fluoride (DFP). Cross-sensitization to related compounds.
Increase in the activities of plasma pseudocholinesterase dependent on the blood glucose level and its relation to the hypersensitivity to acetylcholine in striated muscles of KK-CAy mice with diabetes.
Oral donepezil reduces hypersensitivity after nerve injury by a spinal muscarinic receptor mechanism.
Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil.
Pharmacologic treatments of dementia.
Spinal alpha(2)-adrenergic and muscarinic receptors and the NO release cascade mediate supraspinally produced effectiveness of gabapentin at decreasing mechanical hypersensitivity in mice after partial nerve injury.
[Acetylcholine and cholinesterase activity in experimental allergy in white rats]
[Action of corticotropin on blood cholinesterase activity in normal subjects and respiratory allergy patients.]
[Modifications in the action of cholinesterase in blood and tissue in allergy.]
[Research on serum cholinesterase activity in hypersensitivity of the immediate type. I]
[The behavior of serum cholinesterase in allergic diseases in childhood. (Contribution on the role of liver in allergies]
[Treatment of dementia with Lewy bodies]
Hypersensitivity, Delayed
Immune and nutritional effects of early enteral nutrition after major abdominal operations.
Nutritional status, function of the small intestine and jejunal morphology after total gastrectomy for carcinoma of the stomach.
[Effect of the cholinesterase reactivator dipyroxime in various models of delayed hypersensitivity during acute intoxication by acrylonitrile]
[The mechanism of the effect of the cholinesterase reactivator diethyxime on different models of the development of delayed hypersensitivity in acute dichloroethane poisoning]
Hypertension
A conundrum: general or neuraxial anesthesia and the use of ROTEM.
A study of measurement of serum cholinesterase in type 2 diabetes and hypertension.
A study of the cholinesterases of the canine pancreatic sphincters and the relationship between reduced butyrylcholinesterase activity and pancreatic ductal hypertension.
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
Cognitive decline and survival in Alzheimer's disease according to education level.
Drug-induced urinary incontinence.
Functional Analysis and Molecular Docking studies of Medicinal Compounds for AChE and BChE in Alzheimer's Disease and Type 2 Diabetes Mellitus.
Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
Identification of a point mutation associated with a silent phenotype of human serum butyrylcholinesterase--a case of familial cholinesterasemia.
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Postlaryngectomy pharyngocutaneous fistula: incidence, predisposing factors, and therapy.
Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Relationship between cardiac autonomic function and cognitive function in Alzheimer's disease.
Risk factors for cataract: a case control study.
The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.
Vascular dementia: emerging trends.
What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures.
[Determination of serum cholinesterase in hypertension.]
[Effect of vitamin K on arterial hypertension and blood cholinesterase.]
[Modification of blood cholinesterase and effect of phosphacol on hypertension in dogs.]
Hypertension, Portal
A conundrum: general or neuraxial anesthesia and the use of ROTEM.
[Usefulness of cholinesterase determination in ascitic fluid in the differential diagnosis of ascites]
Hypertension, Pregnancy-Induced
Butyrylcholinesterase activity and pregnancy-associated differences in immunologically relevant peripheral blood leukocyte populations.
Hypertension, Renal
[Acetylcholine-like substance concentration and cholinesterase activity during development of experimental renal hypertension]
[The effects of papaverine, tiphen and dibazol on the level of sympathomimetic amines and cholinesterase activity in the blood of dogs with experimentally induced renal hypertension]
Hyperthyroidism
Altered thyroid hormone status and dichlorvos toxicity in rats.
Differential effects of developmental hypo- and hyperthyroidism on acetylcholinesterase and butyrylcholinesterase activity in the spinal cord of developing postnatal rat pups.
Relationship between butyrylcholinesterase activity and lipid parameters in workers occupationally exposed to pesticides.
Serum electrophoretic lipoprotein factors and pseudocholinesterase activity in thyroid disease.
[Blood coagulation, fibrinolysis and plasma esterase activity in hyperthyroidism treated conservatively and surgically]
[Effects of A.T.P. (adenosinetriphosphoric acid) on the blood cholinesterase of patients with essential hypertension and hyperthyroidism; preliminary report.]
[Studies on serum cholinesterase and on procaine esterase in hyperthyroidism.]
Hypertriglyceridemia
1914G variant of BCHE gene associated with enzyme activity, obesity and triglyceride levels.
Associations between serum cholinesterase and incident hyper-LDL cholesterolemia, hypertriglyceridemia and hypo-HDL cholesterolemia as well as changes in lipid levels in a health screening population.
Increased serum gamma-glutamyltransferase in hypertriglyceridemia: comparison with serum pseudocholinesterase.
Hypesthesia
Cholinesterase demonstration of dermal nerve endings in patients with impaired sensation. A clinical and pathologic study of 41 patients and 37 control subjects.
Hypoalbuminemia
Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.
[Familial early onset cerebellar ataxia with hypoalbuminemia]
Hypoaldosteronism
Genetic screening in the Persian Jewish community: A pilot study.
Hypoglycemia
Hypoglycemia During the Temporary Interruption of Parenteral Nutrition Infusion in Pediatric Hematopoietic Stem Cell Transplantation.
Proximal subtotal pancreatectomy as an alternative to total pancreatectomy for malnourished patients.
[Induced insulin hypoglycemia and pseudocholinesterase in peripheral vein blood in subjects with normal metabolism.]
Hypokalemia
Eighteen cases exposed to sarin in Matsumoto, Japan.
Hypokinesia
[Blood and cardiac cholinesterase activity in rats of different sexes and ages during muscle loading and hypokinesia]
Hypoproteinemia
[A kin with a "silent" pseudocholinesterase gene (author's transl)]
[Malignant rheumatoid arthritis]
Hypotension
Clinical correlates of hypotension in patients with acute organophosphorus poisoning.
Inhibitory effect of fenthion and diazinon on the contraction of rat aorta, and its contribution to lethality.
Intrathecal cholinergic agonists lessen bupivacaine spinal-block-induced hypotension in rats.
Pregnancy decreases the threshold for cocaine-induced convulsions in the rat.
[Clinical analysis of patients with community-acquired pneumonia requiring hospitalization classified by age group]
Hypothyroidism
Altered thyroid hormone status and dichlorvos toxicity in rats.
Differential effects of developmental hypo- and hyperthyroidism on acetylcholinesterase and butyrylcholinesterase activity in the spinal cord of developing postnatal rat pups.
Effects of thyroxin therapy on different analytes related to obesity and inflammation in dogs with hypothyroidism.
Influence of neonatal hypothyroidism and of thyroxine on the acetylcholinesterase and cholinesterase activities in the developing central nervous system of the rat.
Pseudo-internuclear ophthalmoplegia as a sign of overlapping myasthenia gravis in a patient with 'intractable' hypothyroidism.
The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.
The relation between plasma lipid levels and pseudocholinesterase activity in hypothyroidism.
[Blood cholinesterase in rats with experimental thyrotoxicosis and hypothyroidism]
[Cholinesterase of the heart of rats with experimental thyrotoxicosis and hypothyroidism]
Hypoventilation
[Relation between serum cholinesterase polymorphism, long-term apnea and hypoventilation during surgery and in the postoperative period]
Hypoxia-Ischemia, Brain
Administration of Huperzia quadrifariata Extract, a Cholinesterase Inhibitory Alkaloid Mixture, has Neuroprotective Effects in a Rat Model of Cerebral Hypoxia-Ischemia.
Ileus
Postoperative ileus, pregnancy-related cholinesterase deficiency and suxamethonium after-pains. A case report.
Infections
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
Assessment of hepatic oxidative damage, paraoxonase-1 activity, and lipid profile in cattle naturally infected with Ba7besia bigemina.
Changes on the activity of cholinesterase's in an immunomodulatory response of cattle infected by Listeria monocytogenes.
Cholinergic enzymes and inflammatory markers in rats infected by Sporothrix schenckii.
Cholinesterase as inflammatory markers in a experimental infection by Trypanosoma evansi in rabbits.
Cholinesterases as markers of the inflammatory process associated oxidative stress in cattle infected by Babesia bigemina.
Chronological changes in microbial profiles in external and middle ear diseases: a 20-year study in Korea.
Dynamic relationship between infantile hepatitis syndrome and cytomegalovirus infection.
Effects of reversible inhibition of cholinesterase and nicotine on mouse mortality and blood levels of proinflammatory cytokines during the early phase of sepsis.
Endogenous butyrylcholinesterase in SV40 transformed cell lines: COS-1, COS-7, MRC-5 SV40, and WI-38 VA13.
Evaluation of oxidative stress and antioxidant status, serum trace mineral levels and cholinesterases activity in cattle infected with Anaplasma marginale.
Evaluation of some acute phase proteins in cattle naturally infected with Babesia bigemina.
Experimental trichinosis: parasitological, electrophysiological and biochemical studies.
Factors Influencing Cyst Infection in Autosomal Dominant Polycystic Kidney Disease.
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value.
Immune and nutritional effects of early enteral nutrition after major abdominal operations.
Influence of Toxoplasma gondii Acute Infection on Cholinesterase Activities of Wistar Rats.
Influence of toxoplasmosis on acetylcholinesterase activity, nitric oxide levels and cellular lesion on the brain of mice.
Methicillin-resistant Staphylococcus aureus: colonization and development of infection in patients with haematological disorders.
Myasthenic crisis: a retrospective study.
Neospora caninum: Activity of cholinesterases during the acute and chronic phases of an experimental infection in gerbils.
Nippostrongylus brasiliensis: infection decreases plasma butyrylcholinesterase activity in rats.
Nucleos(t)ide analogs improve long-term prognosis in patients with chronic hepatitis B-associated liver failure.
Paraoxonase-1 activity is related to Trichinella spiralis-induced hepatitis in rats.
Pathological physiology of salmonellosis. II. Plasma cholinesterase in infections due to Enterobacteriaceae.
Pharmacology of DMSO.
Potential association of reduced cholinesterase activity with Trypanosoma evansi pathogenesis in buffaloes.
Prognostic factors for chronic severe hepatitis and construction of a prognostic model.
Pseudomonas aeruginosa cholinesterase and phosphorylcholine phosphatase: two enzymes contributing to corneal infection.
Relationship of nematode cholinesterase activity and nematode burdens to the development of resistance to trichostrongyle infections in sheep.
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
Serum cholinesterase activity in patients with malaria infection.
Serum cholinesterase and alkaline phosphatase levels and serum protein fractions in Entamoeba histolytica infections.
Serum cholinesterase: a potential assistant biomarker for hand, foot, and mouth disease caused by enterovirus 71 infection.
Studies on tissue cholinesterase in experimental trichinosis in albino rat. 1. Effect of T. spiralis infection.
Tea toxicity and cholinesterase inhibition of Huilliche herbal medicine.
The effect of Trypanosoma brucei infection of the localization of salivary gland cholinesterase in Glossina morsitans morsitans.
Trypanosoma evansi: Cholinesterase activity in acutely infected Wistar rats.
[Cholinesterase activity in muscle phase of Trichinella pseudospiralis Garkavi (1972) infection in mice]
[Decrease in plasmatic cholinesterase activity in severe bacterial infections: comparison with the decrease observed in severe liver cirrhosis]
[Erythocyte and plasma cholinesterase activity in swine: nutrition and infection.]
[Gerontology]
[Multivariate analysis of hepatic encephalopathy occurrence in patients with liver failure].
Infectious Mononucleosis
Paralysis of accommodation in infectious mononucleosis.
Infertility
Effect of Acetylcholinesterase and Butyrylcholinesterase on Intrauterine Insemination, Contribution to Inflammations, Oxidative Stress and Antioxidant Status; A Preliminary Report.
[Cholinesterase and alkaline phosphatase activity and the SH group content of the blood in the pathogenesis of sterility in cows]
Infertility, Male
[Functions of neuromediators in plants]
Inflammatory Bowel Diseases
A pregnant woman with genetic variants of butyrylcholinesterase and inflammatory bowel disease.
Serum Cholinesterases, a Novel Marker of Clinical Activity in Inflammatory Bowel Disease: A Retrospective Case-Control Study.
Influenza, Human
A top 5 list for French general practice.
Influenza vaccination and the activities of plasma acetylcholinesterase and butyrylcholinesterase in institutionalised elderly patients.
Primary care physician volume and quality of care for older adults with dementia: a retrospective cohort study.
Insulin Coma
[CHOLINESTERASE ACTIVITY OF THE SERUM IN THE COURSE OF INSULIN COMA.]
Insulin Resistance
Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels.
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease.
Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?
Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners.
Butyrylcholinesterase in metabolic syndrome.
Cognition enhancing effect of the aqueous extract of Cinnamomum zeylanicum on non-transgenic Alzheimer's disease rat model: Biochemical, histological, and behavioural studies.
Effects of high-fat diet and age on the blood lipidome and circulating endocannabinoids of female C57BL/6 mice.
Emerging links between type 2 diabetes and Alzheimer's disease.
Liver Enzymes Correlate With Metabolic Syndrome, Inflammation, and Endothelial Dysfunction in Prepubertal Children With Obesity.
Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects.
Maternal circulating levels of some metabolic syndrome biomarkers in gestational diabetes mellitus.
Pharmaceutical reversal of insulin resistance.
Pyridostigmine alleviates cardiac dysfunction via improving mitochondrial cristae shape in a mouse model of metabolic syndrome.
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus.
Relationship between serum butyrylcholinesterase and the metabolic syndrome.
Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance.
Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes.
The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal studies.
Intellectual Disability
Biochemical genetics and mental retardation: a study of hemoglobins, Australia antigen and the enzymes pseudocholinesterase and glucose-6-phosphate dehydrogenase.
Pseudocholinesterase activity and E1 phenotypes in Down's syndrome and mental retardation.
Intestinal Pseudo-Obstruction
Paralytic ileus after discontinuation of cholinesterase inhibitor.
Paralytic ileus as a complication of atropine therapy following severe organophosphate poisoning.
Treatment of paralytic ileus with cholinesterase inhibitors in intravenous drip.
Iron Deficiencies
Anemia: an indicator for malnutrition in the elderly.
Irritable Bowel Syndrome
Serum cholinesterase activity is elevated in female diarrhea-predominant irritable bowel syndrome patients compared to matched controls.
Ischemic Stroke
Admission serum cholinesterase concentration for prediction of in-hospital mortality in very elderly patients with acute ischemic stroke: a retrospective study.
Pre-Stroke Cholinesterase Inhibitor Treatment Is Beneficially Associated with Functional Outcome in Patients with Acute Ischemic Stroke and Pre-Stroke Dementia: The Fukuoka Stroke Registry.
Serum butyrylcholinesterase activity and phenotype associations with lipid profile in stroke patients.
Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality.
[Changes in the acetylcholine level and cholinesterase activity in hemorrhagic and ischemic strokes]
[Secretion of melatonin and serum cholinesterase activity as biological markers of cognitive disorders in the acute stage of ischemic stroke].
Ketosis
Assessment of the platelet parameters and serum butyrylcholinesterase activity in type 1 diabetes patients with ketoacidosis.
Kidney Diseases
Plasma and red cell cholinesterase activity in uremic patterns (effects of hemodialysis and renal transplantation).
Red blood cell and total blood acetylcholinesterase and plasma pseudocholinesterase in humans: observed variances.
[Behavior of serum cholinesterase activity and its relation to the serum protein picture in various kidney diseases in childhood]
[Study of the activity of blood serum cholinesterase in kidney diseases]
Kidney Failure, Chronic
Preoperative serum cholinesterase concentration in chronic renal failure. Clinical experience of suxamethonium in 81 patients undergoing renal transplant.
Serum aspirin esterase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after haemodialysis.
Kwashiorkor
[Plasma cholinesterase activity in kwashiorkor]
[Pseudocholinesterase in kwashiorkor. Importance of a simple test-paper method (Acholest)]
Lambert-Eaton Myasthenic Syndrome
Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems.
Two Lambert-Eaton Myasthenic Syndrome Patients with Ameliorated Activities of Daily Living Due to Cholinesterase Inhibitors.
[Two cases of Lambert-Eaton syndrome with an increase of serum cholinesterase activity]
Language Disorders
Cholinesterases in cerebrospinal fluid. Correlations with clinical measures in Alzheimer's disease.
Laryngeal Neoplasms
[State of the liver after radiotherapy of cancer of the stomach and larynx with metronidazole radiosensitization]
Laryngismus
[Emergency from anesthesia in small children. From laryngospasm to prolonged apnea]
Leiomyoma
[Effects of the administration of estrogens on serum cholinesterase in women with uterine fibromas.]
Leishmaniasis, Visceral
Evaluation of cholinesterase level in an endemic population exposed to malathion suspension formulation as a vector control measure.
Leprosy
A note on atypical serum cholinesterase and genetic factors in leprosy.
Atypical pseudocholinesterase in leprosy.
Cholinesterase in leprosy nerves: a preliminary report.
Correlation between serum choline esterase and serum albumin in leprosy.
Investigation of Association between Susceptibility to Leprosy and SNPs inside and near the BCHE Gene of Butyrylcholinesterase.
Serum atypical pseudocholinesterase and genetic factors in leprosy.
Serum atypical pseudocholinesterase and leprosy.
Serum butyrylcholinesterase activity in leprosy.
Serum cholinesterase variants in African leprosy patients resident in Rhodesia.
Serum pseudocholinesterase variants in Mexican-born patients with lepromatous leprosy.
Susceptibility to leprosy and serum atypical pseudocholinesterase.
Leprosy, Lepromatous
Serum pseudocholinesterase variants in Mexican-born patients with lepromatous leprosy.
Susceptibility to leprosy and serum atypical pseudocholinesterase.
Leprosy, Tuberculoid
Serum enzyme profile in tuberculoid leprosy.
Susceptibility to leprosy and serum atypical pseudocholinesterase.
Lesch-Nyhan Syndrome
Effect of hypoxanthine, antioxidants and allopurinol on cholinesterase activities in rats.
Leukemia
Blood cholinesterase level and duration of life in the leukemias with notes on elevation of blood cholinesterase in certain leukemoid conditions.
Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer.
Coamplification of human acetylcholinesterase and butyrylcholinesterase genes in blood cells: correlation with various leukemias and abnormal megakaryocytopoiesis.
Effect of L-asparaginase therapy upon serum pseudocholinesterase and ceruloplasmin levels in patients with acute leukemia.
Serum cholesterol and apoprotein B levels and serum cholinesterase activity in selected hematologic malignancies.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
[Cholinesterase in the plasma, erythrocytes and whole blood in pernicious anemia and leukemia.]
[THE CLINICAL SIGNIFICANCE OF THE CHOLINESTERASE ACTIVITY OF THE ERYTHROCYTES IN ACUTE LEUKEMIA IN CHILDREN.]
Leukocytosis
Clinical manifestations, laboratory findings, treatment and outcome of acute organophosphate or carbamate intoxication in 102 dogs: A retrospective study.
Latrodectism in Italy: First report of successful treatment of L. tredecimguttatus envenomation using L. mactans antivenom from North America.
Second Line Chemotherapy in Biliary Tract Cancer: Outcome and Prognostic Factors.
The First Use of Pralidoxime in a Child With Rivastigmine Poisoning.
[Action of fenitrothion (Agria 1050) on the development of a surgical infection with Corynebacterium pyogenes in sheep]
[Malignant rheumatoid arthritis]
Lewy Body Disease
A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.
Acute treatment of psychotic symptoms in a newly diagnosed Lewy body dementia patient with an accelerated titration schedule of rivastigmine and de-escalation of antipsychotics.
An audit of a specialist old age psychiatry liaison service to a medium and a high secure forensic psychiatry unit.
Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.
Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Compensatory shifts in visual perception are associated with hallucinations in Lewy body disorders.
Dementia with lewy bodies: therapeutic opportunities and pitfalls.
Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing.
Pharmacotherapy of Parkinson disease dementia and Lewy body dementia.
Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy.
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
The cholinergic deficiency syndrome and its therapeutic implications.
The neuroprotective mechanism of action of the multimodal drug ladostigil.
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
Treatment of attention deficits in neurological disorders.
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]
[Delirious states in elderly persons. Therapeutic modalities]
[Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient]
[Posterior cortical atrophy. Pathology, diagnosis and treatment of a rare form of dementia].
Lipid Metabolism Disorders
[Behavior of cholinesterase activity in lipid metabolism disorders]
Liver Abscess, Amebic
LEFT-SIDED AMOEBIC LIVER ABSCESS WITH PULMONARY INVOLVEMENT, PERICARDITIS, AND PSEUDOCHOLINESTERASE DEFICIENCY.
Plasma cholinesterase and other liver function tests in hepatic amebiasis.
Liver Cirrhosis
A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid.
A variant serum cholinesterase and a confirmed point mutation at Gly-365 to Arg found in a patient with liver cirrhosis.
Abnormalities of serum cholinesterase isozyme in liver cirrhosis and hepatoma (Part II).
Alteration of serum cholinesterase isozyme in patients with liver cirrhosis.
Changes of plasma cholinesterase activity during orthotopic liver transplantation in man.
Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy.
Clinical significance of fasting serum bile acid in the long-term observation of chronic liver disease.
Clinical significance of serum hyaluronan in patients with chronic viral liver disease.
Comparison of the indices of the bromsulphalein test, the serum cholinesterase and the galactose test by hepatic cirrhosis.
Correlation analysis between four serum biomarkers of liver fibrosis and liver function in infants with cholestasis.
Discrimination of liver cirrhosis from chronic hepatitis by analysis of serum cholinesterase isozymes using affinity electrophoresis with concanavalin A or wheat germ agglutinin.
Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of Aleuria aurantia lectin-reactive serum cholinesterase to immunoreactive protein.
Enzyme-linked immunosorbent assay (ELISA) for Aleuria aurantia lectin-reactive serum cholinesterase to differentiate liver cirrhosis and chronic hepatitis.
Gamma-glutamyl transpeptidase to cholinesterase and platelet ratio in predicting significant liver fibrosis and cirrhosis of chronic hepatitis B.
Hypercholinesterasemia in patients with hepatocellular carcinoma: a new paraneoplastic syndrome.
Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases.
Mechanism of feminization in male patients with non-alcoholic liver cirrhosis: role of sex hormone-binding globulin.
Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis.
Plasma amino acids in hepatic encephalopathy.
Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
Serum cholinesterase in patients with fatty liver.
Serum cholinesterase is an excellent biomarker of liver cirrhosis.
Serum cholinesterase: a potential assistant biomarker for hand, foot, and mouth disease caused by enterovirus 71 infection.
Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection.
Serum vitamin D? does not correlate with liver fibrosis in chronic hepatitis C.
Thrombocytopenia in liver cirrhosis.
[Cholinesterase in liver cirrhosis]
[Clinical evaluation of the measurement of hepatosplenic volume ratio by computed tomography]
[Clinical value of measuring the activity of serum cholinesterase and its isoenzyme in chronic hepatitis and liver cirrhosis]
[Correlation between small intestine phosphatase and serum pseudocholinesterase in liver cirrhosis]
[Decrease in plasmatic cholinesterase activity in severe bacterial infections: comparison with the decrease observed in severe liver cirrhosis]
[Mathematical models using conventional laboratory indicators to predict hepatic fibrosis progressing in chronic hepatitis B]
[Multivariate analysis of hepatic encephalopathy occurrence in patients with liver failure].
[Serum cholinesterase in liver cirrhosis and certain carcinomas.]
[The cause of serum cholinesterase activity decrease in hepatitis and liver cirrhosis.]
[The managements of nutrition for hepatic cirrhosis]
Liver Cirrhosis, Alcoholic
Serum albumin is present at higher levels in alcoholic liver cirrhosis as compared to HCV-related cirrhosis.
[Serum levels of pseudocholinesterase in alcoholic cirrhosis patients. Correlation with the extent of anatomo-functional damage. Unfavorable prognostic index]
Liver Diseases
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
Acetylcholinesterase (AChE) inhibition aggravates fasting-induced triglyceride accumulation in the mouse liver.
Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease.
Analysis of open heart surgery in patients with liver cirrhosis.
Assessment of the value of serum cholinesterase as a liver function test for cirrhotic patients.
Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: a systematic review.
Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation.
Changes of plasma cholinesterase activity during orthotopic liver transplantation in man.
Changes of serum cholinesterase isozyme patterns in liver diseases.
Circulating intercellular adhesion molecule 1 predicts non-specific elevation of alpha 1-fetoprotein.
Clinical and analytical considerations in the utilization of cholinesterase measurements.
Clinical application of the measurement of serum asialoglycoproteins to estimate residual liver function in patients with chronic liver diseases with or without hepatocellular carcinoma.
Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease.
Determination of genetic variants of serum cholinesterase in healthy adults and patients with liver diseases.
Development and application of serum cholinesterase activity measurement using benzoylthiocholine iodide.
Discrimination of liver cirrhosis from chronic hepatitis by analysis of serum cholinesterase isozymes using affinity electrophoresis with concanavalin A or wheat germ agglutinin.
Horseshoe kidney and membranous glomerulonephritis with cold activation of complement.
Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients.
Intra-individual variation of analytes in serum from patients with chronic liver diseases.
Low Serum Levels of Zonulin in Patients with HCV-Infected Chronic Liver Diseases.
Mivacurium in special patient groups.
Novel predictors for liver transplantation or death in drug-induced acute liver failure.
Nucleos(t)ide analogs improve long-term prognosis in patients with chronic hepatitis B-associated liver failure.
Pharmacologic treatments of dementia.
Plasma cholinesterase activity in liver disease: its value as a diagnostic test of liver function compared with flocculation tests and plasma protein determinations.
PLASMA ESTERASE ACTIVITY IN PATIENTS WITH LIVER DISEASE AND THE NEPHROTIC SYNDROME.
Predictive value of preoperative serum cholinesterase concentration in patients with liver dysfunction undergoing cardiac surgery.
Preoperative assessment of congestive liver dysfunction using technetium-99 m galactosyl human serum albumin liver scintigraphy in patients with severe valvular heart disease.
Prolonged apnoea after suxamethonium: an analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit.
Pseudocholinesterase in gestational diabetes: positive correlation with LDL and negative correlation with triglyceride.
Readthrough acetylcholinesterase is increased in human liver cirrhosis.
Relationship between urinary fractional excretion of sodium and life prognosis in liver cirrhosis patients.
S protein/vitronectin in chronic liver diseases: correlations with serum cholinesterase, coagulation factor X and complement component C3.
Separation of serum cholinesterase isozymes by an improved polyacrylamide gel electrophoresis and its application for the study of liver diseases (Part I).
Serial serum cholinesterase determinations in liver disease.
Serum butyrylcholinesterase/HDL-cholesterol ratio and atherogenic index of plasma in patients with fatty liver disease.
Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests.
Serum cholinesterase activity in liver disease.
Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients.
Serum cholinesterase activity in the normal individual and in people with liver disease.
Serum cholinesterase in liver disease.
Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D.
Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure.
Similar behaviour of lecithin:cholesterol acyltransferase and pseudocholinesterase in liver disease and hyperlipoproteinemia.
Studies on cholinesterase. IV. On the relationship between cholinesterase of basal ganglia and liver diseases.
Supplementation of antioxidants prevents oxidative stress during a deep saturation dive.
Suxamethonium apnoea associated with pregnancy and liver dysfunction in a treated cretin.
The value of plasma cholinesterase in children with severe liver disease.
Theophylline pharmacokinetics and liver function indexes in chronic liver disease.
Trimethadione metabolism in patients with normal liver and in patients with chronic liver disease.
Variations in serum cholinesterase activity in different age and sex groups.
[A family of pseudocholinesterase deficiency (silent type II)]
[Activity of serum cholinesterase in certain liver diseases, particularly in virus hepatitis]
[Blood cholinesterase and hepatic function: a comparison with BSP and galactose elimination as well as serum albumin concentration]
[Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases]
[Cholinesterase activity of blood serum in liver diseases.]
[Cholinesterase in suprahepatic, arterial and peripheral vein blood in liver disease.]
[Cholinesterase inhibition in liver diseases by additional loading with BC 51 (ubretid).]
[Cholinesterase, iron & transaminase in blood serum: comparative study in acute hepatitis, chronic liver diseases & extrahepatic obstructive jaundice.]
[Clinical experience with a new method for the determination of monoglyceride lipase (author's transl)]
[Comparative laparoscopic, bioptic and clinical enzymological studies in liver cirrhosis and other chronic liver diseases]
[Complex study of glycoproteins in liver disease]
[Course of activity of serum cholinesterase in various liver diseases especially in infectious hepatitis of adults]
[Determination of serum cholinesterase activity and its significance in liver diseases]
[Development of extracorporeal blood purification methods: Molecular Adsorbent Recirculating System (MARS) for hepatic and renal function replacement.]
[Diagnostic and prognostic significance of cholinesterase (CHE) in chronic liver diseases]
[Diagnostic significance of serum cholinesterase in liver diseases]
[Diagnostic value of serum cholinesterase in liver diseases]
[Differences in serum cholinesterase and serum glutamic oxalacetic transaminase activity in liver diseases.]
[Disc electrophoresis in the differential diagnosis of liver diseases. A study of lactate dehydrogenase- and cholinesterase isoenzymes together with the protein pattern in the serum revealed with disc electrophoresis]
[Effect of dibutyryl cyclic AMP in the treatment of hepatocellular carcinoma--intraarterial infusion therapy combined with anticancer agent for hepatocellular carcinoma with portal vein thrombosis]
[Evaluation of screening methods for cholinesterase variants from daily laboratory data]
[Investigation of action of cholinesterase in liver diseases.]
[Investigations on cholinesterase in liver diseases.]
[On the effect of a blood extract on the respiration of human liver sections and the activity of serum cholinesterase in liver diseases.]
[Place of serum cholinesterase in the diagnosis of chronic liver diseases]
[Plasma cholinesterase (CHE, pseudocholinesterase), its importance in liver diseases and prolonged succinyldicholine-induced apnea]
[Prognostic significance of activity of serum cholinesterase, catalase and ceruloplasmin in liver disease]
[Prognostic significance of determination of coagulation factors V and IX and serum cholinesterase in liver diseases]
[Prognostic value of serum cholinesterase activity in liver disease (author's transl)]
[Pseudocholinesterase and liver diseases; new method of determination.]
[Pseudocholinesterase in patients with and without liver diseases (author's transl)]
[Recovery from pancytopenia and liver dysfunction after administration of thiamazole for hyperthyroidism]
[Serum cholinesterase activity (CHE) in different classes of chronic liver diseases (author's transl)]
[Serum cholinesterase and liver diseases.]
[SERUM CHOLINESTERASE AND LIVER DISEASES.]
[Serum cholinesterase isozymes in liver diseases, with evaluation of slab gel electrophoresis in the analysis of isozymes]
[Serum cholinesterase synthesis in children with liver diseases with special reference to acute icteric and anicteric hepatitis]
[Significance of pseudocholinesterase (acylcholinacylhydrolase 3.1.1.8.) in the diagnosis of liver diseases]
[Takato-Ara, Ucko, Hanger, and Mac Lagan tests and serum cholinesterase in liver diseases; serial tests and prognostic value.]
[Testing of the activity of serum cholinesterase in patients with liver disease with the aid of the cholinesterase test-paper "Acholest"]
[Usefulness of serum pseudocholinesterase isoenzymes in acute and chronic liver diseases and neoplasms (experimental and clinical study)]
Liver Diseases, Alcoholic
Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
Relationship between content of hepatic glutathione S-transferases and the kinetics of indocyanine green elimination in various liver diseases.
[Proceedings: Relationship of serum cholinesterase level in chronic alcoholic liver disease and appearance of delirium tremens: therapeutic effect of oximes]
Liver Failure
Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV.
Treatment of hepatocellular carcinoma and the exacerbation of liver function.
[Usefulness of cholinesterase determination in ascitic fluid in the differential diagnosis of ascites]
Liver Failure, Acute
Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support.
Pharmacologic cholinesterase inhibition improves survival in acetaminophen-induced acute liver failure in the mouse.
Proceedings: Serum pseudocholinesterase concentrations in fulminant hepatic failure.
Liver Neoplasms
Probing simple structural modification of ?-mangostin on its cholinesterase inhibition and cytotoxicity.
[Biochemistry in liver cancer]
[Liver and serum cholinesterase activity in primary and metastatic cancer of the liver]
[Resection of centrally located primary liver cancer]
Lordosis
Cholinergic regulation of female sexual behavior in rats demonstrated by manipulation of endogenous acetylcholine.
Lung Diseases
Prognostic nomogram for the severity of acute organophosphate insecticide self-poisoning: a retrospective observational cohort study.
[Serum cholinesterase. Its significance in pulmonary diseases and bronchology]
[State of the autonomic nervous system and cholinesterase activity in blood in chronic non-specific lung diseases]
Lung Diseases, Obstructive
Ipratropium in patients with COPD receiving cholinesterase inhibitors.
Lung Injury
Butyrylcholinesterase in Guinea Pig Lung Lavage: A Novel Biomarker to Assess Lung Injury Following Inhalation Exposure to Nerve Agent VX.
Pulmonary toxicity of the insecticide fenitrothion in the rat following a single field exposure.
Serum cholinesterase activity in patients with burns.
Lung Neoplasms
A new test for the presumptive diagnosis of neoplastic disease. Further investigations of cholinesterase in plasma, whole blood and blood cells on cancer of the lung, extrapulmonary tumors and tuberculosis.
Cholinesterase activity of human lung tumours varies according to their histological classification.
Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer.
Pulmonary resection for non-small cell lung cancer in patients with hepatocellular carcinoma.
[The diagnostic value of serum cholinesterase activity determination in stomach and lung cancer]
[The effect of anesthesia and surgical trauma on the activity of pseudocholinesterase in the blood of patients with suppurative processes in the lung, cancer of the stomach and esophagus]
Lupus Erythematosus, Systemic
Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
Lymphatic Metastasis
Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer.
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Lymphoma, Non-Hodgkin
Relationship between nutritional status and tumor growth in humans.
Lymphopenia
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
Malabsorption Syndromes
Elevated levels of serum pancreatic secretory trypsin inhibitor (PSTI) in patients with malabsorption syndrome.
Malaria
Experimental concomitant toxoplasma and malaria infection in rats.
Serum cholinesterase activity in patients with malaria infection.
Malaria, Cerebral
Acetylcholinesterase activities in cerebrospinal fluid of patients with Plasmodium falciparum cerebral malaria.
Malnutrition
A Case of Pseudocholinesterase Deficiency Resulting From Malnutrition.
Anemia: an indicator for malnutrition in the elderly.
Are single measurements of pseudocholinesterase and albumin markers for inflammatory activity or nutritional status in Crohn's disease?
Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.
Histochemical and biochemical studies of butyrylcholinesterase activity in adult and developing cerebellum. Effects of abnormal thyroid state and undernutrition.
Low serum butyrylcholinesterase is independently related to low fetuin-A in patients on hemodialysis: a cross-sectional study.
Low serum cholinesterase predicts complication risk after orthopedic surgery in elderly patients: an observational pilot study.
Malnutrition and Laboratory Markers in Geriatric Patients. A Comparison of Neurologic-psychiatric, Internal and Trauma Surgical Diseases.
Malnutrition in African adults. I. Serum proteins, cholinesterase, and protein-bound lipid.
Nutritional effects on heart acetylcholinesterase and butyrocholinesterase activity.
Plasma cholinesterase: double-edged parameter in the diagnosis of acute organophosphorus poisoning.
Postnatal malnutrition and brain cholinesterase in rats.
Postnatal malnutrition and regional cholinesterase activities in brain of pigs.
Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices.
Pseudocholinesterase activity as a guide to prognosis in malnutrition.
Serum cholinesterase activity in malnutrition and other childhood disorders.
Serum cholinesterase and histopathology of the liver in severe protein calorie malnutrition.
Serum enzyme abnormalities in protein energy malnutrition.
The effects of nutrition on plasma cholinesterase activity and cocaine toxicity in mice.
The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.
[Cholinesterase activity in fasting & caloric undernutrition.]
[Limits and relevance of the laboratory diagnosis of malnutrition in the elderly]
[Progress in management of severe tuberculosis or tuberculosis with severe complication].
[Special aspects of malnutrition in geriatrics]
[The evaluation of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) level in peripheral blood of patients with chronic lower respiratory tract infection]
Mania
A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania.
A rivastigmine-precipitated manic episode in a patient with Alzheimer-type dementia.
Donepezil-associated manic episode with psychotic features: a case report and review of the literature.
Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial.
Mania after administration of cholinesterase inhibitors in patients with dementia and comorbid bipolar disorder: two case reports.
Mastitis
Biochemical changes in saliva of cows with inflammation: A pilot study.
Maternal Death
Correlation of blood cholinesterase levels with toxicity of sarin in rats.
Melanoma
Cholinesterase and tyrosinase activity in malignant melanoma.
Induction of cellular contractions in the human melanoma cell line SK-mel 28 after muscarinic cholinergic stimulation.
Lycodine type alkaloids from Lycopodiastrum casuarinoides with cytotoxic and cholinesterase inhibitory activities.
[Pseudocholinesterase in patients with and without liver diseases (author's transl)]
Memory Disorders
A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.
Ameliorative effect of tacrine on spatial memory deficit in chronic two-vessel occluded rats is reversible and mediated by muscarinic M1 receptor stimulation.
Aralia cordata protects against amyloid beta protein (25-35)-induced neurotoxicity in cultured neurons and has antidementia activities in mice.
Bergenia ciliata ameliorates streptozotocin-induced spatial memory deficits through dual cholinesterase inhibition and attenuation of oxidative stress in rats.
Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats.
Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors.
Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.
Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil.
Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.
Cognitive Facilitation and Antioxidant Effects of an Essential Oil Mix on Scopolamine-Induced Amnesia in Rats: Molecular Modeling of In Vitro and In Vivo Approaches.
Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.
Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey.
Development of an interactive tailored information application to improve patient medication adherence.
Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation.
Effect of diet supplemented with P. ostreatus and L. subnudus on memory index and key enzymes linked with Alzheimer's disease in streptozotocin-induced diabetes rats.
Effect of rivastigmine on scopolamine-induced memory impairment in rats.
Effects of isovanihuperzine A on cholinesterase and scopolamine-induced memory impairment.
Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats.
Eptastigmine improves eight-arm radial maze performance in aged rats.
Identification of new chromenone derivatives as cholinesterase inhibitors and molecular docking studies.
Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats.
Medial septum tau accumulation induces spatial memory deficit via disrupting medial septum-hippocampus cholinergic pathway.
Methanesulfonyl fluoride (MSF) blocks scopolamine-induced amnesia in rats.
Pelargonidin improves memory deficit in amyloid ?25-35 rat model of Alzheimer's disease by inhibition of glial activation, cholinesterase, and oxidative stress.
Reduced expression of the vesicular acetylcholine transporter causes learning deficits in mice.
Scopolamine-induced deficits in social memory in mice: reversal by donepezil.
Scutellarin protects against A?-induced learning and memory deficits in rats: involvement of nicotinic acetylcholine receptors and cholinesterase.
The effects of THA on medial septal lesion-induced memory defects.
The role of nicotinic receptors in the amelioration of cholinesterase inhibitors in scopolamine-induced memory deficits.
Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?
Meningioma
Biochemical properties of acetyl- and butyrylcholinesterase in human meningioma.
Characterization of activities and forms of cholinesterases in human primary brain tumors.
Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
Monomers and dimers of acetylcholinesterase in human meningioma are anchored to the membrane by glycosylphosphatidylinositol.
Meningism
[Cholinesterase in plasma and cerebrospinal fluid in patients with viral meningitis]
Meningitis
Ricinus communis agglutinin I reacting and non-reacting butyrylcholinesterase in human cerebrospinal fluid.
Meningitis, Bacterial
Cholinesterase modulations in patients with acute bacterial meningitis.
CSF acetyl and butyryl cholinesterase activities in children with bacterial meningitis.
Meningitis, Viral
[Cholinesterase in plasma and cerebrospinal fluid in patients with viral meningitis]
Meningococcal Infections
[Catecholamine excretion and cholinesterase activity in meningococcal infection in children]
Metabolic Syndrome
Butyrylcholinesterase activity and metabolic syndrome in obese patients.
Butyrylcholinesterase and ?-Glutamyltransferase Activities and Oxidative Stress Markers Are Altered in Metabolic Syndrome, But Are Not Affected by Body Mass Index.
Butyrylcholinesterase in metabolic syndrome.
Butyrylcholinesterase interactions with amylin may protect pancreatic cells in metabolic syndrome.
Butyrylcholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity.
Changes in Cholinesterase Activity in Blood of Adolescent with Metabolic Syndrome after Supplementation with Extract from Aronia melanocarpa.
Functional Analysis and Molecular Docking studies of Medicinal Compounds for AChE and BChE in Alzheimer's Disease and Type 2 Diabetes Mellitus.
Nicotinamide reduces inflammation and oxidative stress via the cholinergic system in fructose-induced metabolic syndrome in rats.
Plasma cholinesterase is associated with Chinese adolescent overweight or obesity and metabolic syndrome prediction.
Plasma proteomics reveals markers of metabolic stress in HIV infected children with severe acute malnutrition.
Relationship between butyrylcholinesterase activity and lipid parameters in workers occupationally exposed to pesticides.
Relationship Between Paraoxonase-1 and Butyrylcholinesterase Activities and Nutritional Status in Mexican Children.
Relationship between serum butyrylcholinesterase and the metabolic syndrome.
Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach.
Serum gamma-glutamyltransferase and/or serum cholinesterase as markers of the metabolic syndrome.
The cholinesterases: Analysis by pharmacogenomics in man.
Weakened cholinergic blockade of inflammation associates with diabetes-related depression.
[Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs]
Methemoglobinemia
Propanil-chloracne and methomyl toxicity in workers of a pesticide manufacturing plant.
Miosis
Assessment of direct cholinesterase inhibitory activity by pupillary miosis.
Biological monitoring of metabolites of sarin and its by-products in human urine samples.
Cholinergic Crisis Owing to Distigmine Bromide Complicated by Hyperosmolar Hyperglycemic State.
Clinical signs and biochemical changes in calves caused by injection of ivermectin.
Efficacy assessment of a combined anticholinergic and oxime treatment against topical sarin-induced miosis and visual impairment in rats.
Elevated frequency of sister chromatid exchanges in lymphocytes of victims of the Tokyo sarin disaster and in experiments exposing lymphocytes to by-products of sarin synthesis.
Evaluation of miosis, behavior and cholinesterase inhibition from low-level, whole-body vapor exposure to soman in African green monkeys (Chlorocebus sabeus)*
Fresh frozen plasma as a successful antidotal supplement in acute organophosphate poisoning.
Opposite changes in blood pressure and pulse rate in two patients with distigmine and rivastigmine intoxication.
Sarin poisoning on Tokyo subway.
Study of respiratory failure in organophosphate and carbamate poisoning.
Suspected chlorpyrifos toxicosis in a llama, and plasma pseudocholinesterase activity in llamas given chlorpyrifos.
The possible role of intravenous lipid emulsion in the treatment of chemical warfare agent poisoning.
Tissue distribution of DDVP after fatal ingestion.
[Acute respiratory failure associated with cholinergic crisis: report of five cases and review of the literature].
[Effect of ethyl-p-nitrophenyl phenylphosphonothiate (EPN) on tryptophan pyrrolase activity in relation to miosis and change in serum cholinesterase activities]
[Long QT syndrome after organophosphate insecticide poisoning]
[Othe suitability of paraoxon miosis of the human eye for testing of cholinesterase reactivators]
Motor Neuron Disease
Unusual form of motor neuron disease in Kenya.
Mouth Diseases
Serum cholinesterase: a potential assistant biomarker for hand, foot, and mouth disease caused by enterovirus 71 infection.
Mouth Neoplasms
Significance of serum butyrylcholinesterase levels in oral cancer.
Movement Disorders
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.
Cognitive dysfunction and dementia in Parkinson disease.
Metabolic treatment of syndrome linked with Parkinson's disease and hypothalamus pituitary gonadal hormones by turmeric curcumin in Bisphenol-A induced neuro-testicular dysfunction of wistar rat.
Unexpected extrapyramidal symptoms and pulmonary aspergillosis in exertional heatstroke with fulminant liver failure: a case report.
Mucopolysaccharidosis III
A patient with Sanfilippo syndrome and pseudocholinesterase deficiency, further complicated by post-tonsillectomy haemorrhage.
Multiple Sclerosis
Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis.
Butyrylcholinesterase activity in multiple sclerosis neuropathology.
Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation.
Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis.
Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis.
Imaging Butyrylcholinesterase in Multiple Sclerosis.
Improvement of motor function in multiple sclerosis by use of protopam chloride.
Serum cholinesterase in patients with multiple sclerosis.
[CHOLINESTERASE ACTIVITY OF THE CEREBROSPINAL FLUID OF MULTIPLE SCLEROSIS PATIENTS.]
[Cholinesterase therapy of multiple sclerosis.]
[Cholinesterase, myelin and the treatment of multiple sclerosis.]
[Histochemical demonstration of glial enzyme activity. II. Reagent and neoplastic glia]
[On the determination of the cholinesterase content of human sera by means of indicator paper (Archolest). II. Enzyme content in multiple sclerosis and other neurologic diseases]
[Registries for neurological drugs landscape].
Multiple System Atrophy
Mesial Frontal Lobe Infarction Presenting as Pisa Syndrome.
Muscle Cramp
Hazards associated with aerial spraying of organophosphate insecticides in Israel.
Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients.
Muscle Hypotonia
The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa.
Muscle Spasticity
CHOLINESTERASE LEVELS IN SPASTIC CHILDREN.
Congenital megacolon; a comparison of the spastic and hypertrophied segments with respect to Cholinesterase activities and sensitivities to Acetylcholine, DFP and the barium ion.
Muscle Weakness
Congenital myasthenia associated with facial malformations in Iraqi and Iranian Jews. A new genetic syndrome.
Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.
Environmental Toxicology and Health Effects Associated with Methyl Parathion Exposure - A Scientific Review.
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by Muscle Specific Kinase autoantibody.
The Relevance of Blepharoptosis in Diagnostic Suspicion of Myopathies.
[Legionella pneumonia caused by aspiration of hot spring water after sarin exposure]
Muscular Atrophy
Acetylcholinesterase inhibitor responsive myasthenia in a Filipino male with X-linked recessive spinal and bulbar muscular atrophy.
Muscular Atrophy, Spinal
Acetylcholinesterase and ATPases in motor neuron degenerative diseases.
Muscular Diseases
A light and electron microscopic histochemical study on the mechanism of DFP-induced acute and subacute myopathy.
Chronic inhibition of cholinesterase as a cause of myopathy.
Clinical aspects of MuSK antibody positive seronegative MG.
Endplates after esterase inactivation in vivo: correlation between esterase concentration, functional response and fine structure.
Genetic screening in the Persian Jewish community: A pilot study.
Presynaptic effects of neuromuscular cholinesterase inhibition.
The Relevance of Blepharoptosis in Diagnostic Suspicion of Myopathies.
[Nosographic approach of heriditary myopathies. Attempt at classification and diagnosis by means of erythrocyte cholinesterase and serum pseudocholinesterase analysis]
Muscular Dystrophies
Cholinesterase activity and inherited muscular dystrophy of the cicken.
Early onset myasthenia gravis with atypical features.
Molecular forms of acetylcholinesterase and pseudocholinesterase in chicken skeletal muscles: their distribution and change with muscular dystrophy.
Muscular dystrophy alters the processing of light acetylcholinesterase but not butyrylcholinesterase forms in liver of Lama2(dy) mice.
Muscular dystrophy with laminin deficiency decreases acetylcholinesterase activity in thymus of dystrophic Lama2dy mice.
Muscular dystrophy with laminin deficiency decreases the content of butyrylcholinesterase tetramers in sciatic nerves of Lama2dy mice.
[Cholinesterase activity and dibucaine number in progressive muscular dystrophy]
[Nosographic approach of heriditary myopathies. Attempt at classification and diagnosis by means of erythrocyte cholinesterase and serum pseudocholinesterase analysis]
[Serum enzyme dynamics in progressive muscular dystrophies]
Myalgia
Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.
Suxamethonium-induced jaw stiffness and myalgia associated with atypical cholinesterase: case report.
Suxamethonium-induced muscle pains are not related to cholinesterase activity.
Myasthenia Gravis
Acute and repeated restraint stress have little effect on pyridostigmine toxicity or brain regional cholinesterase inhibition in rats.
Acute effects of oral pyridostigmine bromide on conditioned operant performance in rats.
Atypical cholinesterase in a patient with myasthenia gravis.
Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems.
Cholinesterase activity of blood and muscle in myasthenia gravis.
Cholinesterase based amperometric biosensors for assay of anticholinergic compounds.
Cholinesterase inhibition and signs and symptoms in myasthenia gravis.
Cholinesterase inhibitors in myasthenia gravis.
Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
Clinical pharmacokinetics of cholinesterase inhibitors.
D-Penicillamine induced myasthenia gravis.
Diagnostic algorithms for neuromuscular diseases.
Early onset myasthenia gravis with atypical features.
Effect of pyridostigmine (Mestinon) on human platelet aggregation.
Effects of Distigmine on Electrical Field Stimulation-Induced Contraction of Mouse Urinary Bladder Smooth Muscles.
Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Experience in the treatment of myasthenia gravis with double filtration plasmapheresis.
Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis.
Ipratropium in patients with COPD receiving cholinesterase inhibitors.
Isaac's syndrome associated with myasthenia gravis and thymoma.
IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies.
Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.
Medical treatment options for ocular myasthenia gravis.
MuSK Myasthenia Gravis Presenting with Bilateral Vocal Cord Abduction Paresis: A Case Report and Literature Review.
Myasthenia gravis: prognostic significance of clinical data in the prediction of post-thymectomy respiratory crises.
Natural cholinesterase inhibitors from marine organisms.
New Insights into the Exploitation of Vitis vinifera L. cv. Aglianico Leaf Extracts for Nutraceutical Purposes.
Pharmacology and toxicology of cholinesterase inhibitors: uses and misuses of a common mechanism of action.
Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
Potentiation of pyridostigmine bromide toxicity in mice by selected adrenergic agents and caffeine.
Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors-implications for early Myasthenia gravis treatment.
Prolonged postoperative apnea complicating gynecologic surgery; atypical cholinesterase and myasthenia gravis.
Pseudo-internuclear ophthalmoplegia as a sign of overlapping myasthenia gravis in a patient with 'intractable' hypothyroidism.
Reactive oxygen species mediate pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and NMDA receptors.
Slow-binding inhibition of acetylcholinesterase by a 6-methyluracil alkyl-ammonium derivative: mechanism and advantages for myasthenia gravis treatment.
Sustainable Effects of Distigmine Bromide on Urinary Bladder Contractile Function.
The edrophonium test.
The effect of cholinesterase inhibitors of SFEMG in myasthenia gravis.
The effect of muscular exercise on the serum cholinesterase level in normal adults and in patients with myasthenia gravis.
Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients.
Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravis.
Ultrastructural effects of pyridostigmine on neuromuscular junctions in rat diaphragm.
[Cholinesterase activity in myasthenia gravis]
[DUODENAL ULCER AND PROTRACTED CHOLINESTERASE INHIBITION. OBSERVATION OF 2 PATIENTS WITH MYASTHENIA GRAVIS.]
[Effect of polymethylene-bis-(N-methyl-carbamic acid-m-trimethylammonium-phenol) BC 40, BC 47, BC 48 on cholinesterase activity and muscle activity in myasthenia gravis pseudoparalytica.]
[Mechanism of the Long-lasting Potentiating Effect of Distigmine on Urinary Bladder Motility].
[Myasthenia gravis and LE nephritis: problems of treatment with cholinesterase inhibitors during long-term dialysis (author's transl)]
[Myasthenia gravis]
[Study of plasma cholinesterase in myasthenia gravis]
[THE BEHAVIOR OF SERUM CHOLINESTERASE IN THE COURSE OF PSEUDOPARALYTIC MYASTHENIA GRAVIS. A CONTRIBUTION TO THE DISTINCTION OF VARIOUS FORMS OF THE MYASTHENIC SYNDROME.]
[Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring]
Myasthenic Syndromes, Congenital
Congenital myasthenic syndromes.
Early onset myasthenia gravis with atypical features.
Identification of previously unreported mutations in CHRNA1, CHRNE and RAPSN genes in three unrelated Italian patients with congenital myasthenic syndromes.
Myelodysplastic Syndromes
Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol.
Myocardial Infarction
Amyloid-? peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients.
Amyloid-beta Peptides in Plasma and Cognitive Decline After 1 Year Follow-Up in Alzheimer's Disease Patients.
Estimation of plasma cholinesterase in myocardial infarction.
National Veterans Health Administration hospitalizations for syncope compared to acute myocardial infarction, fracture, or pneumonia in community-dwelling elders: outpatient medication and comorbidity profiles.
Pseudocholinesterase in acute myocardial infarction.
Role of plasma pseudocholinesterase activity in the diagnosis of acute myocardial infarction with special reference to cardiac arrhythmias.
Serum pseudocholinesterase activity in acute myocardial infarction.
Serum pseudocholinesterase in acute myocardial infarction.
Some observations on the cholinesterase activity of plasma in myocardial infarction.
The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.
[Behavior of serum cholinesterase after myocardial infarction.]
[Change in blood cholinesterase activity in patients with myocardial infarct]
[Cholinesterase activity of the heart in experimental myocardial infarct]
[Cholinesterase activity of the human heart in hypertrophy and myocardial infarct]
[Cholinesterase and monoaminoxidase activity of the ischemic and non-ischemic portions of the heart in the acute phase of myocardial infarction]
[Clinical course of early myocardial infarction and changes in the cholinesterase activity in the serum]
[Enzyme diagnosis of liver dysfunction in acute myocardial infarct and its complications]
[Plasma esterase activity in acute myocardial infarct]
Myocardial Ischemia
Vagal modulation of high mobility group box-1 protein mediates electroacupuncture-induced cardioprotection in ischemia-reperfusion injury.
[Cholinesterase activity of blood monocytes in healthy subjects and ischemic heart disease patients]
[Diagnostic coefficients of ischemic heart disease in diabetes mellitus]
Myocarditis
[On the problem of the effect of strophanthin K on the activity of cardiac cholinesterase in experimental myocarditis.]
Myopia
Risk factors for cataract: a case control study.
Myxedema
Serum electrophoretic lipoprotein factors and pseudocholinesterase activity in thyroid disease.
Narcolepsy
Potentiation of a functional autoantibody in narcolepsy by a cholinesterase inhibitor.
Nasopharyngitis
A top 5 list for French general practice.
Necrobiotic Disorders
[Clinico-morphologic and histochemical changes in the neuromuscular apparatus in acute carbophos poisoning]
Neoplasm Metastasis
Breast cancer metastasis alters acetylcholinesterase activity and the composition of enzyme forms in axillary lymph nodes.
Cholinesterase activities and biochemical determinations in patients with prostate cancer: influence of Gleason score, treatment and bone metastasis.
Prognostic Significance of Hematopoietic-cell Serglycin for the Survival of Hepatocellular Carcinoma: A Single-center Retrospective Study.
Prognostic significance of host- and tumor-related factors in patients with gastric cancer.
Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer.
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Value of gamma-glutamyltransferase in the diagnosis of liver metastases.
Neoplasms
"Nutritional" markers as prognostic indicators of postoperative sepsis in cancer patients.
A multicellular spheroid-based sensor for anti-cancer therapeutics.
A new test for the presumptive diagnosis of neoplastic disease. Further investigations of cholinesterase in plasma, whole blood and blood cells on cancer of the lung, extrapulmonary tumors and tuberculosis.
Acetylcholinesterase and butyrylcholinesterase activities in human thyroid cancer cells.
Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas.
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors.
Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer.
Amplification of butyrylcholinesterase and acetylcholinesterase genes in normal and tumor tissues: putative relationship to organophosphorous poisoning.
Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer.
Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.
BACTERIOSTATIC CHEMOTHERAPEUTIC AND MALIGNANT TUMOR GROWTH; CHANGE OF SERUM CHOLINESTERASE ACTIVITY UNDER PROLONGED ADMINISTRATION OF BACTERIOSTATIC CHEMOTHERAPEUTIC.
Bee venom attenuates neurodegeneration and motor impairment and modulates the response to L-dopa or rasagiline in a mice model of Parkinson's disease.
Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint.
Biochemical abnormalities of the serum in anorexia nervosa.
Biochemical properties of acetyl- and butyrylcholinesterase in human meningioma.
Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors.
Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma.
Butyrylcholinesterase: An economical marker of disease activity in oral squamous cell carcinoma before and after therapy.
Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation.
Cell origin of human adenovirus type 12-induced subcutaneous tumor in Syrian hamsters.
Cerebrospinal fluid cholinergic biomarkers are associated with postoperative delirium in elderly patients undergoing Total hip/knee replacement: a prospective cohort study.
Characterization of activities and forms of cholinesterases in human primary brain tumors.
Chemistry and biology of the genus Voacanga.
Cholesteryl esters in human malignant neoplasms.
Cholinergic system and cell proliferation.
Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer.
Cholinesterase activity and enzyme components in healthy and cancerous human colorectal sections.
Cholinesterase activity of cerebral tumors and tumorous cysts.
Cholinesterase activity of human lung tumours varies according to their histological classification.
Cholinesterase in experimental tumors.
Cholinesterase nevus: cholinesterases in pigmented tumors of the skin.
Cholinesterase response in the rhabdomyosarcoma tumor and small intestine of the BALB/c mice and the radioprotective actions of exogenous ATP after lethal dose of neutron radiation.
Chronic variable stress induces oxidative stress and decreases butyrylcholinesterase activity in blood of rats.
Clinical and analytical considerations in the utilization of cholinesterase measurements.
Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV.
Colorimetric method for measuring pseudocholinesterase, acetylcholinesterase and whole blood cholinesterase. Its use in the presumptive diagnosis of cancer.
Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.
Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue.
Comprehensive profiling of phytochemical compounds, antioxidant activities, anti-HepG2 cell proliferation, and cholinesterase inhibitory potential of Elaeagnus mollis leaf extracts.
Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.
Diagnostic and prognostic significance of serum cholinesterase and lactate dehydrogenase in breast cancer.
Diagnostic significance of serum cholinesterase and lactate dehydrogenase in skin malignancy.
Does Alzheimer's disease protect against cancers? A nationwide population-based study.
Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis.
Effect of Ginger and Turmeric Rhizomes on Inflammatory Cytokines Levels and Enzyme Activities of Cholinergic and Purinergic Systems in Hypertensive Rats.
Ellagic acid and rosmarinic acid attenuate doxorubicin-induced testicular injury in rats.
Enzyme histochemistry of ovarina lipoid cell hyperplasia in a masculinized patient.
Estimation of serum cholinesterase & lactate dehydrogenase levels for diagnosis & prognosis in lymphoreticular malignancy.
Experience from a real-life cohort: outcome of patients with hepatocellular carcinoma following transarterial chemoembolization.
Exploring cancer development in adulthood: cholinesterase depression and genotoxic effect from chronic exposure to organophosphate pesticides among rural farm children.
Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma.
Expression of alternatively terminated unusual human butyrylcholinesterase messenger RNA transcripts, mapping to chromosome 3q26-ter, in nervous system tumors.
Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types.
Expression of muscarinic binding sites in primary human brain tumors.
Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma.
Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
HER-2 amplification but not butyrylcholinesterase multability reflects aggressiveness of European-originated ovarian tumors.
Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
Immunological characterization of partially purified cholinesterase from ascitic fluid of Ehrlich tumor.
INFLUENCE OF TUMOR ON ACTIVITIES OF CATALASE AND CHOLINESTERASE OF THE LIVER OF HOST ANIMAL.
Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease.
Long-term prognostic factors of patients with hepatocellular carcinoma who survive over 10 years after hepatectomy.
Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.
Lycodine type alkaloids from Lycopodiastrum casuarinoides with cytotoxic and cholinesterase inhibitory activities.
Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection.
Modified properties of serum cholinesterases in primary carcinomas.
Molecular forms of acetyl- and butyrylcholinesterase in human glioma.
Molecular mechanism of inflammatory response in mouse liver caused by exposure to CeCl(3).
Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE Deletion on the Neuroblastoma Growth In Vitro and In Vivo.
Muscarinic cholinergic signaling and overactive bladder-like symptoms associated with invasive bladder cancer.
Natural genomic amplification of cholinesterase genes in animals.
Nicotinamide reduces inflammation and oxidative stress via the cholinergic system in fructose-induced metabolic syndrome in rats.
Origin of oncologic anesthetic techniques.
Paraoxonase-1 activity is related to Trichinella spiralis-induced hepatitis in rats.
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis.
Phytochemical profile of Paulownia tomentosa (Thunb). Steud.
Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy.
Postlaryngectomy pharyngocutaneous fistula: incidence, predisposing factors, and therapy.
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Pretreatment serum pseudocholinesterase level as a novel prognostic biomarker for upper tract urothelial carcinoma.
Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy.
Prognostic index for survival in patients after treatment for primary hepatocellular carcinoma.
Prognostic significance of bioelectrical impedance phase angle in advanced cancer: preliminary observations.
Prognostic significance of host- and tumor-related factors in patients with gastric cancer.
Prognostic value of immunoscore to identify mortality outcomes in adults with HBV-related primary hepatocellular carcinoma.
Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
Prophylactic effects of ellagic acid and rosmarinic acid on doxorubicin-induced neurotoxicity in rats.
Pseudocholinesterase activity in cerebrospinal fluid as a biomarker of solid central nervous system tumors in children.
Putative role of endothelial lipase in dialysis patients with hypoalbuminemia and inflammation.
Relationship between nutritional status and tumor growth in humans.
Risk factors and cancer recurrence associated with postoperative complications after thoracoscopic lobectomy for clinical stage I non-small cell lung cancer.
Risk factors for early death due to recurrence after resection of large hepatocellular carcinomas.
Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer.
Serum butyrylcholinesterase and zinc in breast cancer.
Serum cholesterol levels in patients with cancer. Relationship with nutritional status.
Serum cholinesterase activity in malignant neoplasms.
Serum cholinesterase levels in patients with cancer.
Serum cholinesterase: a potential assistant biomarker for hand, foot, and mouth disease caused by enterovirus 71 infection.
Serum enzyme activity in bone tumors and osteomyelitis (LDH, GOT, GPT, CPK, CHE, ALP, AP, PP, ALD).
Serum pseudocholinesterase activity & protein bound fucose level in oral malignancy.
Serum pseudocholinesterase levels in murine C3H mammary adenocarcinoma.
Significance of serum butyrylcholinesterase levels in oral cancer.
Significance of serum tumor markers in patients with carcinoma of the ovary.
Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
Studies of cholinesterase activity. VI. The depression of serum cholinesterase activity by a locally implanted human tumor in the guinea pig.
STUDIES OF CHOLINESTERASE ACTIVITY. VII. KINETIC CONSTANTS OF SERUM CHOLINESTERASE IN NORMAL POPULATIONS AND THOSE WITH NEOPLASMS.
STUDIES OF CHOLINESTERASE PHENOMENA AT INFLAMMATION AND CANCER.
Studies on the cholinesterase forms present in the ascitic fluid of Ehrlich tumour.
Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer.
Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases.
The Cholinergic System and Inflammation: Common Pathways in Delirium Pathophysiology.
The expression of cholinesterases in human renal tumours varies according to their histological types.
The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Two new isoxazolines from the husks of Xanthoceras sorbifolia Bunge.
[Behavior of cholinesterase in relation to anesthesia in patients with tumors during various stages of growth]
[Behavior of cholinesterase in the blood of patients affected by malignant neoplasms of the oropharynx]
[Behavior of the cholinesterase activity of the blood in patients with malignant neoplasms.]
[Changes in the activity of serum lactate dehydrogenase and serum cholinesterase in surgical treatment of cancer of the colon]
[Cholinesterase activity in experimental tumors.]
[Cholinesterase activity in the tissues of glial tumors of the brain]
[Cholinesterase activity in tumors and neoplastic cysts of the brain.]
[Cholinesterase activity of blood serum in neoplasms.]
[Cholinesterase activity of the blood and tissue in cases of cervical erosions and cancer]
[Cholinesterase content of the brain in cerebral tumors and paralysis agitans.]
[Cholinesterase of Ehrlich's mouse ascites tumor.]
[Decrease of serum cholinesterase in colorectal cancer]
[Determination of the level of cholinesterase activity in the jugular and carotid blood and in the general venous circulation in patients with cerebral neoplasms.]
[Diagnostic value of biochemical tumor markers in serum of patients with cancer of the ovary]
[Enzymes of benign and malignant tumors of the liver; cholinesterase and tributyrinase.]
[Histochemical demonstration of glial enzyme activity. II. Reagent and neoplastic glia]
[Impact of Chai Qin Cheng Qi decoction on cholinergic anti-inflammatory pathway in rats with severe acute pancreatitis]
[In connection with the paradoxical activity of adrenalin in cancer patients and its effect on the action of cholinesterase.]
[Liver and serum cholinesterase activity in primary and metastatic cancer of the liver]
[Mineral metabolism and tumor growth. II. Potassium content of the tumor, acetylcholine, cholinesterase and lymphocytes in the blood.]
[Muscle and tumor tissue cholinesterase activity during Jensen sarcoma growth]
[On variations of the muscle-relaxant effects of d-tubocurarine in patients with neoplasms. II. Behavior of the plasma cholinesterase and electrolyte activity.]
[Possibilities and limitations of control of the course of tumor treatment by serum cholinesterase determination]
[Prostaglandin E(2) and omeprazole in treating poisoning related acute mucosal lesion]
[Reduced nutritional status of the surgical tumor patient--a risk factor for postoperative complications?]
[Relation between cholinesterase activity and incorporation of amino acids into proteins. II. Incorporation of C14-labeled glycine into homogenized tissue of tumor homo- and heterografts under the influence of acetylphosphate.]
[Resection of centrally located primary liver cancer]
[Serum cholinesterase and erythrocyte acetylcholinesterase in 89 cases of cancer]
[State of the liver after radiotherapy of cancer of the stomach and larynx with metronidazole radiosensitization]
[Studies of the activity of ceruloplasmin, SGOT, SGPT and cholinesterase in various neoplasm types]
[Studies on serum esterases in cancer. Cholinesterase and arylesterase activity]
[STUDIES ON SIGNIFICANCE OF THE FALL OF THE BLOOD CHOLINESTERASE LEVEL IN CASE OF MALIGNANT TUMOR. EXPERIMENTAL AND CLINICAL RESEARCH.]
[The toxicity and biological effects of organophosphorus epoxides]
[Usefulness of serum pseudocholinesterase isoenzymes in acute and chronic liver diseases and neoplasms (experimental and clinical study)]
Neoplasms, Neuroepithelial
Activation of acetyl- and butyrylcholinesterase by enzymatic removal of sialic acid from intact neuroblastoma and astroblastoma cells in culture.
Neoplastic Processes
[Serum cholinesterase activity in the differential diagnosis of neoplastic processes]
Nephritis
[Myasthenia gravis and LE nephritis: problems of treatment with cholinesterase inhibitors during long-term dialysis (author's transl)]
Nephrosis
Serum cholinesterase activity and protein-bound iodine fluctuations during therapy of a case of nephrosis.
[Serum cholinesterase in lipid nephrosis.]
Nephrosis, Lipoid
[Value of determination of blood cholinesterase in lipoid nephrosis.]
Nephrotic Syndrome
Activity of serum enzymes in puromycin aminonucleoside-induced nephrotic syndrome.
Hereditary serum cholinesterase deficiency associated with severe lipid deposition in the kidney.
PLASMA ESTERASE ACTIVITY IN PATIENTS WITH LIVER DISEASE AND THE NEPHROTIC SYNDROME.
Relationship between serum cholinesterase and low density lipoproteins in children with nephrotic syndrome.
[DETERMINATION OF THE ENZYMATIC ACTIVITY IN CHILDHOOD. V. SERUM CHOLINESTERASE IN NEPHROTIC SYNDROME.]
Nervous System Diseases
A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.
Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
Anti-inflammatory and acetylcholinesterase activity of extract, fractions and five compounds isolated from the leaves and twigs of Artemisia annua growing in Cameroon.
Antiaggregation Potential of Padina gymnospora against the Toxic Alzheimer's Beta-Amyloid Peptide 25-35 and Cholinesterase Inhibitory Property of Its Bioactive Compounds.
Anticholinesterase and antioxidant potentials of Nonea micrantha Bioss. & Reut along with GC-MS analysis.
Cholinesterase inhibitors from Sargassum and Gracilaria gracilis: seaweeds inhabiting South Indian coastal areas (Hare Island, Gulf of Mannar).
Cholinesterase inhibitors: beyond Alzheimer’s disease.
Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: a preliminary anti- Alzheimer's study.
Computational and Kinetic Studies of Acetylcholine Esterase Inhibition by Phenserine.
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
Drug-induced sialorrhoea and excessive saliva accumulation.
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Exploring the role of BCHE in the onset of Diabetes, Obesity and Neurological Disorders.
Inhibition of enzymes associated with metabolic and neurological disorder by dried pomegranate sheets as a function of pomegranate cultivar and fruit puree.
Natural cholinesterase inhibitors from marine organisms.
Potential association of reduced cholinesterase activity with Trypanosoma evansi pathogenesis in buffaloes.
Nervous System Neoplasms
Expression of alternatively terminated unusual human butyrylcholinesterase messenger RNA transcripts, mapping to chromosome 3q26-ter, in nervous system tumors.
Neural Tube Defects
A prospective study of amniotic fluid cholinesterases: comparison of quantitative and qualitative methods for the detection of open neural tube defects.
Acetylcholinesterase and butyrylcholinesterase measurement in the pre-natal detection of neural tube defects and other fetal malformations.
Amniotic fluid cholinesterase measurement as a rapid method for the exclusion of fetal neural tube defects.
Amniotic fluid cholinesterase of valproate-induced exencephaly in the mouse: an animal model for prenatal diagnosis of neural tube defects.
Cholinesterase evaluation in the prenatal diagnosis of open neural tube defects.
Cholinesterases exhibiting aryl acylamidase activity in human amniotic fluid.
Comparison of the modified gel disc electrophoresis of amniotic fluid cholinesterase with other methods in the prenatal diagnosis of neural tube defects.
Determination of amniotic fluid acetylcholinesterase activity in the antenatal diagnosis of foetal malformations: the first ten years.
Diagnosis of neural tube defects by estimation of amniotic fluid acetylcholinesterase.
False-positive acetylcholinesterase with early amniocentesis.
Gel electrophoresis of maternal and fetal serum cholinesterases from normal pregnancies and of those affected by neural tube defects.
Prenatal diagnosis of neural tube defects using the cholinesterases.
Prenatal diagnosis of neural tube defects. V. The value of amniotic fluid cholinesterase studies.
Serum cholinesterase in the mothers of neural tube defect progeny.
[Determination of alpha-fetoprotein, cholinesterase and alpha 2-macroglobulin in the amniotic fluid in the diagnosis of neural tube defects]
[Determination of the acetylcholinesterase activities of the amniotic fluid on a centrifugal analyzer]
[Prenatal diagnosis of abnormalities of the neuroectodermal tube. Limitations of the assay of amniotic alpha fetoprotein and acetylcholinesterase and value of the qualitative study of cholinesterases. Apropos of 6 cases of anencephaly]
[Prenatal diagnosis of neural tube defects. Value of electrophoresis of cholinesterases]
Neuralgia
Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.
Oral donepezil reduces hypersensitivity after nerve injury by a spinal muscarinic receptor mechanism.
Potential of nafimidone derivatives against co-morbidities of epilepsy: In vitro, in vivo, and in silico investigations.
Relief of hypersensitivity after nerve injury from systemic donepezil involves spinal cholinergic and ?-aminobutyric acid mechanisms.
The antiallodynic effects of intrathecal cholinesterase inhibitors in a rat model of neuropathic pain.
Neurilemmoma
Characterization of molecular forms of acetyl- and butyrylcholinesterase in human acoustic neurinomas.
Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
Neuritis
Cholinesterase activities in the autonomic nervous system of rabbits with experimental allergic neuritis: a biochemical study.
Cholinesterase activities in the somatic nervous system of rabbits with experimental allergic neuritis.
Neuritis, Autoimmune, Experimental
Cholinesterase activities in the autonomic nervous system of rabbits with experimental allergic neuritis: a biochemical study.
Cholinesterase activities in the somatic nervous system of rabbits with experimental allergic neuritis.
Neurobehavioral Manifestations
A population-based study of dosing and persistence with anti-dementia medications.
A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.
Acetylcholinesterase and butyrylcholinesterase inhibition by nectriapyrone and tryptophol isolated from endophytic fungus Phomopsis sp.
Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies.
Apathy: a practical guide for neurologists.
Behavioral effects of organophosphate in man.
Behavioral symptomatology and psychopharmacology of Lewy body dementia.
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Dementia with cerebrovascular disease: the benefits of early treatment.
Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
Metrifonate: update on a new antidementia agent.
New drugs for Alzheimer's disease.
New therapeutic approaches to cognitive impairment.
Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
Present and prospective clinical therapeutic regimens for Alzheimer's disease.
The cholinergic hypothesis of Alzheimer's disease: a review of progress.
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
[Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia--common features and differences].
[Treatment for non-cognitive symptoms in Alzheimer's disease]
Neuroblastoma
Activation of acetyl- and butyrylcholinesterase by enzymatic removal of sialic acid from intact neuroblastoma and astroblastoma cells in culture.
Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma.
Cholinesterases in neural development: new findings and toxicologic implications.
Cholinesterases modulate cell adhesion in human neuroblastoma cells in vitro.
Design, Synthesis, and Evaluation of Donepezil-Like Compounds as AChE and BACE-1 Inhibitors.
Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells.
Expression of alternatively terminated unusual human butyrylcholinesterase messenger RNA transcripts, mapping to chromosome 3q26-ter, in nervous system tumors.
Modulation of the number of muscarinic receptors in mouse neuroblastoma cells by soman.
Morphine tolerance in a human neuroblastoma line: changes in choline acetylase and cholinesterase activities.
Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE Deletion on the Neuroblastoma Growth In Vitro and In Vivo.
Probing simple structural modification of ?-mangostin on its cholinesterase inhibition and cytotoxicity.
Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
Tacrine interacts with different sites on nicotinic receptor subtypes in SH-SY5Y neuroblastoma and M10 cells.
[Rapid simultaneous isolation of microsomes and plasma membranes from neuroblastoma C 1300 N 18 cells]
Neurodegenerative Diseases
5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
A Novel Way To Radiolabel Human Butyrylcholinesterase for Positron Emission Tomography through Irreversible Transfer of the Radiolabeled Moiety.
Abietane-type diterpenoids from the roots of Caryopteris mongolica and their cholinesterase inhibitory activities.
Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems.
Advances in the pharmacological management of Parkinson disease.
Alkaloids pharmacological activities - Prospects for the development of phytopharmaceuticals for neurodegenerative diseases.
Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2 R Ligands To Combat Neurodegenerative Disorders.
Amyloid, Cholinesterase, Melatonin, and Metals and Their Roles in Aging and Neurodegenerative Diseases.
Anticeramide antibody and butyrylcholinesterase in peripheral neuropathies.
Anticholinergic and antioxidant activities of usnic acid-an activity-structure insight.
Antioxidant activity and acetylcholinesterase inhibition of grape skin anthocyanin (GSA).
Benzobicyclo[3.2.1]octene Derivatives as a New Class of Cholinesterase Inhibitors.
Biochemical Profiling and Elucidation of Biological Activities of Beta vulgaris L. Leaves and Roots Extracts.
Biological evaluation of synthetic ?,?-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-? aggregation.
Biphenylalkoxyamine Derivatives-Histamine H3 Receptor Ligands with Butyrylcholinesterase Inhibitory Activity.
Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease.
Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool.
Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds.
Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.
Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold.
Design, synthesis and cholinesterase inhibitory properties of new oxazole benzylamine derivatives.
Development of an Efficient Protocol for Cimifugin Isolation from Peucedanum schottii and Evaluation of Enzyme Inhibitory Activity.
Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management.
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Effect of viologen-phosphorus dendrimers on acetylcholinesterase and butyrylcholinesterase activities.
Effects of Resveratrol and other Polyphenols on the most common Brain Age-Related Diseases.
Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon4, and hyperhomocysteinemia in neurodegenerative dementias.
Fluorescent Determination of Butyrylcholinesterase Activity and Its Application in Biological Imaging and Pesticide Residue Detection.
Honey as the Potential Natural Source of Cholinesterase Inhibitors in Alzheimer's Disease.
Imaging Butyrylcholinesterase in Multiple Sclerosis.
Immobilization of transgenic plant cells towards bioprinting for production of a recombinant biodefense agent.
In vitro anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida).
Increased cholinergic activity under conditions of low estrogen leads to adverse cardiac remodeling.
Indole Alkaloids And Semisynthetic Indole Derivatives As Multifunctional Scaffolds Aiming The Inhibition Of Enzymes Related To Neurodegenerative Diseases - A Focus On Psychotria L. Genus.
Indole alkaloids of Psychotria as multifunctional cholinesterases and monoamine oxidases inhibitors.
Inhibitory potential of the leaves and berries of Myrtus communis L. (myrtle) against enzymes linked to neurodegenerative diseases and their antioxidant actions.
Local salt substitutes "Obu-otoyo" activate acetylcholinesterase and butyrylcholinesterase and induce lipid peroxidation in rat brain.
Melatonin as a structural template in the development of novel drugs for neurodegenerative disorders.
Molecular dynamics and regulation of butyrylcholinesterase cholinergic activity by RNA binding proteins.
Multifunctional Mercapto-tacrine Derivatives for Treatment of Age-related Neurodegenerative Diseases.
Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3 R Antagonism for Neurodegenerative Diseases.
Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update.
New indane derivatives containing 2-hydrazinothiazole as potential acetylcholinesterase and monoamine oxidase-B inhibitors.
New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.
Phosphodiesterase inhibitors say NO to Alzheimer's disease.
Phytochemical profile of a blend of black chokeberry and lemon juice with cholinesterase inhibitory effect and antioxidant potential
Phytochemical profile of a blend of black chokeberry and lemon juice with cholinesterase inhibitory effect and antioxidant potential.
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
RP-UHPLC-MS Chemical Profiling, Biological and In Silico Docking Studies to Unravel the Therapeutic Potential of Heliotropium crispum Desf. as a Novel Source of Neuroprotective Bioactive Compounds.
Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses.
Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer.
Synthesis, biological evaluation and molecular modeling of substituted 2-aminobenzimidazoles as novel inhibitors of acetylcholinesterase and butyrylcholinesterase.
Ten years of cholinesterase inhibitors.
The cholinergic deficiency syndrome and its therapeutic implications.
The use of chemometrics to study multifunctional indole alkaloids from Psychotria nemorosa (Palicourea comb. nov.). Part II: Indication of peaks related to the inhibition of butyrylcholinesterase and monoamine oxidase-A.
Treatment of Apathy in Huntington's Disease and Other Movement Disorders.
Treatment of Mild Cognitive Impairment.
Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson's Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage.
UHPLC-ESI-ORBITRAP-MS analysis of the native Mapuche medicinal plant palo negro (Leptocarpha rivularis DC. - Asteraceae) and evaluation of its antioxidant and cholinesterase inhibitory properties.
Neurodermatitis
[Blood enzyme activities in men and women with certain diseases]
[Blood levels of acetylcholine and serum cholinesterase activity in children with neurodermatitis constitutionalis with and without bronchial asthma]
Neuroectodermal Tumors, Primitive
[Cholinesterase activity in transplantable tissue cultures]
Neuroendocrine Tumors
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Neurofibroma
CHOLINESTERASE ACTIVITY IN NEUROFIBROMAS IN VITRO.
Neuroinflammatory Diseases
Alendronate reduces the cognitive and neurological disturbances induced by combined doses of d-galactose and aluminum chloride in mice.
Effect of anti-dementia drugs on LPS induced neuroinflammation in mice.
Evaluating the Memory Enhancing Effects of Angelica gigas in Mouse Models of Mild Cognitive Impairments.
Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review.
The modulatory role of prime identified compounds in Geophila repens in mitigating scopolamine-induced neurotoxicity in experimental rats of Alzheimer's disease via attenuation of cholinesterase, ?-secretase, MAPt levels and inhibition of oxidative stress imparts inflammation.
Neuroleptic Malignant Syndrome
Anticholinergic toxicity masquerading as neuroleptic malignant syndrome: a case report and review.
Effect of Delirium on Physical Function in Noncardiac Thoracic Surgery Patients.
Neurologic Manifestations
Activity of Paraoxonase/Arylesterase and Butyrylcholinesterase in Peripheral Blood of Gulf War Era Veterans With Neurologic Symptom Complexes or Post-Traumatic Stress Disorder.
Activity of Paraoxonase/Arylesterase and Butyrylcholinesterase in Peripheral Blood of Gulf War Era Veterans With Neurologic Symptom Complexes or Post-Traumatic Stress Disorder: Erratum.
Muscarinic receptor-mediated pyridostigmine-induced neuronal apoptosis.
Neurotoxicity resulting from coexposure to pyridostigmine bromide, deet, and permethrin: implications of Gulf War chemical exposures.
Neuroma
Myelinated sensory and alpha motor axon regeneration in peripheral nerve neuromas.
Neuroma, Acoustic
Characterization of molecular forms of acetyl- and butyrylcholinesterase in human acoustic neurinomas.
Neuromuscular Diseases
Acetylcholinesterase and ATPases in motor neuron degenerative diseases.
Cumulative reduction in serum cholinesterase following repeated therapeutic plasma exchange.
Deep neuromuscular blockade and surgical conditions during laparoscopic ventral hernia repair: A randomised, blinded study.
ECT Modified by Atracurium.
[Research on serum cholinesterase in some neuromuscular diseases.]
Neurosyphilis
Donepezil Improved Cognitive Deficits in a Patient With Neurosyphilis.
Neutropenia
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
Nevus
CHOLINESTERASE IN JUNCTION NEVUS.
Cholinesterase in the cutaneous nevus.
Cholinesterase in the skin. II. Cholinesterases in pigmented nevi.
Cholinesterase nevus: cholinesterases in pigmented tumors of the skin.
Clinical factors that affect blood gases in non-smoking women with chronic liver disease.
[Studies on classification of nevus pigmentosus and cholinesterase activity of nevus cell]
Nevus, Pigmented
Cholinesterase in the skin. II. Cholinesterases in pigmented nevi.
Non-alcoholic Fatty Liver Disease
Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer.
Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients.
Serum cholinesterase in patients with fatty liver.
Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD).
Nutrition Disorders
[Serum cholinesterase in childhood. II. Serum cholinesterase activity and serum protein level in acute dyspepsia and chronic nutrition disorders]
Obesity
A Novel Way To Radiolabel Human Butyrylcholinesterase for Positron Emission Tomography through Irreversible Transfer of the Radiolabeled Moiety.
A study of pseudocholinesterase induction in experimental obesity.
Acetylcholinesterase and butyrylcholinesterase activities in obese Beagle dogs before and after weight loss.
Association between RAPH1 Gene Haplotypes and CHE2 Locus Phenotypes.
Butyrylcholinesterase and obesity in individuals with the CHE2 C5+ and CHE2 C5- phenotypes.
Butyrylcholinesterase as a prognostic marker: a review of the literature.
Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet.
Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling.
Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool.
Effect of BCHE single nucleotide polymorphisms on lipid metabolism markers in women.
Effect of pomegranate extracts on brain antioxidant markers and cholinesterase activity in high fat-high fructose diet induced obesity in rat model.
Effects of energetic restriction diet on butyrylcholinesterase in obese women from southern Brazil - A longitudinal study.
Emerging links between type 2 diabetes and Alzheimer's disease.
Exploring the role of BCHE in the onset of Diabetes, Obesity and Neurological Disorders.
Functional Analysis and Molecular Docking studies of Medicinal Compounds for AChE and BChE in Alzheimer's Disease and Type 2 Diabetes Mellitus.
Gestational diabetes mellitus (GDM) decreases butyrylcholinesterase (BChE) activity and changes its relationship with lipids.
GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE, and secondary associations with metabolic risk factors.
Liver Enzymes Correlate With Metabolic Syndrome, Inflammation, and Endothelial Dysfunction in Prepubertal Children With Obesity.
Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects.
Molecular forms of butyrylcholinesterase and obesity.
Plasma cholinesterase is associated with Chinese adolescent overweight or obesity and metabolic syndrome prediction.
Production of butyrylcholinesterase by Caco-2 cells: lack of relationship with triglyceride production.
Pseudocholinesterase in obesity: hypercaloric diet induced changes in experimental obese mice.
Relationship between butyrylcholinesterase activity and lipid parameters in workers occupationally exposed to pesticides.
Relationship between serum butyrylcholinesterase and obesity in dogs: A preliminary report.
Serum butyrylcholinesterase and the risk of future type 2 diabetes: The Kansai Healthcare Study.
Serum Cholinesterase Is Inversely Associated with Body Weight Change in Men Undergoing Routine Health Screening.
The butyrylcholinesterase knockout mouse a research tool in the study of drug sensitivity, bio-distribution, obesity and Alzheimer's disease.
Treating Cocaine Addiction, Obesity, and Emotional Disorders by Viral Gene Transfer of Butyrylcholinesterase.
Variations in serum cholinesterase activity in different age and sex groups.
[Behavior of serum pseudocholinesterase in fasting therapy of obesity]
[Serum cholinesterase activity in non-alcoholic fatty liver. Effect of obesity on the activity and role of its measurement in the differential diagnosis in chronic hepatitis]
[Ultrasonic and laboratory studies on fatty liver in white-collar workers]
Obesity, Abdominal
Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels.
Relationship between serum butyrylcholinesterase and the metabolic syndrome.
Thrombotic tendency in diabetes mellitus. Revisiting and revising a study initiated 30 years ago.
Obstetric Labor, Premature
Imbalances emerge in cardiac autonomic cell signaling after neonatal exposure to terbutaline or chlorpyrifos, alone or in combination.
Occupational Diseases
Acute, severe cholinesterase inhibitors poisonings in the material of occupational diseases and toxicology ward in Poznań.
Oligodendroglioma
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors.
Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
Onchocerciasis
[Drop in blood cholinesterase in the course of treatment of onchocerciasis by an organophosphorus compound (Metrifonate)]
Ophthalmoplegia
Early onset myasthenia gravis with atypical features.
Opisthorchiasis
[Biochemical characteristics of hepatic functions in different clinical forms of chronic opisthorchiasis]
[Changes in the activity of gamma-glutamyltransferase and cholinesterase in the blood of patients with opisthorchiasis at different phases of the disease]
Osteomyelitis
Serum enzyme activity in bone tumors and osteomyelitis (LDH, GOT, GPT, CPK, CHE, ALP, AP, PP, ALD).
Osteoporosis
Drug use differs by care level. A cross-sectional comparison between older people living at home or in a nursing home in Oslo, Norway.
Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.
Otitis
Correlation between peri-operative complication in middle ear cholesteatoma surgery using STAMCO, ChOLE, and SAMEO-ATO classifications.
Otitis Media
A top 5 list for French general practice.
Otitis Media with Effusion
A top 5 list for French general practice.
Otosclerosis
[Serum cholinesterase activity in otosclerosis.]
[Serum cholinesterase, otospongiosis and the autonomic nervous system.]
[Study of the activity of true and false blood cholinesterase with the aim of finding directed therapy of vestibular disorders due to operation on the stapes for otosclerosis]
Ovarian Hyperstimulation Syndrome
Pseudocholinesterase deficiency: a dangerous, unrecognized complication of the ovarian hyperstimulation syndrome.
Overweight
Butyrylcholinesterase activity in young men and women: Association with cardiovascular risk factors.
Clinical studies on plasma protein C. Correlation with serum cholinesterase.
Plasma cholinesterase is associated with Chinese adolescent overweight or obesity and metabolic syndrome prediction.
Plasma fibronectin in overweight men and women: correlation with serum triglyceride levels and serum cholinesterase activity.
Plasma protein S-antigen (PS:Ag) in selected disease states.
Relationship Between Paraoxonase-1 and Butyrylcholinesterase Activities and Nutritional Status in Mexican Children.
Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes.
Total cholinesterase in plasma: biological variations and reference limits.
Pancreatic Neoplasms
Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer.
Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.
Hepatic changes and serum ferritin in pancreatic cancer and other gastrointestinal diseases: the role of cholestasis.
Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.
Pancreatitis
Baseline Serum Cystatin C Is a Potential Predictor for Acute Kidney Injury in Patients with Acute Pancreatitis.
Effects of insecticide, diazinon, on pancreas of dog, cat and guinea pig.
Total cholesterol level for assessing pancreatic insufficiency due to chronic pancreatitis.
[Impact of Chai Qin Cheng Qi decoction on cholinergic anti-inflammatory pathway in rats with severe acute pancreatitis]
[The serum enzymogram for the evaluation of the effectiveness of hemosorption in patients with acute destructive pancreatitis]
[Use of cholinesterase in treatment of acute pancreatitis]
Pancreatitis, Chronic
Hepatic changes and serum ferritin in pancreatic cancer and other gastrointestinal diseases: the role of cholestasis.
THE CONCENTRATION OF ACETYLCHOLINE AND THE LEVEL CHOLINESTERASE ACTIVITY IN THE SERUM OF PATIENTS WITH GASTRIC ULCER, DUODENAL ULCER AND ALCOHOLIC CHRONIC PANCREATITIS.
Paralysis
Activity and polymorphisms of butyrylcholinesterase in a Polish population.
An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans.
Antagonism of succinylcholine paralysis in a patient with atypical pseudocholinesterase.
Awareness during emergence from anaesthesia: significance of neuromuscular monitoring in patients with butyrylcholinesterase deficiency.
Biochemical and clinical profile after organophosphorus poisoning--a placebo-controlled trial using pralidoxime.
Cholinergic approaches to the treatment of progressive supranuclear palsy.
Cholinesterase phenotyping: clinical aspects and laboratory applications.
Correlation of plasma cholinesterase activity and duration of action of succinylcholine during pregnancy.
Correlative electrophysiological and anatomical studies concerning the site of origin of escape rhythm during complete atrioventricular block in the dog.
Customized anesthetic preservation of ictal threshold in electroconvulsive therapy: role of adjunctive remifentanil with etomidate.
Cyclodextrins and the emergence of sugammadex.
Delayed recovery from paralysis associated with plasma cholinesterase deficiency.
Delayed recovery from paralysis by succinylcholine in patient with preoperatively unrecognized and inherited pseudocholinesterase deficiency.
Dementia with Lewy bodies with supranuclear gaze palsy: a matter of diagnosis.
Differential cholinesterase inhibition and muscarinic receptor changes in CD-1 mice made tolerant to malathion.
Donepezil in the treatment of progressive supranuclear palsy.
Edrophonium increases mivacurium concentrations during constant mivacurium infusion, and large doses minimally antagonize paralysis.
Electroconvulsive Therapy Considerations for Transgendered Patients.
Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine.
Hereditary pseudocholinesterase deficiency discovery after electroconvulsive therapy.
Markedly prolonged paralysis after mivacurium in a patient apparently heterozygous for the atypical and usual pseudocholinesterase alleles by conventional biochemical testing.
Neuropharmacology of the parasitic trematode, Schistosoma mansoni.
New Insights into Butyrylcholinesterase Activity Assay: Serum Dilution Factor as a Crucial Parameter.
Paralysis of accommodation in infectious mononucleosis.
Plasma cholinesterase activity and neuromuscular paralysis by succinylcholine.
Premature awakening and underuse of neuromuscular monitoring in a registry of patients with butyrylcholinesterase deficiency.
Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors.
Prolonged apnea following succinylcholine administration in undiagnosed acute organophosphate poisoning.
Prolonged Neuromuscular Paralysis Following Rapid-Sequence Intubation with Succinylcholine (April).
Prolonged paralysis after a test dose of mivacurium in a patient with atypical serum cholinesterase.
Prolonged Paralysis After Electroconvulsive Therapy Due to Butyrylcholinesterase Gene Mutation.
Prolonged paralysis associated with succinylcholine--a case report.
Prolonged Paralysis Following Emergent Cesarean Section with Succinylcholine Despite Normal Dibucaine Number.
Prolonged paralysis following suxamethonium and the use of neostigmine.
Prolonged paralysis in pseudocholinesterase deficiency.
Prolonged paralysis related to mivacurium: a case study.
Prolonged succinylcholine-induced apnea caused by atypical cholinesterase: report of case.
Pseudocholinesterase activity of human whole blood, bank blood, and blood protein solutions.
Pseudocholinesterase-mediated hydrolysis is superior to neostigmine for reversal of mivacurium-induced paralysis in vitro.
RELATIONSHIP BETWEEN DEPRESSION OF BRAIN OR PLASMA CHOLINESTERASE AND PARALYSIS IN CHICKENS CAUSED BY CERTAIN ORGANIC PHOSPHORUS COMPOUNDS.
Reversal of succinylcholine induced apnea with an organophosphate scavenging recombinant butyrylcholinesterase.
Screening patients with prolonged neuromuscular blockade after succinylcholine and mivacurium.
Suxamethonium apnoea associated with plasmaphoresis.
The antagonism of muscle relaxants by ambenonium and methoxyambenonium in the cat.
The early toxicology of physostigmine : a tale of beans, great men and egos.
Train-of-four nerve stimulation in the management of prolonged neuromuscular blockade following succinylcholine.
Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Unexpected prolonged neuromuscular block after mivacurium: a case report.
[Danish Cholinesterase Research Unit diagnoses patients with prolonged paralysis after succinylcholine and mivacurium.]
[Danish Cholinesterase Research Unit diagnoses patients with prolonged paralysis after succinylcholine and mivacurium].
[Electromyographic investigation on the indication and therapy of poliomyelitic paralysis with cholinesterase inhibitors.]
[Electrophysiological aspects of intermediate syndrome in organophosphate poisonings]
[Localization of cholinesterase in the transverse striated muscles of dogs with experimental lead-induced paralysis]
[Neuromuscular blockades. Agents, monitoring and antagonism]
[On the monitoring of neuromuscular blockade during anaesthesia (author's transl)]
[Plasma cholinesterase activity in transverse paralysis]
Paraneoplastic Syndromes
Hypercholinesterasemia in patients with hepatocellular carcinoma: a new paraneoplastic syndrome.
Parasitemia
Status of oxidative stress, trace elements, sialic acid and cholinesterase activity in cattle naturally infected with Babesia bigemina.
Parasitic Diseases
Cholinesterase activity after treatment with mebendazole, thiabendazole and metronidazole in patients with various parasitic diseases.
Effects of agricultural pond eutrophication on survival and health status of Scinax nasicus tadpoles.
Paresis
Cholinesterase levels in blood plasma and erythrocytes from calves, normal delivering cows and cows suffering from parturient paresis.
[Action of cholinesterase & electrophoretic blood protein fractions in epilepsy & paresis.]
[Cholinesterase, iron and serum protein electrophoretic patterns in serum of patients with hemiparesis of cerebrovascular origin treated at Ladek-Spa]
Parkinson Disease
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia.
Acetyl- and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's disease.
Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease.
Acquired Localized Hypertrichosis Induced by Rivastigmine.
Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice.
An association between organophosphate pesticides exposure and Parkinsonism amongst people in an agricultural area in Ubon Ratchathani Province, Thailand.
An examination of three prescribing cascades in a cohort of older adults with dementia.
Assessing cognitive change in Parkinson's disease: development of practice effect-corrected reliable change indices.
Assessment of cholinesterase and tyrosinase inhibitory and antioxidant effects of Hypericum perforatum L. (St. John's wort)
Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.
Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy.
Cholinesterase inhibition in Parkinson's disease.
Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis.
Cholinesterase inhibitors for Parkinson's disease dementia.
Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis.
Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and mechanisms for treatment response.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.
Comparison of recovery profiles in patients with Parkinson's disease for 2 types of neuromuscular blockade reversal agent following deep brain stimulator implantation.
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
Dementia in Parkinson's disease: cause and treatment.
Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.
Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type.
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.
Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Effect of Delirium on Physical Function in Noncardiac Thoracic Surgery Patients.
Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.
Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease.
Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data.
Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.
Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays.
Feeling the need ... the need for speed (of processing training) in Parkinson disease.
Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.
Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Mesial Frontal Lobe Infarction Presenting as Pisa Syndrome.
Metabolic treatment of syndrome linked with Parkinson's disease and hypothalamus pituitary gonadal hormones by turmeric curcumin in Bisphenol-A induced neuro-testicular dysfunction of wistar rat.
Metabolite Profiling by Hyphenated Liquid Chromatographic Mass Spectrometric Technique (HPLC-DAD-ESI-Q-TOF-MS/MS) and Neurobiological Potential of Haplophyllum sahinii and H. vulcanicum Extracts.
Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
New Therapeutic Strategies for Lewy Body Dementias.
Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review.
Nutraceutical Potential of Phenolics from 'Brava' and 'Mansa' Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in Comparison with Those of 'Picual' and 'Cornicabra'.
Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment.
Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series.
Pharmacokinetic rationale for the rivastigmine patch.
Pharmacotherapy of Parkinson disease dementia and Lewy body dementia.
Phytochemical profile of a blend of black chokeberry and lemon juice with cholinesterase inhibitory effect and antioxidant potential.
Pisa syndrome in a patient with pathologically confirmed Parkinson's disease.
Reversible Pisa syndrome associated to subdural haematoma: case-report.
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.
Rivastigmine in Parkinson's disease dementia.
Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Serum Butyrylcholinesterase Activity: A Biomarker for Parkinson's Disease and Related Dementia.
The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia.
The cholinergic deficiency syndrome and its therapeutic implications.
The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia.
The interplay of cholinergic function, attention, and falls in Parkinson's disease.
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
The use of atypical antipsychotics in nursing homes.
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Treatment of attention deficits in neurological disorders.
Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Treatment of psychosis in Parkinson's disease: safety considerations.
Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson's Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage.
When a Parkinson's disease patient starts to hallucinate.
[Cholinesterase content of the brain in cerebral tumors and paralysis agitans.]
[Cholinesterase inhibitors for the treatment of dementia in Parkinson's disease.]
[Dementia in Parkinsn's disease.]
[Dementia in Parkinson's disease]
[New attempt at treating Huntington's chorea (preliminary report)]
[Psychological and cognitive problems in Parkinson disease--therapeutic possibilities]
[Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia.]
Parkinsonian Disorders
An association between organophosphate pesticides exposure and Parkinsonism amongst people in an agricultural area in Ubon Ratchathani Province, Thailand.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Mesial Frontal Lobe Infarction Presenting as Pisa Syndrome.
Psychiatric aspects of Parkinson's disease.
Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson's Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage.
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?]
[Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient]
[Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors]
Parvoviridae Infections
Changes in choline and cholinesterase in saliva of dogs with parvovirus infection.
Parvovirus b19 infection after plasma exchange for myasthenia gravis.
Pediatric Obesity
Cholinesterase and paraoxonase (PON1) enzyme activities in Mexican-American mothers and children from an agricultural community.
Plasma cholinesterase is associated with Chinese adolescent overweight or obesity and metabolic syndrome prediction.
Pelvic Inflammatory Disease
Evaluation of pelvic inflammatory disease potential in cholinesterase inhibitor pesticide-exposed females.
Peptic Ulcer
Pharmacologic treatments of dementia.
Serum cholinesterase activity in children with gastroduodenitis or peptic ulcer disease.
[Association of mutant alleles of serum cholinesterase with various multi-factorial and infectious diseases]
[Changes in blood ceruloplasmin, catalase and pseudocholinesterase activity in patients with peptic ulcers of the stomach and duodenum depending on the type of anesthesia and preoperative care]
[Changes of the aluminum and silicon contents and cholinergic activity of the blood depending on the course of the gastroduodenal ulcer]
[Clinical significance of the determination of whole blood cholinesterase activity in patients with peptic ulcer]
[Content of catecholamines and acetylcholine and the cholinesterase activity in the stomach tissues in certain complications of peptic ulcer]
[Etiology of peptic ulcer under the influence of cholinesterase poisons.]
[Modifications of blood cholinesterase activity in peptic ulcer and gastric cancer.]
[Trial treatment of gastroduodenal ulcers with pyridine-2-aldoxime methyl methanesulfonate (RP 7676), a cholinesterase reactivator.]
Periapical Periodontitis
[Cholinesterase in periodontal membrane suffering from so-called pyorrhea and apical periodontitis]
Pericarditis
LEFT-SIDED AMOEBIC LIVER ABSCESS WITH PULMONARY INVOLVEMENT, PERICARDITIS, AND PSEUDOCHOLINESTERASE DEFICIENCY.
Periodontal Diseases
Clinical associations between acetylcholine levels and cholinesterase activity in saliva and gingival crevicular fluid and periodontal diseases.
Periodontitis
Determination of pseudocholinesterase activity in the gingival crevicular fluid, saliva, and serum from patients with juvenile periodontitis and rapidly progressive periodontitis.
Relationship between periodontitis and hepatic condition in Japanese women.
The effect of periodontal therapy on salivary pseudocholinesterase activity.
Peripheral Arterial Disease
Serum Cholinesterase Levels Are Associated With 2-Year Ischemic Outcomes After Angioplasty and Stenting for Peripheral Artery Disease.
Peripheral Nervous System Diseases
Anticeramide antibody and butyrylcholinesterase in peripheral neuropathies.
Muscular dystrophy with laminin deficiency decreases the content of butyrylcholinesterase tetramers in sciatic nerves of Lama2dy mice.
The effects of occupational exposure to chlorpyrifos on the peripheral nervous system: a prospective cohort study.
Peritonitis
Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis.
[Changes in the cholinesterase activity and the acetylcholine and catecholamine contents in the intestinal tissues of rats with experimental peritonitis]
[Effect of transfusion of UV-irradiated blood on the changes in serum cholinesterase activity in patients with peritonitis]
Persian Gulf Syndrome
Cholinesterase inhibitors and stress: effects on brain muscarinic receptor density in mice.
Peripheral cholinergic function in humans with chronic fatigue syndrome, Gulf War syndrome and with illness following organophosphate exposure.
Pyridostigmine bromide and Gulf War syndrome.
Pharyngitis
Investigation of a fatality among parathion applicators in California.
Pheochromocytoma
Quantification of acetylcholine in cell culture systems by semi-micro high-performance liquid chromatography and electrospray ionization mass spectrometry.
Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells.
Pigmentation Disorders
Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile.
Synthesis of calix[4]azacrown substituted sulphonamides with antioxidant, acetylcholinesterase, butyrylcholinesterase, tyrosinase and carbonic anhydrase inhibitory action.
Plague
Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits.
Pleural Effusion
Light's criteria revisited: consistency and comparison with new proposed alternative criteria for separating pleural transudates from exudates.
Pleural fluid to serum cholinesterase ratio for the separation of transudates and exudates.
Pleural to serum cholinesterase ratio in separation of transudative and exudative pleural effusions.
[Diagnostic efficiency of pseudocholinesterase level in discrimination of transudates-exudates]
[Distinguishing pleural transudates and exudates through the quantification of biochemical parameters]
[Kwashiorkor syndrome in exudative enteropathy]
[Pleural fluid to serum cholinesterase ratio to discriminate between transudates and exudates: reevaluation in 177 patients]
Pneumonia
Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer's Disease: A Nested Case-Control Study.
Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients.
Early onset pneumonia in patients with cholinesterase inhibitor poisoning.
Identification of missense mutation (G365R) of the butyrylcholinesterase (BCHE) gene in a Japanese patient with familial cholinesterasemia.
Microfabricated potentiometric sensor for personalized methacholine challenge tests during the COVID-19 pandemic.
Outpatient medications and hip fractures in the US: a national veterans study.
Pneumonia Risk with Cholinesterase Inhibitors.
Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
Risk Prediction of Postoperative Pneumonia After Subtotal Esophagectomy Based on Preoperative Serum Cholinesterase Concentrations.
Serum cholinesterase associated with COVID-19 pneumonia severity and mortality.
The effect of community-acquired pneumonia on plasma esterases in older people.
[Cholinesterase activity in blood serum of healthy children and in pneumonia]
[The value of determination of serum cholinesterase levels in judgment of severity and prognosis in patients with severe pneumonia].
Pneumonia, Aspiration
Drug-induced sialorrhoea and excessive saliva accumulation.
Poliomyelitis
[CHOLINESTERASE ACTIVITY IN THE TISSUES OF WHITE MICE WITH EXPERIMENTAL POLIOMYELITIS.]
[Cholinesterase activity of different tissues of white mice in experimental poliomyelitis.]
[Studies on changes in cholinesterase activities in blood under acupuncture treatment of sequelae of poliomyelitis]
Polycystic Kidney, Autosomal Dominant
[A family of adult polycystic kidney disease associated with pseudocholinesterase deficiency]
Polyendocrinopathies, Autoimmune
Genetic screening in the Persian Jewish community: A pilot study.
Polyneuropathies
Histochemically demonstrable non-specific cholinesterase as an indicator of peripheral nerve lesion in carbon disulphide-induced polyneuropathy.
Organophosphorus poisoning and anaesthesia.
Polyuria
Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3.
Pre-Eclampsia
BIOMARKERS IN PREECLAMPTIC WOMEN WITH NORMOGLYCEMIA AND HYPERGLYCEMIA.
Butyrylcholinesterase (BChE) activity is associated with the risk of preeclampsia: influence on lipid and lipoprotein metabolism and oxidative stress.
Effect of magnesium and preeclampsia on plasma cholinesterase activity.
Effect of magnesium on plasma cholinesterase activity.
Effect of pre-eclampsia on plasma cholinesterase activity.
Evaluation of the Relationship between Adenosine Deaminase, Myeloperoxidase, Cholinesterase, Preeclampsia Severity and Neonatal Outcomes.
Reduced pseudocholinesterase activity in patients with HELLP syndrome.
Suxamethonium apnoea associated with pregnancy and liver dysfunction in a treated cretin.
[Activity of blood cholinesterase in normal pregnancy and in pregnancy toxemias]
[Behavior of the cholinesterase activity in the blood and cerebrospinal fluid of women in late pregnancy toxemias]
[Urinary excretion of adrenaline and noradrenaline, acetylcholine and cholinesterase content of the blood in women with late pregnancy toxemia]
Premature Ejaculation
The Control of Male Sexual Responses.
Pressure Ulcer
Predicting the outcome of long-term care by clinical and functional indices: the role of nutritional status.
Primary Dysautonomias
Pilot study of pyridostigmine in constipated patients with autonomic neuropathy.
Prostatic Hyperplasia
Drug-induced urinary incontinence.
Prostatic Neoplasms
Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development.
Cholinesterase activities and biochemical determinations in patients with prostate cancer: influence of Gleason score, treatment and bone metastasis.
Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy.
Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
[Liver disorder owing to estrogen therapy in prostatic cancer. The correlation between serum level of cholinesterase and dose of diethylstilbestrol diphosphate]
Protein Deficiency
An assessment of the clinical usefulness of plasma ribonuclease assays.
[Malnutrition in old age - diagnosis and therapy]
[Nutritional states in a medical clinic]
Protein-Energy Malnutrition
Butyrylcholinesterase as a prognostic marker: a review of the literature.
Dual significance of hepatic cholinesterase as an index of liver involvement and state of protein-calorie malnutrition.
Effect of vitamin A on cholinesterase activity in normal children and in children with protein-calorie malnutrition.
Serum cholinesterase and histopathology of the liver in severe protein calorie malnutrition.
Serum enzyme abnormalities in protein energy malnutrition.
Proteinuria
Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care.
[Cholinesterase, arylesterase and proteinuria. A clinical trial in glomerular and tubular proteinuria (author's transl)]
Pruritus
Cholinesterase levels in the skin in cholinogenic urticaria and pruritus.
Hematological biomarkers in farm workers exposed to organophosphorus pesticides in the Gaza Strip.
Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients.
[Development of extracorporeal blood purification methods: Molecular Adsorbent Recirculating System (MARS) for hepatic and renal function replacement.]
Psoriasis
A study of fructose-1,6-diphosphatealdolase, lactatedechydrogenase, leucineaminopeptidase, aspartate- and alanine-transaminase, alkaline phosphatase and cholinesterase in the blood serum of patients with psoriasis.
[Blood enzyme activities in men and women with certain diseases]
[Investigation on activity of serum cholinesterase and on therapeutic effect of intravenous novocain in psoriasis.]
[Studies on serum cholinesterase and the effect of intravenous novocain in psoriasis.]
[The dermal amyelinic system and its endings in psoriasis]
Psychomotor Agitation
Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease.
Pulmonary Disease, Chronic Obstructive
Alterations in acetylcholinesterase and butyrylcholinesterase activities in chronic obstructive pulmonary disease: relationships with oxidative and inflammatory markers.
Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study.
COPD Exacerbation and Cholinesterase Therapy in Dementia Patients.
Decreased activity of butyrylcholinesterase in blood plasma of patients with chronic obstructive pulmonary disease.
Epidemiology of Dementia in Elderly Chronic Obstructive Pulmonary Disease Patients Living in China's Northwestern High-Elevation Area.
Ipratropium in patients with COPD receiving cholinesterase inhibitors.
Pharmacologic treatments of dementia.
Pulmonary Edema
2-pyridine aldoxime methiodide in the treatment of post-operative acute pulmonary edema: possible role of cholinesterase.
Pulmonary Heart Disease
Serum cholinesterase and euglobulin lysis time in chronic cor pulmonale.
[Cholinesterase in patients with pulmonary heart disease]
Pyelonephritis
[Enzymological evaluation of the hepatotoxicity of ampicillin and its therapeutic form, roscillin, in the treatment of pyelonephritis in pregnancy]
Pyloric Stenosis
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Rabies
[Inhibition of cholinesterase activity in the brain of rats by phosphoorganic inhibitors with different degrees of hydrophobia]
Raynaud Disease
[Ganglial cholinesterase in Raynaud's disease.]
Red-Cell Aplasia, Pure
Parvovirus b19 infection after plasma exchange for myasthenia gravis.
Renal Insufficiency
A case of fatal ingestion of malathion.
Adverse drug reactions during heatwaves.
Pseudocholinesterase in gestational diabetes: positive correlation with LDL and negative correlation with triglyceride.
Risk factors for cataract: a case control study.
Serum cholinesterase deficiency in renal failure.
Renal Insufficiency, Chronic
[Levels of plasma pseudocholinesterase in chronic renal insufficiency patients and hemodialysis]
Reperfusion Injury
Vagal modulation of high mobility group box-1 protein mediates electroacupuncture-induced cardioprotection in ischemia-reperfusion injury.
Respiratory Insufficiency
Allergic reaction to suxamethonium during emergency caesarean section and pseudocholinesterase deficiency in the same patient.
Effects of cholinesterase inhibitors and serotonin-1A receptor agonists on morphine-induced ventilatory depression and antinociception in rats.
Fresh frozen plasma as a successful antidotal supplement in acute organophosphate poisoning.
Metrifonate for Alzheimer's disease.
Respiratory failure triggered by cholinesterase inhibitors may involve activation of a reflex sensory pathway by acetylcholine spillover.
The possible role of intravenous lipid emulsion in the treatment of chemical warfare agent poisoning.
[Acute respiratory failure associated with cholinergic crisis: report of five cases and review of the literature].
[Bowel obstruction-induced cholinergic crisis with progressive respiratory failure following distigmine bromide treatment].
[Respiratory depression in the newborn due to a congenital anomaly in plasma cholinesterase]
[Therapeutic effects of benthiactzine against respiratory failure induced by cholinesterase inhibitor in rats]
Respiratory Paralysis
Management of acute childhood poisonings caused by selected insecticides and herbicides.
Mechanism of the clonidine-induced protection against acetylcholinesterase inhibitor toxicity.
Poisoning from oral ingestion of carbofuran (Furadan 4F), a cholinesterase-inhibiting carbamate insecticide, and its effects on cholinesterase activity in various biological fluids.
Succinylcholine drug interactions during electroconvulsive therapy.
Restless Legs Syndrome
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Retinal Detachment
Prognosis of primary rhegmatogenous retinal detachments. 1. Associations between clinical detachment characteristics, subretinal fluid butyrylcholinesterase and visual outcome following scleral buckling procedures.
Subretinal fluid butyrylcholinesterase. 1. Source of the enzyme and factors affecting its concentration in subretinal fluid from primary rhegmatogenous retinal detachments.
[Activity of alkaline phosphatase, cholinesterase and aspartic aminopherase in subretinal fluid in retinal detachment]
[Butyrylcholinesterase activity in the subretinal fluid in retinal detachment]
Rhabdomyolysis
Postsynaptic neuromuscular dysfunction in organophosphate induced intermediate syndrome.
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.
Rhabdomyosarcoma
Cholinesterase response in the rhabdomyosarcoma tumor and small intestine of the BALB/c mice and the radioprotective actions of exogenous ATP after lethal dose of neutron radiation.
Rheumatic Diseases
Studies on the cholinesterase activity of red cell, plasma and synovial fluid with special reference to rheumatic diseases.
[Activity of cholinesterase in the blood serum in rheumatism in children.]
[Association of mutant alleles of serum cholinesterase with various multi-factorial and infectious diseases]
[Behavior of serum cholinesterase in rheumatic diseases]
[Behavior of several enzymes (oxalacetic and pyruvic transaminases, lacticodehydrogenase and cholinesterase in serum) in rheumatic disease.]
[Blood cholinesterase effects in rheumatic disease.]
[Change in cholinesterase activity in children with rheumatism in relation to various factors]
[Cholinesterase power of the serum in rheumatic disease.]
[Correlation between the content of acetylcholine 2nd cholinesterase in the blood and state of the autonomic nervous system in children with rheumatism]
[Crenotherapy in rheumatism and blood cholinesterase activity.]
[Diphenylamine and pseudocholinesterase tests in the evaluation of dynamics of inflammatory forms of rheumatic diseases]
[Fluctuations in blood acetylcholine and cholinesterase levels in children with rheumatism]
[Protein fractions and cholinesterase in the blood serum as an indication of the activity of rheumatism in children.]
[Serum cholinesterase activity in rheumatic disease.]
[The blood serum cholinesterase activity in children with rheumatism]
Rheumatic Fever
[ACTIVITY OF SERUM CHOLINESTERASE IN RHEUMATIC FEVER OF CHILDHOOD.]
Rheumatic Heart Disease
[Cholinesterase activity in rheumatic heart disease.]
[SERUM CHOLINESTERASE ACTIVITY IN RHEUMATIC HEART DISEASE.]
Rhinitis, Allergic, Seasonal
[Study of serum cholinesterase in patients with pollinosis in relation to specific desensitizing treatment.]
Salmonella Infections
Pathological physiology of salmonellosis. II. Plasma cholinesterase in infections due to Enterobacteriaceae.
[Physiopathology of Salmonella infections. IV. Regeneration of blood cholinesterase in children during active typhoid fever and during convalescence.]
Sarcoma, Experimental
[Muscle and tumor tissue cholinesterase activity during Jensen sarcoma growth]
Sarcoma, Kaposi
A histochemical study of cholinesterase activity in Kaposi's sarcoma.
Sarcopenia
Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia.
Low serum cholinesterase predicts complication risk after orthopedic surgery in elderly patients: an observational pilot study.
Urinary titin N-terminal fragment concentration is an indicator of preoperative sarcopenia and nutritional status in patients with gastrointestinal tract and hepatobiliary pancreatic malignancies.
Schistosomiasis
Effect of hycanthone and niridazole on cholinesterase levels in experimental schistosomiasis.
Evaluation of serum choline esterase and albumin in bilharziasis.
Metrifonate for Alzheimer's disease.
Schistosomiasis, metriphonate, cholinesterase, and suxamethonium.
THE SERUM CHOLINESTERASE LEVELS IN BILHARZIASIS.
Schistosomiasis haematobia
Schistosoma haematobium in Ajara community of Badagry. Metrifonate trials in the treatment of the disease.
Schistosomiasis mansoni
[Changes in serum cholinesterase in schistosomiasis mansoni]
Scoliosis
Corrected scoliosis, cholinesterase deficiency, and cesarean section: a case report.
[Decreased cholinesterase activity in the serum of juveniles with idiopathic scoliosis]
Seizures
Acetylcholine, cholinesterase, eserine and convulsions.
Acute administration of diazepam or midazolam minimally alters long-term neuropathological effects in the rat brain following acute intoxication with diisopropylfluorophosphate.
Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice.
Anatomical localization and time course of Fos expression following soman-induced seizures.
Anticonvulsant actions of anticholinergic drugs in soman poisoning.
Anticonvulsant and antilethal effects of the phencyclidine derivative TCP in soman poisoning.
Blockade of hippocampal long-term potentiation following soman pretreatment in the rat.
Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats.
Caramiphen edisylate: an optimal antidote against organophosphate poisoning.
Cerebral blood flow and metabolism in soman-induced convulsions.
Characterization of cholinergic regulation of seizures by the midline thalamus.
Characterization of status epilepticus induced by two organophosphates in rats.
Cholinergic actions of diazepam and atropine sulfate in soman poisoning.
Cholinergic involvement in cobalt-induced epilepsy in the rat.
Comparative seizure inducing properties of various cholinesterase inhibitors: antagonism by diazepam and midazolam.
Distortion product otoacoustic emissions as non-invasive biomarkers and predictors of soman-induced central neurotoxicity: a preliminary study.
Effects of anticholinergic-antiparkinsonian drugs on striatal neurotransmitter levels of rats intoxicated with soman.
Effects of antidepressants on longevity and dementia onset among adults with Down syndrome: a retrospective study.
Effects of antimuscarinic antiparkinsonian drugs on brightness discrimination performance in rats.
Effects of single exposure to chlorphenvinphos, an organophosphate insecticide, on electrical activity (EEG) of the rat brain.
Effects of soman poisoning on mitochondrial respiratory enzyme activity in the mouse hippocampus and cerebral cortex.
Efficacy of antidotal treatment against sarin poisoning: the superiority of benactyzine and caramiphen.
Grand mal seizures after 2-chloroprocaine epidural anesthesia in a patient with plasma cholinesterase deficiency.
Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus. Review of current data and perspectives.
Magnesium sulfate treatment against sarin poisoning: dissociation between overt convulsions and recorded cortical seizure activity.
Mapping of cerebral metabolic activation in three models of cholinergic convulsions.
Mapping of cortical metabolic activation in soman-induced convulsions in rats.
MK-801 protects against seizures induced by the cholinesterase inhibitor soman.
Modeling and simulation of organophosphate-induced neurotoxicity: Prediction and validation by experimental studies.
Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig.
Neurochemical mechanisms in soman-induced seizures.
Organophosphorus nerve agents-induced seizures and efficacy of atropine sulfate as anticonvulsant treatment.
Persistent neuroinflammation and cognitive impairment in a rat model of acute diisopropylfluorophosphate intoxication.
Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman.
Pharmacokinetics of Three Oximes in a Guinea Pig Model and Efficacy of Combined Oxime Therapy.
Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX.
Prediction of soman-induced cerebral damage by distortion product otoacoustic emissions.
Pregnancy decreases the threshold for cocaine-induced convulsions in the rat.
Pretreatment with human serum butyrylcholinesterase alone prevents cardiac abnormalities, seizures, and death in Göttingen minipigs exposed to sarin vapor.
Regulatory effects of acutely repeated nicotine treatment towards central muscarinic receptors.
Root extract of Anacyclus pyrethrum ameliorates seizures, seizure-induced oxidative stress and cognitive impairment in experimental animals.
SCH 23390 affords protection against soman-evoked seizures in the freely moving guinea-pig: a concomitant neurochemical, electrophysiological and behavioural study.
Scopolamine-induced convulsions in food given fasted mice: effects of physostigmine and MK-801.
Seizures in an Alzheimer's disease patient as a complication of colonoscopy premedication with meperidine.
Strain differences in seizure responses and brain cholinesterase activity in rats.
The involvement of the central cholinergic and endorphinergic systems in the nitrous oxide withdrawal syndrome in mice.
The possible role of intravenous lipid emulsion in the treatment of chemical warfare agent poisoning.
The role of genetic background in susceptibility to chemical warfare nerve agents across rodent and non-human primate models.
Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties.
Variation in the expression of c-fos after intoxication by soman. Comparative study using in situ hybridization and immunohistochemistry.
[Cerebral cholinesterase under conditions of a generalized convulsive seizure]
[Experimental studies on the influence of some anticonvulsive drugs and of metrazol convulsions on the activity of cerebral cholinesterase]
[MODIFIED CHOLINESTERASE ACTIVITY OF THE BRAIN IN CONVULSIONS FOLLOWING ANTICONVULSANT THERAPY.]
[Role of the acetylcholine--cholinesterase system in the development of epilepsy]
Sepsis
"Nutritional" markers as prognostic indicators of postoperative sepsis in cancer patients.
A Sustained Reduction in Serum Cholinesterase Enzyme Activity Predicts Patient Outcome following Sepsis.
Association between early serum cholinesterase activity and 30-day mortality in sepsis-3 patients: A retrospective cohort study.
Changes in choline and cholinesterase in saliva of dogs with parvovirus infection.
Cholinesterase inhibitors improve survival in experimental sepsis: a new way to activate the cholinergic anti-inflammatory pathway.
Effect of physostigmine on recovery from septic shock following intra-abdominal infection - Results from a randomized, double-blind, placebo-controlled, monocentric pilot trial (Anticholium® per Se).
Effects of a peripheral cholinesterase inhibitor on cytokine production and autonomic nervous activity in a rat model of sepsis.
Effects of reversible inhibition of cholinesterase and nicotine on mouse mortality and blood levels of proinflammatory cytokines during the early phase of sepsis.
Immune and nutritional effects of early enteral nutrition after major abdominal operations.
In Vivo Effects of Neostigmine and Physostigmine on Neutrophil Functions and Evaluation of Acetylcholinesterase and Butyrylcholinesterase as Inflammatory Markers during Experimental Sepsis in Rats.
Modulation of immune functions in polymorphonuclear neutrophils induced by physostigmine, but not neostigmine, independent of cholinergic neurons.
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis.
Profile of serum cholinesterase in systemic sepsis syndrome (septic shock) in intensive care unit patients.
Prognostic value of serum cholinesterase activities in sepsis patients.
Species- and concentration-dependent differences of Acetyl- and Butyrylcholinesterase sensitivity to physostigmine and neostigmine.
The effect of plasmapheresis on plasma cholinesterase levels in a patient with organophosphate poisoning.
[Clinical analysis of patients with community-acquired pneumonia requiring hospitalization classified by age group]
[Decrease in plasmatic cholinesterase activity in severe bacterial infections: comparison with the decrease observed in severe liver cirrhosis]
[The neuroendocrine axis and the pathophysiology of sepsis]
Shock, Septic
Value of Serum Cholinesterase Activity in the Diagnosis of Septic Shock Due to Bacterial Infections.
[Prolonged apnea after suxamethonium administration during staphylococcal toxic shock]
[Value of serum cholinesterase in the prognosis of septic shock].
Sialorrhea
Much caution does no harm! Organophosphate poisoning often causes pancreatitis.
[Long QT syndrome after organophosphate insecticide poisoning]
[Sugammadex, a new drug for reversion of muscle relaxants].
Sick Sinus Syndrome
Sick Sinus Syndrome Observed in a Patient with Cholinesterase Deficiency.
Situs Inversus
Atypical cholinesterase in a patient with situs inversus totalis.
Sjogren's Syndrome
Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase.
Skin Abnormalities
[Clinical and biochemical alterations in rats treated with high doses of vitamin A]
Skin Diseases
[Blood cholinesterase & skin diseases.]
[Cholinesterase activity: histaminolytic capacity and the determination of histamine in the skin of healthy subjects and patients with various allergic dermatoses. Relation of histamine to mastocytes.]
[Differences in blood cholinesterase activity as a possible differential diagnostic criterion of eczema, atopic dermatosis and allergic eczema-like dermatitis]
[SERUM CHOLINESTERASE AND SKIN DISEASES.]
Sleep Apnea, Obstructive
Influence of obstructive sleep apnea on serum butyrylcholinesterase activity and ischemia-modified albumin levels.
Reduction of sleep-disordered breathing after physostigmine.
Sleep Deprivation
Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation.
Sleep Initiation and Maintenance Disorders
A top 5 list for French general practice.
Environmental Toxicology and Health Effects Associated with Methyl Parathion Exposure - A Scientific Review.
Treatment of visual hallucinations with ramelteon in two patients with dementia Lewy bodies.
[Primary care general internal medicine: relevant information in 2005]
Sleep Wake Disorders
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.
New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.
New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.
Spasm
Break the Spasm with Succinylcholine, but Risk Intraoperative Awareness with Undiagnosed Pseudocholinesterase Deficiency.
Spina Bifida Cystica
Ratio of amniotic fluid acetylcholinesterase to pseudocholinesterase as an antenatal diagnostic test for exomphalos and gastroschisis.
Ratio of immunochemically determined amniotic fluid acetylcholinesterase to butyrylcholinesterase in the differential diagnosis of fetal abnormalities.
Scanning gel densitometry of amniotic fluid acetylcholinesterase and butyrylcholinesterase: quantification of 'faint-positive' bands in fetal malformations.
Spinal Cord Injuries
Effect of distigmine combined with propiverine on bladder activity in rats with spinal cord injury.
Spinal Muscular Atrophies of Childhood
Serum cholinesterase activity in infantile and juvenile spinal muscular atrophy.
Splenic Infarction
Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications.
Spondylitis, Ankylosing
Proceedings: Frequency of the atypical gene E1-a of serum cholinesterase among patients with ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Butyrylcholinesterase: An economical marker of disease activity in oral squamous cell carcinoma before and after therapy.
Estimation of Serum Butyryl Cholinesterase in Patients with Oral Squamous Cell Carcinoma: A Cross-Sectional Study.
Starvation
Cholinesterase activity in starvation.
Effect of starvation and refeeding on the circadian rhythms of hematological and clinico-biochemical values, and water intake of rats.
The effect of starvation on the cholinesterase activity of the liver and serum of young male rats.
Status Epilepticus
Acute administration of diazepam or midazolam minimally alters long-term neuropathological effects in the rat brain following acute intoxication with diisopropylfluorophosphate.
Changes in mouse brain metabolism following a convulsive dose of soman: a proton HRMAS NMR study.
Characterization of status epilepticus induced by two organophosphates in rats.
Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus. Review of current data and perspectives.
Modeling and simulation of organophosphate-induced neurotoxicity: Prediction and validation by experimental studies.
Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig.
Persistent neuroinflammation and cognitive impairment in a rat model of acute diisopropylfluorophosphate intoxication.
Pharmacological dissociation of the motor and electrical aspects of convulsive status epilepticus induced by the cholinesterase inhibitor soman.
Spontaneous recurrent seizures after status epilepticus induced by soman in Sprague-Dawley rats.
Steatorrhea
Secondary impairment of pancreatic function as a cause of severe malabsorption in intestinal giardiasis: a case report.
Stomach Diseases
The Role of Cholinesterase in Differential Diagnosis between Gastric Cancer and Benign Gastric Diseases.
[The behavior of liver cholinesterase in liver, gallbladder and stomach diseases]
Stomach Neoplasms
Alterations of serum cholinesterase in patients with gastric cancer.
Cholinesterase is Associated With Prognosis and Response to Chemotherapy in Advanced Gastric Cancer.
Goodyschle A, a new butenolide with significant BchE inhibitory activity from Goodyera schlechtendaliana.
Prognostic significance of host- and tumor-related factors in patients with gastric cancer.
Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer.
The Role of Cholinesterase in Differential Diagnosis between Gastric Cancer and Benign Gastric Diseases.
[Modifications of blood cholinesterase activity in peptic ulcer and gastric cancer.]
[The effect of anesthesia and surgical trauma on the activity of pseudocholinesterase in the blood of patients with suppurative processes in the lung, cancer of the stomach and esophagus]
Stomach Ulcer
THE CONCENTRATION OF ACETYLCHOLINE AND THE LEVEL CHOLINESTERASE ACTIVITY IN THE SERUM OF PATIENTS WITH GASTRIC ULCER, DUODENAL ULCER AND ALCOHOLIC CHRONIC PANCREATITIS.
[Changes in acetylcholine concentration and cholinesterase activity in gastric tissues following reproduction of "steroid" stomach ulcers in animals]
[Prostaglandin E(2) and omeprazole in treating poisoning related acute mucosal lesion]
Stomatitis
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
Stomatitis, Aphthous
[Relapsing Aphthous ulcer treated with traditional Chinese medicine and Western medicine therapy and the determination of urinary 17-ketosteroid and serum cholinesterase]
Strabismus
Prolonged apnea caused by inherited cholinesterase deficiency after strabismus surgery.
Sugammadex affects emergence agitation in children undergoing strabismus surgery.
Stroke
Admission serum cholinesterase concentration for prediction of in-hospital mortality in very elderly patients with acute ischemic stroke: a retrospective study.
Amyloid-? peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients.
Amyloid-beta Peptides in Plasma and Cognitive Decline After 1 Year Follow-Up in Alzheimer's Disease Patients.
Atherosclerosis and arteriosclerosis parameters in stroke patients associate with paraoxonase polymorphism and esterase activities.
Education plays a greater role than age in cognitive test performance among participants of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
Effect of cholinergic medication, before and after focal photothrombotic ischemic cortical injury, on histological and functional outcome in aged and young adult rats.
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Increased monoamine metabolite concentrations and cholinesterase activities in cerebrospinal fluid of patients with acute stroke.
Neuropharmacological modulation of cognitive deficits after brain damage.
New developments on drug treatment rehabilitation.
Pre-Stroke Cholinesterase Inhibitor Treatment Is Beneficially Associated with Functional Outcome in Patients with Acute Ischemic Stroke and Pre-Stroke Dementia: The Fukuoka Stroke Registry.
Quantum dot labeling of butyrylcholinesterase maintains substrate and inhibitor interactions and cell adherence features.
Serum butyrylcholinesterase activity and phenotype associations with lipid profile in stroke patients.
Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality.
Stupor
[Effect of cholinesterase inhibitors in hysteric stupor]
[Influence of the inhibition of cerebral cholinesterase on duration of narcosis.]
[Modifications of the serum cholinesterase level following pentothal narcosis.]
[Potentiation of the barbital narcosis in mice using cholinmimetic and cholinesterase blockers]
[The effect of streptomycin on neuromuscular conductivity in cats treated with several phosphoorganic cholinesterase inhibitors]
Supranuclear Palsy, Progressive
Cholinergic approaches to the treatment of progressive supranuclear palsy.
Donepezil in the treatment of progressive supranuclear palsy.
Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors.
Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Syncope
ACP Journal Club. Review: cholinesterase inhibitors but not memantine increase syncope in older adults with mild cognitive impairment or dementia.
Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases.
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.
Causes of syncope in patients with Alzheimer's disease treated with donepezil.
Cholinesterase inhibitors were associated with increased risk for syncope and its consequences in older persons with dementia.
Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.
National Veterans Health Administration hospitalizations for syncope compared to acute myocardial infarction, fracture, or pneumonia in community-dwelling elders: outpatient medication and comorbidity profiles.
Prevalence of positive carotid sinus massage and related risk of syncope in patients with Alzheimer's disease.
Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures.
Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors.
Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.
Syncope with cholinesterase inhibitors.
Synucleinopathies
Hallucinations in Neurodegenerative Diseases.
Syringomyelia
[Changes in the blood acetylcholine and cholinesterase indices of syringomyelia patients]
Tachycardia
Bidirectional tachycardia induced by herbal aconite poisoning.
Clinical signs and biochemical changes in calves caused by injection of ivermectin.
Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats.
Neonatal cholinesterase inhibitor poisoning: materno-fetal exchange of pesticide.
Pyridostigmine enhances atrial tachyarrhythmias in aging spontaneously hypertensive rats.
The inhibition of cholinesterases by pancuronium.
The role of enhanced vagal activity on ischemic ventricular tachycardia: pharmacologic basis of inefficiency.
[Autonomic status and neurohumoral regulation in patients with refractory tachyarrhythmia]
[The treatment of tachycardia attacks with a new cholinesterase antagonist.]
Tardive Dyskinesia
Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.
Temporomandibular Joint Disorders
Light therapy modulates serotonin levels and blood flow in women with headache. A preliminary study.
Teratoma
Scanning gel densitometry of amniotic fluid acetylcholinesterase and butyrylcholinesterase: quantification of 'faint-positive' bands in fetal malformations.
Tetanus
Cholinesterase restoring therapy in tetanus.
Serum cholinesterase in tetanus.
The action of tetanus toxin on the acetylcholine and cholinesterase contents of the rabbit's iris.
The effect of tetanus toxin on the choline esterase activity of the muscles of rats.
[Activity and localization of cholinesterase in the spinal cord of rabbits in experimental tetanus]
[Behavior of serum and erythrocyte cholinesterase in experimental tetanus in rabbits]
[Blood cholinesterase activity in patients with tetanus]
[Changes in the localization of cholinesterase in striated muscles in tetanus]
[Cholinesterase activity of the central nervous system and of muscles in a dynamic study of experimental tetanus poisoning]
[Cholinesterase inhibition in nerve tissue of animals intoxicated with tetanus toxin.]
[Comparison of serum cholinesterase during an industrial organo-phosphorated intoxication and in the course of tetanus (author's transl)]
[Compensatory effect developed by oximes in comparison with cholinesterase inhibited in vitro by tetanus toxin]
[Competition of an oxime in the binding of cholinesterase and tetanus toxin]
[Evolution of tetanus and levels of pseudocholinesterase]
[Histochemical study of cholinesterase distribution in the spinal cord and spinal ganglia of rabbits in experimental tetanus intoxication]
[Possible interference between tetanus toxin and organo-phosphorus esters in blocking of cholinesterase]
[Research on a causal therapy of tetanus: combination of antitoxin with cholinesterase restoration in the treatment of clinical tetanus in man]
[Risks in the diagnosis and treatment of tetanus in the exercise of medical practice]
[The cholinesterase activity of motor plates in experimental tetanus toxin-induced tetanus.]
Thrombocytopenia
A conundrum: general or neuraxial anesthesia and the use of ROTEM.
Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
Do patients with liver cirrhosis undergoing cardiac surgery have acceptable outcomes?
In vivo gene amplification in non-cancerous cells: cholinesterase genes and oncogenes amplify in thrombocytopenia associated with lupus erythematosus.
Methicillin-resistant Staphylococcus aureus: colonization and development of infection in patients with haematological disorders.
Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications.
Thrombocytopenia in liver cirrhosis.
Thrombosis
Coagulation factor XIII and atherothrombosis. A mini-review.
Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.
Dilute blood clot lysis time and electrophoretic lipoprotein fractions in a population sample of healthy Romanians.
Health benefit of fucosterol from marine algae: a review.
Prognostic index for survival in patients after treatment for primary hepatocellular carcinoma.
Thymoma
Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.
[Myasthenia, from the internist's point of view.]
Thyroid Diseases
Pseudocholinesterase activity in thyroid disease.
Serum electrophoretic lipoprotein factors and pseudocholinesterase activity in thyroid disease.
Thyroid Neoplasms
Acetylcholinesterase and butyrylcholinesterase activities in human thyroid cancer cells.
Thyroiditis
Definition, at the molecular level, of a thyroglobulin-acetylcholinesterase shared epitope: study of its pathophysiological significance in patients with Graves' ophthalmopathy.
Thyrotoxicosis
[ Acetylcholine and cholinesterase during experimental thyrotoxicosis]
[Blood cholinesterase in rats with experimental thyrotoxicosis and hypothyroidism]
[Cholinesterase of the heart of rats with experimental thyrotoxicosis and hypothyroidism]
Tonsillitis
[Indices of the activity of cholinesterase in chronic tonsillitis.]
Torsades de Pointes
Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.
Tourette Syndrome
CSF cholinesterase activity in Gilles de la Tourette's syndrome.
Toxemia
Plasma cholinesterase activity in normal pregnance and in eclamptogenic toxemias.
Toxic Optic Neuropathy
Ocular effects of organophosphates: a historical perspective of Saku disease.
Repeated spike exposure to the insecticide chlorpyrifos interferes with the recovery of visual sensitivity in rats.
The effects of physostigmine on the electroretinogram in the beagle dog.
Tremor
Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Comparisons of the acute effects of cholinesterase inhibitors using a neurobehavioral screening battery in rats.
Effects of sarin on temperature and activity of rats as a model for gulf war syndrome neuroregulatory functions.
Electromyographical differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat.
Impact of organophosphate exposure on farmers' health in Kulon Progo, Yogyakarta: Perspectives of physical, emotional and social health.
Mechanism of the clonidine-induced protection against acetylcholinesterase inhibitor toxicity.
Mechanism Underlying Organophosphate Paraoxon-Induced Kinetic Tremor.
Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses.
Vitamin K3 (menadione) redox cycling inhibits cytochrome P450-mediated metabolism and inhibits parathion intoxication.
[Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease.]
Trichinellosis
Studies on tissue cholinesterase in experimental trichinosis in albino rat. 1. Effect of T. spiralis infection.
Studies on tissue cholinesterase in experimental trichinosis in albino rat. 2 effects of treatment with Mintezol and 5-fluorouracil-Endoxan.
[Cholinesterase activity amd the mast cell number in rats with experimental trichinosis]
Tricuspid Valve Insufficiency
Prognostic Value of Prothrombin Time International Normalized Ratio in Acute Decompensated Heart Failure?- A Combined Marker of Hepatic Insufficiency and Hemostatic Abnormality.
Trismus
[Risks in the diagnosis and treatment of tetanus in the exercise of medical practice]
Trisomy 18 Syndrome
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Tuberculosis
A new test for the presumptive diagnosis of neoplastic disease. Further investigations of cholinesterase in plasma, whole blood and blood cells on cancer of the lung, extrapulmonary tumors and tuberculosis.
Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.
Synthesis of readily available fluorophenylalanine derivatives and investigation of their biological activity.
[Activity and genetic heterogeneity of the serum cholinesterase of tuberculosis patients]
[Activity of cholinesterase and phenyloxidase in blood in experimental tuberculosis of guinea pigs]
[Association of mutant alleles of serum cholinesterase with various multi-factorial and infectious diseases]
[Autoantibodies, acetylcholine, cholinesterase and fibrinolytic properties of blood in experimental tuberculosis]
[Primary care general internal medicine: relevant information in 2005]
[Progress in management of severe tuberculosis or tuberculosis with severe complication].
[Serum cholinesterase in infantile tuberculosis.]
[STUDIES ON BLOOD ENZYMES IN TUBERCULOSIS. II. ACTIVITY OF PSEUDOCHOLINESTERASE IN PATIENTS WITH VARIOUS FORMS OF TUBERCULOSIS AND TRANSMINASE (GOT) ACTIVITY IN THE PROTEIN FRACTIONS OF THE BLOOD SERUM.]
[STUDIES ON BLOOD ENZYMES IN TUBERCULOSIS. III. PROGNOSTIC VALUE OF THE DETERMINATION OF PSEUDOCHOLINESTERASE ACTIVITY IN TUBERCULOSIS.]
[STUDIES ON BLOOD ENZYMES IN TUBERCULOSIS. IV. EFFECT OF TUBERCULIN ON THE ACTIVITY OF PSEUDOCHOLINESTERASE.]
Tuberculosis, Pulmonary
Cholinesterase activity in pulmonary tuberculosis.
[Hourly variations of blood cholinesterase in pulmonary tuberculosis patients.]
[Research on cholinesterase activity and its significance in pulmonary tuberculosis.]
[Serum cholinesterase in pulmonary tuberculosis.]
[Studies on cholinesterase (CEA) activity and its significance in pulmonary tuberculosis; study methods and results.]
[Study of cholinesterase activity in pulmonary tuberculosis and its significance; review of literature.]
[The clinical importance of serum cholinesterase activity in the course of pulmonary tuberculosis.]
Tuberculosis, Renal
[Activity of copper oxidase (ceruloplasmin), cholinesterase and 1-phosphomonoesterase of blood serum in renal tuberculosis]
Typhoid Fever
[Activity of serum cholinesterase and catalase in patients with typhoid and dysentery]
[Physiopathology of Salmonella infections. IV. Regeneration of blood cholinesterase in children during active typhoid fever and during convalescence.]
[The activity of serum cholinesterase and catalase as an index of the course of abdominal typhus]
Unconsciousness
Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.
Effect of physostigmine on the loss of consciousness induced by midazolam, etomidate and althesin.
Microinjection of propofol into the perifornical area induces sedation with decreasing cortical acetylcholine release in rats.
Study of respiratory failure in organophosphate and carbamate poisoning.
Uremia
[Nutrition problems in kidney diseases]
Urinary Bladder Neck Obstruction
Underactive bladder: A review of the current treatment concepts.
Urinary Bladder Neoplasms
Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
Urinary Bladder, Neurogenic
Relationship between serum cholinesterase level and urinary bladder activity in patients with or without overactive bladder and/or neurogenic bladder.
[Acute respiratory failure associated with cholinergic crisis: report of five cases and review of the literature].
Urinary Bladder, Overactive
Relationship between serum cholinesterase level and urinary bladder activity in patients with or without overactive bladder and/or neurogenic bladder.
[Oral anticholinergics in overactive bladder.]
Urinary Bladder, Underactive
Distigmine Bromide Produces Sustained Potentiation of Guinea-Pig Urinary Bladder Motility by Inhibiting Cholinesterase Activity.
Effects of ?1 antagonist and cholinesterase inhibitor on cystometric parameters in lumbar canal stenosis rats with underactive bladder.
Effects of Distigmine on Electrical Field Stimulation-Induced Contraction of Mouse Urinary Bladder Smooth Muscles.
The Long-Lasting Enhancing Effect of Distigmine on Acetylcholine-Induced Contraction of Guinea Pig Detrusor Smooth Muscle Correlates with Its Anticholinesterase Activity.
Urinary Incontinence
A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs.
Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
Drug-induced urinary incontinence.
Etiology and predictors of urinary incontinence and its effect on quality of life.
Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia.
Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study.
Trospium and cognition in patients with late onset Alzheimer disease.
Urinary Incontinence, Urge
Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia.
Urinary dysfunction and autonomic control in amyloid neuropathy.
Urinary Tract Infections
[Gerontology]
Urticaria
Cholinesterase levels in the skin in cholinogenic urticaria and pruritus.
Plasma esterase activity in patients with aspirin-sensitive asthma or urticaria.
Response of chronic nonspecific urticaria to plasma cholinesterase.
Uterine Cervical Neoplasms
Muscarinic cholinergic signaling in cervical cancer cells affects cell motility via ERK1/2 signaling.
Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy.
Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy.
Significance of serum butyrylcholinesterase levels in oral cancer.
The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Uterine Inertia
[Iron, copper and cholinesterase in blood of women during labor in uterine inertia]
Uterine Neoplasms
Significance of serum tumor markers in patients with carcinoma of the ovary.
[Uterine cancer and enzymatic activity of the blood. II. Specific and aspecific cholinesterase.]
Varicose Veins
A simple clinical score predicts high risk for upper gastrointestinal hemorrhages from varices in patients with chronic liver disease.
[Splenic venous hemodynamics in portal hypertension]
Vascular Diseases
A versatile equation to describe reversible enzyme inhibition and activation kinetics: modeling beta-galactosidase and butyrylcholinesterase.
Cholinesterase activity in serum during general anesthesia in patients with or without vascular disease.
Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
[Blood cholinesterase activity and the content of free catecholamines in the urine in obliterating vascular diseases]
Vasculitis
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
Effects of insecticide, diazinon, on pancreas of dog, cat and guinea pig.
Virus Diseases
Japanese Encephalitis Virus Infection Results in Transient Dysfunction of Memory Learning and Cholinesterase Inhibition.
[Cholinesterase activity in the blood and liver of mice with mouse hepatitis virus infection]
Vitiligo
Butyrylcholinesterase is present in the human epidermis and is regulated by H(2)O(2): More evidence for oxidative stress in vitiligo.
Genetic and biochemical evidence implicates the butyrylcholinesterase gene BCHE in vitiligo pathogenesis.
The effects of galangin on a mouse model of vitiligo induced by hydroquinone.